**Supplementary Material: Table of Contents**

The living systematic review was registered in the PROSPERO prospective register of systematic reviews (CRD 42020179703) and a protocol was uploaded to the Open Science Framework prior to initiation (https://osf.io/96csg/).

**Supplementary Material 1.** Search Strategies

**Supplementary Material 2.** Inclusion and Exclusion Coding Guides

**Supplementary Material 3.** Risk of Bias and Adequacy of Study Methods and Reporting

**Supplementary Table 1.** Characteristics of Included Studies with References

**Supplementary Table 2.** Risk of Bias and Adequacy of Methods and Reporting

**Supplementary Table 3.** Individual Study Results for General Mental Health

**Supplementary Table 4.** Individual Study Results for Anxiety Symptoms

**Supplementary Table 5.** Individual Study Results for Depression Symptoms

**Supplementary Figure 1.** Sensitivity Analysis of General Mental Health conducted with results from Savage et al. from October 2020 instead of April 2020

**Supplementary Figure 2.** Sensitivity Analysis of Anxiety Symptoms conducted with results from Henry et al. from September to October 2020 instead of April 2020

**Supplementary Figure 3.** Sensitivity Analysis of Anxiety Symptoms conducted with results from Henry et al. from March 2021 instead of April 2020

**Supplementary Figure 4.** Sensitivity Analysis of Depression Symptoms conducted with results from Henry et al. from September to October 2020 instead of April 2020

**Supplementary Figure 5.** Sensitivity Analysis of Depression Symptoms conducted with results from Henry et al. from March 2021 instead of April 2020

**References of Included Studies**

**Supplementary Material 1: Search Strategies**

**Ovid MEDLINE All**

†New subject heading added to original search on January 27, 2021

1. Quarantine/

2. social isolation/ or loneliness/ or physical distancing/†

3. psychology.fs. or psychology/

4. Mental Health/

5. mental disorders/

6. social stigma/

7. Fear/

8. Anxiety/

9. Depression/

10. Stress, Physiological/ or Stress, Psychological/

11. Anger/

12. Irritable Mood/

13. Grief/

14. burnout, psychological/ or burnout, professional/

15. or/1-15

16. (Quarantine\* or Self-isolation or isolation or social distanc\* or shelter\*-in-place or psych\* or mental health or mental illness\* or mental disorder\* or stigma or fear\* or anxiety or anxious or depression or depressive or loneliness or stress\* or trauma\* or post-traumatic or posttraumatic or anger or mood\* or irritability or irritable or emotional disturbance\* or grief or burned out or burnout).tw,kf.

17. ((exp coronavirus/ or exp coronavirus infections/ or (betacoronavirus\* or beta coronavirus\* or coronavirus\* or corona virus\*).mp.) and (exp china/ or (china or chinese or hubei or wuhan).af.)) or (coronavirus\* or corona virus\* or betacoronavirus\* or beta coronavirus\*).mp.

18. (severe acute respiratory syndrome coronavirus 2 or "SARS CoV-2" or "SARSCoV 2" or SARSCoV2 or cov2 or "sars 2" or COVID or "coronavirus 2" or covid19 or nCov or ((new or Novel) adj3 coronavirus\*) or ncp).mp. or ((exp pneumonia/ or pneumonia.mp.) and wuhan.af.)

19. 17 or 18

20. 15 or 16

21. 19 and 20

22. ("20191231" or 2020\* or 2021\* or 2022\*).dt,ez,da.

23. 21 and 22

**Embase (Ovid)**

1. exp coronavirinae/

2. exp Coronavirus infection/

3. (betacoronavirus\* or beta coronavirus\* or coronavirus\* or corona virus\*).mp.

4. 1 or 2 or 3

5. exp China/

6. (china or chinese or hubei or wuhan).af.

7. 5 or 6

8. 4 and 7

9. (betacoronavirus\* or beta coronavirus\* or coronavirus\* or corona virus\*).mp.

10. (severe acute respiratory syndrome coronavirus 2 or "SARS CoV-2" or "SARSCoV 2" or SARSCoV2 or cov2 or "sars 2" or COVID or "coronavirus 2" or covid19 or nCov or ((new or Novel) adj3 coronavirus\*) or ncp).mp.

11. (exp pneumonia/ or pneumonia.mp.) and wuhan.af.

12. 8 or 9 or 10 or 11

13. quarantine/

14. social isolation/ or isolation/ or patient isolation/

15. loneliness/

16. psychology/

17. mental health/

18. mental disease/

19. social stigma/

20. fear/

21. anxiety/

22. depression/

23. physiological stress/ or mental stress/

24. anger/

25. irritability/

26. exp grief/

27. exp burnout/

28. (mental disorder\* or Quarantine\* or Self-isolation or isolation or social distanc\* or shelter\*-in-place or psych\* or mental health or mental illness\* or stigma or fear\* or anxiety or anxious or depression or depressive or loneliness or stress\* or trauma\* or post-traumatic or posttraumatic or anger or mood\* or irritability or irritable or emotional disturbance\* or grief or burned out or burnout).tw,kw.

29. or/13-27

30. 12 and 29

31. ("20191231" or 2020\* or 2021\* or 2022\*).dc.

32. 30 and 31

**PsycINFO (Ovid)**

1. (coronavirus\* or corona virus\* or betacoronavirus\* or beta coronavirus\*).mp.

2. (severe acute respiratory syndrome coronavirus 2 or "SARS CoV-2" or "SARSCoV 2" or SARSCoV2 or cov2 or "sars 2" or COVID or "coronavirus 2" or covid19 or nCov or ((new or Novel) adj3 coronavirus\*) or ncp).mp. or ((exp pneumonia/ or pneumonia.mp.) and wuhan.af.)

3. 1 or 2

4. ("20191231" or 2020\* or 2021\* or 2022\*).up.

5. 3 and 4

**CINAHL**

|  |  |
| --- | --- |
| **Search ID#** | **Search Terms** |
| S26 | S11 AND S25 |
| S25 | S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 |
| S24 | TI ( (mental disorder\* or Quarantine\* or Self-isolation or isolation or social distanc\* or shelter\*-in-place or psych\* or mental health or mental illness\* or stigma or fear\* or anxiety or anxious or depression or depressive or loneliness or stress\* or trauma\* or post-traumatic or posttraumatic or anger or mood\* or irritability or irritable or emotional disturbance\* or grief or burned out or burnout) ) OR AB ( (mental disorder\* or Quarantine\* or Self-isolation or isolation or social distanc\* or shelter\*-in-place or psych\* or mental health or mental illness\* or stigma or fear\* or anxiety or anxious or depression or depressive or loneliness or stress\* or trauma\* or post-traumatic or posttraumatic or anger or mood\* or irritability or irritable or emotional disturbance\* or grief or burned out or burnout) ) |
| S23 | (MH "Burnout, Professional") |
| S22 | (MH "Grief+") |
| S21 | (MH "Anger") |
| S20 | (MH "Stress, Physiological") OR (MH "Stress, Psychological") |
| S19 | (MH "Depression") |
| S18 | (MH "Anxiety") |
| S17 | (MH "Fear") |
| S16 | (MH "Stigma") |
| S15 | (MH "Mental Health") or (MH "Mental Disorders") |
| S14 | (MH "Psychology") |
| S13 | (MH "Social Isolation") OR (MH "Loneliness") or (MH “Social Distancing”) or (MH “Stay at Home Orders”) † |
| S12 | (MH "Quarantine") |
| S11 | S7 OR S8 OR S9 OR S10 |
| S10 | ( (MH "Pneumonia+") or TI (pneumonia) OR AB (pneumonia) ) AND ( TI (wuhan) OR AB (wuhan) OR AF (wuhan) ) |
| S9 | TI ( (severe acute respiratory syndrome coronavirus 2 or "SARS CoV-2" or "SARSCoV 2" or SARSCoV2 or cov2 or "sars 2" or COVID or "coronavirus 2" or covid19 or nCov or ((new or Novel) N3 coronavirus\*) ) OR AB ( (severe acute respiratory syndrome coronavirus 2 or "SARS CoV-2" or "SARSCoV 2" or SARSCoV2 or cov2 or "sars 2" or COVID or "coronavirus 2" or covid19 or nCov or ((new or Novel) N3 coronavirus\*) ) or (MH “Covid 19”) † |
| S8 | TI ( (betacoronavirus\* or beta coronavirus\* or coronavirus\* or corona virus\*) ) OR AB ( (betacoronavirus\* or beta coronavirus\* or coronavirus\* or corona virus\*)) |
| S7 | S5 AND S6 |
| S6 | S1 OR S2 |
| S5 | S3 OR S4 |
| S4 | TI ( (china or chinese or hubei or wuhan) ) OR AB ( (china or chinese or hubei or wuhan) ) OR AF ( (china or chinese or hubei or wuhan) ) OR SO ( (china or chinese or hubei or wuhan) ) |
| S3 | (MH "China+") |
| S2 | TI ( (betacoronavirus\* or beta coronavirus\* or coronavirus\* or corona virus\*) ) OR AB ( (betacoronavirus\* or beta coronavirus\* or coronavirus\* or corona virus\*) ) |
| S1 | (MH "Coronavirus+") OR (MH "Coronavirus Infections+") |

**Web of Science**

TOPIC: (Quarantine\* or "Self-isolation" or isolation or "social distanc\*" or "shelter\*-in-place" or psych\* or "mental health" or "mental illness\*" or "mental disorder\*" or stigma or fear\* or anxiety or anxious or depression or depressive or loneliness or stress\* or trauma\* or "post-traumatic" or posttraumatic or anger or mood\* or irritability or irritable or "emotional disturbance\*" or grief or "burned out" or burnout) AND TOPIC: ((coronavirus\* or "corona virus\*" or betacoronavirus\* or "beta coronavirus\*" or "severe acute respiratory syndrome coronavirus 2" or "SARS CoV-2" or "SARSCoV 2" or SARSCoV2 or cov2 or "sars 2" or COVID or "coronavirus 2" or covid19 or nCov or "Novel coronavirus\*" or "new coronavirus\*"))

Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=Year to date

**China National Knowledge Infrastructure**

Restricted to disciplines: Medical and Public Health & Social science

TI=(隔离+封城+社交距离+方舱+心理+心理健康+精神卫生+精神疾病+心理疾病+污名+耻辱+羞辱+恐惧+焦虑+抑郁+孤独+压力+应激+创伤+创伤后+愤怒+情绪+心情+易怒+情绪障碍+心理障碍+哀伤+悲伤+悲痛+悲哀+忧郁+倦怠)\*(新冠+新型冠状) OR AB=(隔离+封城+社交距离+方舱+心理+心理健康+精神卫生+精神疾病+心理疾病+污名+耻辱+羞辱+恐惧+焦虑+抑郁+孤独+压力+应激+创伤+创伤后+愤怒+情绪+心情+易怒+情绪障碍+心理障碍+哀伤+悲伤+悲痛+悲哀+忧郁+倦怠)\*(新冠+新型冠状)

**Wanfang**

题名:("隔离"+封城+"社交距离"+方舱+心理+"心理健康"+"精神卫生"+"精神疾病"+"心理疾病"+污名+耻辱+羞辱+恐惧+焦虑+抑郁+孤独+压力+应激+创伤+"创伤后"+愤怒+情绪+心情+易怒+”情绪障碍"+"心理障碍”+哀伤+悲伤+悲痛+悲哀+忧郁+倦怠)\*("新冠"+"新型冠状")+摘要:("隔离"+封城+"社交距离"+方舱+心理+"心理健康"+"精神卫生"+"精神疾病"+"心理疾病"+污名+耻辱+羞辱+恐惧+焦虑+抑郁+孤独+压力+应激+创伤+"创伤后"+愤怒+情绪+心情+易怒+"情绪障碍"+"心理障碍"+哀伤+悲伤+悲痛+悲哀+忧郁+倦怠)\*("新冠"+"新型冠状")

We made several amendments to the original search strategies. Since the Wanfang database cannot export more than 5000 references at once, we broke the search strategies into two or more smaller search strings to get all the references. The four changes on September 1, 2020, September 28, 2020, October 15, 2020 and October 18, 2020 are all for this purpose.

To make this process more efficient, the disciplines of the China National Knowledge Infrastructure database were restricted to Medical and Public Health AND Social science subgroup 2 and those of Wanfang database were restricted to Medicine and Health AND Culture, Science, Education and PE disciplines on October 23, 2020.

September 1, 2020

**Wanfang**

题名:("隔离"+封城+"社交距离"+方舱+心理+"心理健康"+"精神卫生"+"精神疾病"+"心理疾病"+污名+耻辱+羞辱+恐惧+焦虑)\*("新冠"+"新型冠状")+摘要:("隔离"+封城+"社交距离"+方舱+心理+"心理健康"+"精神卫生"+"精神疾病"+"心理疾病"+污名+耻辱+羞辱+恐惧+焦虑)\*("新冠"+"新型冠状")

题名:("隔离"+封城+"社交距离"+方舱+抑郁+孤独+压力+应激+创伤+"创伤后"+愤怒+情绪+心情+易怒+"情绪障碍"+"心理障碍"+哀伤+悲伤+悲痛+悲哀+忧郁+倦怠)\*("新冠"+"新型冠状")+摘要:("隔离"+封城+"社交距离"+方舱+抑郁+孤独+压力+应激+创伤+"创伤后"+愤怒+情绪+心情+易怒+"情绪障碍"+"心理障碍"+哀伤+悲伤+悲痛+悲哀+忧郁+倦怠)\*("新冠"+"新型冠状")

September 28, 2020

**Wanfang**

题名:("隔离"+封城+"社交距离"+方舱+心理+"心理健康"+"精神卫生"+"精神疾病"+"心理疾病"+污名+耻辱+羞辱+恐惧+焦虑)\*("新冠"+"新型冠状")+摘要:("隔离"+封城+"社交距离"+方舱+心理+"心理健康"+"精神卫生"+"精神疾病"+"心理疾病"+污名+耻辱+羞辱+恐惧+焦虑)\*("新冠"+"新型冠状")

题名:("隔离"+封城+"社交距离"+方舱+抑郁+孤独+压力+应激+创伤+"创伤后")\*("新冠"+"新型冠状")+摘要:("隔离"+封城+"社交距离"+方舱+抑郁+孤独+压力+应激+创伤+"创伤后")\*("新冠"+"新型冠状")

题名:("隔离"+封城+"社交距离"+方舱+愤怒+情绪+心情+易怒+"情绪障碍"+"心理障碍"+哀伤+悲伤+悲痛+悲哀+忧郁+倦怠)\*("新冠"+"新型冠状")+摘要:("隔离"+封城+"社交距离"+方舱+愤怒+情绪+心情+易怒+"情绪障碍"+"心理障碍"+哀伤+悲伤+悲痛+悲哀+忧郁+倦怠)\*("新冠"+"新型冠状")

October 15, 2020

**Wanfang**

题名:("隔离"+封城+"社交距离"+方舱+心理+"心理健康"+"精神卫生"+"精神疾病"+"心理疾病")\*("新冠"+"新型冠状")+摘要:("隔离"+封城+"社交距离"+方舱+心理+"心理健康"+"精神卫生"+"精神疾病"+"心理疾病")\*("新冠"+"新型冠状")

题名:("隔离"+封城+"社交距离"+方舱+污名+耻辱+羞辱+恐惧+焦虑+抑郁+孤独+压力)\*("新冠"+"新型冠状")+摘要:("隔离"+封城+"社交距离"+方舱+污名+耻辱+羞辱+恐惧+焦虑+抑郁+孤独+压力)\*("新冠"+"新型冠状")

题名:("隔离"+封城+"社交距离"+方舱+应激+创伤+"创伤后"+愤怒+情绪+心情+易怒+"情绪障碍"+"心理障碍"+哀伤+悲伤+悲痛+悲哀+忧郁+倦怠)\*("新冠"+"新型冠状")+摘要:("隔离"+封城+"社交距离"+方舱+应激+创伤+"创伤后"+愤怒+情绪+心情+易怒+"情绪障碍"+"心理障碍"+哀伤+悲伤+悲痛+悲哀+忧郁+倦怠)\*("新冠"+"新型冠状")

October 18, 2020

**Wanfang**

题名:("隔离"+封城+"社交距离"+方舱+心理+"心理健康"+"精神卫生"+"精神疾病"+"心理疾病")\*("新冠"+"新型冠状")+摘要:("隔离"+封城+"社交距离"+方舱+心理+"心理健康"+"精神卫生"+"精神疾病"+"心理疾病")\*("新冠"+"新型冠状")

题名:("隔离"+封城+"社交距离"+方舱+污名+耻辱+羞辱+恐惧+焦虑+抑郁)\*("新冠"+"新型冠状")+摘要:("隔离"+封城+"社交距离"+方舱+污名+耻辱+羞辱+恐惧+焦虑+抑郁)\*("新冠"+"新型冠状")

题名:("隔离"+封城+"社交距离"+方舱+孤独+压力)\*("新冠"+"新型冠状")+摘要:("隔离"+封城+"社交距离"+方舱+孤独+压力)\*("新冠"+"新型冠状")

题名:("隔离"+封城+"社交距离"+方舱+应激+创伤+"创伤后"+愤怒+情绪+心情+易怒+"情绪障碍"+"心理障碍"+哀伤+悲伤+悲痛+悲哀+忧郁+倦怠)\*("新冠"+"新型冠状")+摘要:("隔离"+封城+"社交距离"+方舱+应激+创伤+"创伤后"+愤怒+情绪+心情+易怒+"情绪障碍"+"心理障碍"+哀伤+悲伤+悲痛+悲哀+忧郁+倦怠)\*("新冠"+"新型冠状")

October 23, 2020

**China National Knowledge Infrastructure**

Restricted to disciplines: Medical and Public Health & Social science subgroup 2

TI=(隔离+封城+社交距离+方舱+心理+心理健康+精神卫生+精神疾病+心理疾病+污名+耻辱+羞辱+恐惧+焦虑+抑郁+孤独+压力+应激+创伤+创伤后+愤怒+情绪+心情+易怒+情绪障碍+心理障碍+哀伤+悲伤+悲痛+悲哀+忧郁+倦怠)\*(新冠+新型冠状) OR AB=(隔离+封城+社交距离+方舱+心理+心理健康+精神卫生+精神疾病+心理疾病+污名+耻辱+羞辱+恐惧+焦虑+抑郁+孤独+压力+应激+创伤+创伤后+愤怒+情绪+心情+易怒+情绪障碍+心理障碍+哀伤+悲伤+悲痛+悲哀+忧郁+倦怠)\*(新冠+新型冠状)

**Wanfang**

Restricted to disciplines: Medicine and Health & Culture, Science, Education and PE

题名:("隔离" or 封城 or "社交距离" or 方舱 or 心理 or "心理健康" or "精神卫生" or "精神疾病" or "心 理疾病" or 污名 or 耻辱 or 羞辱 or 恐惧 or 焦虑 or 抑郁 or 孤独 or 压力 or 应激 or 创伤 or "创伤后" or 愤怒 or 情绪 or 心情 or 易怒 or "情绪障碍" or "心理障碍" or 哀伤 or 悲伤 or 悲痛 or 悲哀 or 忧郁 or 倦怠) and ("新冠" or "新型冠状") or 摘要:("隔离" or 封城 or "社交距离" or 方舱 or 心理 or "心理健康" or "精神卫生" or "精神疾病" or "心理疾病" or 污名 or 耻辱 or 羞辱 or 恐惧 or 焦虑 or 抑郁 or 孤独 or 压力 or 应激 or 创伤 or "创伤后" or 愤怒 or 情绪 or 心情 or 易怒 or "情绪障碍" or "心理障碍" or 哀伤 or 悲伤 or 悲痛 or 悲哀 or 忧郁 or 倦怠) and ("新冠" or "新型冠状")

**MedRxiv (pre-prints)**

Search 1: (isolation OR “mental health” OR “mental illness” OR “mental disorder”) AND (COVID OR covid19)

Search 2: (psychology OR psychological OR psychosocial OR anxiety OR depression OR stress or trauma) AND (COVID OR covid19)

**Open Science Framework (pre-prints)**

(isolation OR psychology OR psychological OR psychosocial OR “mental health” OR “mental illness” OR “mental disorder” OR anxiety OR depression OR stress or trauma) AND (coronavirus OR COVID OR covid19)

**Supplementary Material 2: Inclusion and Exclusion Coding Guides for Main Changes Review Plus Additional Criteria for Present Report**

Title and Abstract Review:

**Exclude: not original human data or a case study or case series. If it is clear from the title and abstract that the article is not an original report of primary data, but, for example, a letter, editorial, systematic review or meta-analysis, or it is a single case study or case series, then it is excluded. Studies reporting only on animal, cellular, or genetic data are also excluded. Conference abstracts are included.**

**Exclude: not a study of any population affected by the COVID-19 outbreak. If it is clear from the title or abstract that the study is not about any population affected by the COVID-19 outbreak, it is excluded. Studies that include fewer than 100 participants, are excluded. If a longitudinal study has baseline sample size with at least 100 participants, but no follow-up with at least 100 participants, then we exclude the study (and document); if its baseline and at least one follow-up have more than 100 participants, we include the study.**

**Exclude: not a study which reports mental health symptom changes longitudinally pre-COVID-19 to COVID-19 or during COVID-19. If it is clear from the title or abstract that the study does not report proportions of participants meeting diagnostic criteria using a validated diagnostic interview or validated mental health scale, or proportions of symptoms (based on a threshold or measured continuously) prior to and after the start of COVID-19, or longitudinally during COVID-19, then it will be excluded.**

**For pre-COVID versus during-COVID studies, pre- and during- samples must include the same cohort, not different representative samples. Pre- and during-samples should have less than 10% difference in the participants in the sample\* or should statistically account for missing data, i.e., if N between the samples differs by more than 10%, modelling or imputation is needed to evaluate results for all participants. Pre-COVID data needs to be collected prior to 2020 (or at least 80% of the participants’ data need be collected prior to 2020 if collection spans from 2019 to 2020) and after 2018(or at least 80% of the participants’ data need to be collected after 2018 if collection spans from pre-2018 to 2018).**

For studies with multiple waves across COVID, if there are pre-pandemic time points, the most recent pre-pandemic wave needs to be in 2018 or later; if the most recent pre-pandemic wave spans from pre-2018 to 2018, at least 80% of the data need to be collected in 2018. Studies with multiple waves across COVID-19 must have at least two time points that have less than 10% difference in the participants in the sample\*, or should statistically account for missing data, regardless of whether or not the study has pre-COVID assessments. If outcomes from the study are only shown graphically without eligible numerical values, exclude the study. At least 90% of participants in assessments from two time points need to be the same participants. In a three-wave survey, if N-T1 = 1000, N – T2 = 500, and N – T3 = 500, T2 and T3 would only be eligible if at least 90% of the participants at each time point were the same. It is not enough to just have a total N within 10%.

**Include: study eligible to be included in full-text review.**

Full-text Review:

**Exclude: not original human data or a case study or case series. If the article is not an original report of primary data, but, for example, a letter, editorial, systematic review or meta-analysis, or it is a single case study or case series, then it is excluded. Studies reporting only on animal, cellular, or genetic data are also excluded. Conference abstracts are included.**

**Exclude: not a study of any population affected by the COVID-19 outbreak. If it is clear from the full text that the study is not about any population affected by the COVID-19 outbreak, it is excluded. Studies that include fewer than 100 participants, are excluded. If a longitudinal study has baseline sample size with at least 100 participants, but no follow-up with at least 100 participants, then we exclude the study (and document); if its baseline and at least one follow-up have more than 100 participants, we include the study.**

**Exclude: not a study which reports mental health symptom changes longitudinally pre-COVID-19 to COVID-19 or during COVID-19. If it is clear from the title or abstract that the study does not report continuous scores of symptom levels or proportions of participants meeting the threshold on a validated scale, or diagnostic criteria using a validated diagnostic interview prior to and after the start of COVID-19, or longitudinally during COVID-19, then it will be excluded.**

For pre-COVID versus during-COVID studies, pre- and during- samples must include the same cohort, not different representative samples. Pre- and during-samples should have less than 10% difference in the participants in the sample\* or should statistically account for missing data, i.e., if N between the samples differs by more than 10%, modelling or imputation is needed to evaluate results for all participants. Pre-COVID data needs to be collected prior to 2020 (or at least 80% of the participants’ data need be collected prior to 2020 if collection spans from 2019 to 2020) and after 2018 (or at least 80% of the participants’ data need to be collected after 2018 if collection spans from pre-2018 to 2018).

For studies with multiple waves across COVID, if there are pre-pandemic time points, the most recent pre-pandemic wave needs to be in 2018 or later; if the most recent pre-pandemic wave spans from pre-2018 to 2018, at least 80% of the data need to be collected in 2018. Studies with multiple waves across COVID-19 must have at least two time points that have less than 10% difference in the participants in the sample, or should statistically account for missing data, regardless of whether or not the study has pre-COVID assessments. If outcomes from the study are only shown graphically without eligible numerical values, exclude the study

**Include: study eligible for inclusion in systematic review.**

**Additional Criterion for Present Report: (1) Eligible pre-COVID-19 assessments had to be done** between January 1, 2018 and December 31, 2019; (2) Only studies that compared pre-COVID-19 and COVID-19 assessments were included but not studies with longitudinal data only during COVID-19.

**Supplementary Material 3: Risk of Bias and Adequacy of Study Methods and Reporting**

**Q1. Was the sample frame appropriate to address the target population?**

**Yes: The sampling frame was a true or close representation of the target population.**

**No: The sampling frame was NOT a true or close representation of the target population.**

**Unclear: Not enough information provided to determine.**

**Q2. Were study participants recruited in an appropriate way?**

**Yes:** A census was undertaken, OR, some form of random selection was used to select the sample (e.g. simple random sampling, stratified random sampling, cluster sampling, systematic sampling).

**No:** A census was NOT undertaken, AND some form of random selection was NOT used to select the sample.

**Unclear:** Not enough information provided to determine.

**Q3. Was the sample size adequate?**

**Yes:** There is evidence that the authors conducted a sample size calculation to determine an adequate sample size OR the study was large enough (e.g., a large national survey) whereby a sample size calculation is not required. In these cases, sample size can be considered adequate. If at least 200 participants are included for continuous outcomes and 250 for proportions, this is considered low risk.

**No:** The authors did not reach their intended sample size, or no sample size calculation is provided and there are < 100 participants for continuous outcomes, or < 125 for proportions.

**Unclear:** No sample size calculation is provided, and between 100-199 participants are included for continuous outcomes or between 125-249 for proportions.

**Q4. Were the study participants and setting described in detail?**

**Yes:** Data included age, sex, and at least 1 socioeconomic indicator (e.g., income, education, work status).

**No:** The minimum sociodemographic variables have not been reported.

**Unclear:** Not stated

**Q5. Was the response rate adequate and was the data analysis conducted with sufficient coverage?**

**Yes:** The overall response rate or response rate for intended subgroups was >/=75%, OR, an analysis was performed that established that there was not a substantive difference in relevant demographic characteristics between responders and non-responders within a subgroup (if non-response too high (e.g., > 50%), code “No”)

**No:** The overall response rate or response rate for subgroups was <75%, and if any analysis comparing responders and non-responders was done, it showed a meaningful difference in relevant demographic characteristics between responders and non-responders.

**Unclear:** Not enough information provided to determine.

**Q6. Were valid methods used for the identification of the outcome variable?**

**Yes:** The study instrument had been shown to have reliability and validity, e.g., test-retest, piloting, validation in a previous study, etc.

**No:** The study instrument had NOT been shown to have reliability or validity.

**Unclear:** Not stated.

**Q7. Was the mental health outcome measured in a standard, reliable way for all participants?**

**Yes:** All self-report data were collected directly from the participants. Any clinical interview data includes at least information about the interviewers’ level of education or training received. The same mode of data collection was used for all participants. All aspects of this question must be present (where relevant).

**No:** In some instances, data were collected from a proxy (e.g., a spouse). The qualifications of clinical interviewers are not reported or not appropriate. The same mode of data collection was NOT used for all participants. If any aspects of this item are absent, it is high risk.

**Unclear**: Not stated.

**Q8. Was there appropriate statistical analysis?**

**Yes:** Continuous variables report (1) mean (SD) of change or (2) pre mean (SD) and post mean (SD) with/out correlation between pre and post scores. For dichotomous variables, numerator, denominator, and percentages are clearly reported. Continuous variables are not artificially dichotomized. The statistical analyses section is detailed enough for readers to understand change scores (see STROBE reporting guidelines, if necessary).

**No:** Continuous variables do not include a report of the (1) mean (SD) of change or (2) pre mean (SD) and post mean (SD) with/out correlation between pre and post scores. For dichotomous variables, the numerator, denominator, or percentages are not clearly reported. The statistical analyses section does not clearly describe the methods used to assess change scores.

**Q9. Was the follow-up rate adequate, and if not, was the low follow-up rate managed appropriately?**

**Yes:** At least 75% of those who participated in the pre-COVID-19 assessment(s) provided follow-up responses and had their responses included in the follow-up, OR, an analysis was performed that showed no substantive difference in relevant demographic characteristics between participants who stayed in the study and drop-outs (if dropout too high (e.g. > 50%), code “No”).

**No:** Less than 75% of those participated in the pre-COVID-19 assessment(s) provided responses and had their responses included in the follow-up, and if any analysis comparing participants who stayed in the study and drop-outs was done, it showed a substantive difference in relevant demographic characteristics between the two groups.

**Unclear:** Not stated.

**Supplementary Table 1. Characteristics of unique studies (N=137) from included cohorts (N=134)a**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **First Author** | **Outcome Domains** | | | **Description of Participants** | **Country(ies) of Participants** | **Pre- and Post-COVID-19 Data Collection** | **N Participants** | **Participant Age** | **% Female or Women** |
| **General Mental Health** | **Anxiety Symptoms** | **Depression Symptoms** | **Mean (SD) or % in Range of Years** |
| **General Population** | | | | | | | | | |
| BulbuliaS1 | K6 |  |  | Convenience sample of adults aged 18 to 65 from the New Zealand Attitudes and Values Study (NZAVS) | New Zealand | NR/2018 | 940 | 52 (13) | 65% |
|  |
| 03-04/2020 |
| CastelliniS2 | BSI-GSI |  |  | Convenience sample of adults aged 18 to 60 years recruited via “convenience and snowballing” methods | Italy | 12/2019 | 130 | 34 (14)b | 75% |
|  |
| 04-05/2020 |
| ChanS3 |  | HAI |  | Convenience sample of adults based in Hong Kong and participated in a previous study prior to the pandemic | Hong Kong, China | 07/2019 | 279 | 27 (9) | 74% |
|  |
| 07/2020 |
| FinucaneS4 | K6 |  |  | Participants from the Pittsburgh Hill/Homewood Research on Neighborhood Changes and Health study | USA | 05-09/2018 | 419 | 62 (14) | 82% |
|  |
| 06-09/2020 |
| GeS5 |  | GAD-7 | PHQ-9 | Convenience sample of adults recruited from the WeChat of China online social media platform | China | 01-12/2019 | 1,547-1,978 | Anxiety sample = 30 (10); Depression sample = 33 (11) | Anxiety sample: 29; Depression sample: 26 |
|  |
| 02-03/2020 |
| HaliwaS6 |  | Sample 1: GAD-7 Sample 2: DASS-21-Anxiety Sample 3: GAD-7 | Sample 1:PHQ-8 Sample 2: DASS-21-Depression Sample 3: PHQ-8 | U.S. residents recruited through Amazon’s Mechanical Turk | USA | 09-12/2019 | Sample 1: 300; Sample 2: 146; Sample 3: 142 | Sample 1: 41 (12); Sample 2: 44 (13); Sample 3: 41 (13) | Sample 1: 59; Sample 2: 53; Sample 3: 50 |
|  |
| 04-06/2020 |
| KanburS7 | SCL-90-R | SCL-90-R Anxiety | SCL-90-R Depression | Turkish office workers who were enrolled in another study before the pandemic | Turkey | NR/2019 | 400 | NR | NR |
|  |
| NR/2020 |
| Katz, BS8 | RRQ | DASS-21 Anxiety | DASS-21 Depression | Convenience sample of adults recruited via an online crowdsourcing research platform | Canada, Ireland, UK, USA | 04/2019 | 218 | 43 (13) | 54% |
| DToS |  |
|  | 04/2020 |
| LatikkaS9 | GHQ-12 |  |  | Participants from the Social Media at Work in Finland Survey | Finland | 09-10/2019 | 840 | 44 (11) | 44% |
|  |
| 03-04/2020 |
| Megias-RoblesS10 | PANAS-NA |  |  | Convenience sample of participants recruited from an adult community sample | Spain | 11/2019 | 102 | 30 (13) | 66% |
|  |
| 04/2020 |
| PierceS11 | GHQ-12 |  |  | National probability-based sample of adults aged ≥ 18 years (United Kingdom Household Longitudinal Study) | UK | Pre-COVID-19 wavesc | 15,376S11,d  10,918S12 | 18-34 (12)e | 47%S11 58%S12 |
| DalyS12 |  | 35-49 (22)e |
|  | 04-09/2020 | 50-64 (34)e |
|  |  | 65+ (32)e |
| ShimuraS13 | BJSQ (Psychological and Physical) |  |  | Convenience sample of office workers who started remote work in 2020 | Japan | NR/2019 | 3,123 | 37 (11) | 43% |
|  |
| NR/2020 |
| SoltanzadehS14 | GHQ-28 |  |  | Employees of three oil refineries in southern Iran who had at least 1 year of work experience | Iran | 11/2019 | 823-850 | 35 (13) | 19% |
|  |
| 07/2020 |
| ThygesenS15 | SWEMWBS |  |  | Participants from Danish Health and Wellbeing Survey | Denmark | 09-12/2019 | 4,234 | Age range (%): 15-44 (27); 45-59 (30); 60-74 (33); 75+ (10) | 58% |
|  |
| 09-11/2020 |
| van der VeldenS16 | MHI-5 |  |  | National probability-based sample of adults aged ≥ 18 years (Longitudinal Internet Studies for the Social Sciences) | The Netherlands | 03/2019 | 3,983 | 18-34 (25)f | 51% |
| van der VeldenS17 | 11-12/2019 | 4,064 | 35-49 (23)f |
|  |  |  | 50-64 (26)f |
|  | 03/2020 |  | 65+ (26)f |
|  | 11-12/2020 |  |  |
| WanbergS18 |  |  | PHQ-8 | Individuals aged 30 to 80 years from the RANT American Life Panel | USA | 04-06/2019 | 1,143 | 53 (14) | 56% |
|  |
| 04/2020 |
| **Older Adults** | | | | | | | | | |
| BartlettS19 |  | HADS-A | HADS-D | Adults aged ≥ 50 years from the Island Study Linking Ageing and Neurodegenerative Disease | Australia | 10/2019 | 1,671 | 63 (7) | 73% |
|  |
| 04-06/2020 |
| BriggsS20 |  |  | CES-D-8 | Nationally representative sample of community-dwelling older adults aged ≥ 50 years who took part in the Irish Longitudinal Study on Ageing (TILDA) | Ireland | NR/2018 | 3,490 | 70 (14) | 56% |
|  |
| 07-11/2020 |
| CreeseS21 |  | GAD-7 | PHQ-9 | National convenience sample of adults aged ≥ 50 years recruited via publicity | UK | 10/2019 | 3,281 | 67 (7) | 80% |
|  |
| 05-06/2020 |
| EliasenS22 | WHOQOL-BREF |  |  | Participants from the Faroese Septuagenarians cohort | Denmark | 12/2017-01/2019g | 227 | 84 (1) | 52% |
| WHOQOL-BREF (psychological health) |  |
| 06-07/2020 |
| HerreraS23 |  | GAI-SF | PHQ-9 | Participants from the V National Survey on Quality of Life in Older Adults | Chile | 11/2019 | 721 | 72 (NR) | 70% |
|  |
| 09/2020 |
| KeraS24 | WHO-5-J |  |  | Community-dwelling older adults living in Itabashi Ward, Tokyo, who had participated in the Otassha Study | Japan | 09-10/2019 | 533 | 73 (6) | 62% |
|  |
| 06-07/2020 |
| KiviS25 | SWLS |  |  | “Nationally representative” sample of older adults born 1949 to 1955 | Sweden | NR/2019 | 1,071 | 68 (2) | 47% |
|  |
| 03-04/2020 |
| LeeS26 |  |  | PHQ-9 | Participants from the PopulatiON HEalth and Eye Disease PRofile in Elderly Singaporeans study | Singapore | 12/2017-11/2019g | 496 | 74 (8) | 55% |
|  |
| 05-06/2020 |
| MartínezS27 | PWBS |  | CES-D | Community-dwelling older adults aged 65 to 87 years | Spain | 10/2019 | 141 | 73 (5) | 60% |
| PERMA - PA |  |
| PERMA - NA | 04/2020 |
| OkelyS28 | WEMWBS |  |  | Surviving members of cohort of all children born in 1936 and attending school in Scotland in 1947 | Scotland (UK) | NR/2017-NR/2019g | 137 | 84 (NR) | 48% |
|  |
| 05-06/2020 |
| RentscherS29 |  | STAI-State | CES-D | Women aged ≥ 60 years who were nonmetastatic breast cancer survivors | USA | 02-06/2019 | 262 | 68 (5) | 100% |
|  |
| 05-09/2020 |
| RentscherS29 |  | STAI-State | CES-D | Women aged ≥ 60 years who were matched controls | USA | 02-06/2019 | 165 | 68 (6) | 100% |
|  |
| 05-09/2020 |
| SardellaS30 | SF-12 Mental Component Summary |  |  | Participants aged ≥ 65 | Italy | 10/2018-10/2019 | 104 | 80 (7) | 70% |
|  |
| 04/2020 |
| SiewS31 | WHOQOL-AGE | GAI-SF |  | Participants from the Community Health and Intergenerational study | Singapore | 02/2018-01/2020h | 411 | 69 (6) | 65% |
|  |
| 05-06/2020 |
| van den BesselaarS32 |  | HADS-A | CES-D-10 | Participants from the Longitudinal Aging Study Amsterdam | The Netherlands | NR/2018-2019 | 984-1,068 | 74 (8) | 53% |
|  |
| 06-10/2020 |
| van TilburgS33 | MHI-5 |  |  | National probability-based sample of adults aged ≥ 65 years (Longitudinal Internet Studies for the Social Sciences) | The Netherlands | 10-11/2019 | 1,679 | 73 (NR) | 49% |
|  |
| 05/2020 |
| Wang, YiS34 | K10 |  |  | Adults aged ≥ 60 years who were part of the Shandong Rural Elderly Health Cohort (SREHC) | China | 05-06/2019 | 2,745 | Median (Age range): 70 (60-100) | 64% |
|  |
| 08-09/2020 |
| Wong, SS35 |  | GAD-7 | PHQ-9 | Adults aged ≥ 60 with ≥ 2 chronic medical conditions from 4 primary care clinics | Hong Kong, China | 04/2018-03/2019 | 583 | 71 (6) | 73% |
|  |
| 03-04/2020 |
| YuS36 |  | GAI | GDS | Individuals aged 60 to 99 years living in the western region of Singapore | Singapore | 02/2018-01/2020h | 419 | 69 (6) | 66% |
|  |
| 05-06/2020 |
| **Young Adults** | | | | | | | | | |
| IslamS37 | K10 |  |  | Individuals aged 20 to 21 who took part in the Longitudinal Study of Australian Children (LSAC) survey | Australia | NR/2018 | 1,110 | 21 (0) | 59% |
|  |
| 10-12/2020 |
| MarmetS38 |  |  | MDI | Swiss adult men who enrolled in a longitudinal cohort in 2010-2011 during medical evaluation for mandatory military service | Switzerland | 04/2019-02/2020h | 2,345 | 29 (13) | 0% |
|  |
| 05-06/2020 |
| RimfeldS39 |  | SMGAD-A | SMFQ | Adult twins born 1994-1996 who were enrolled in a longitudinal cohort at age 18 months | UK | NR/2018 | 3,563-3,694 | 24-26 (100%) | 63% |
|  |
| 04-05/2020 |
| RommS40 |  |  | PHQ-2 | Adults aged 18 to 34 years in one of the six metropolitan statistical areas who participated in the Vape Shop Advertising, Place characteristics and Effects Surveillance study | USA | 09/2019 | 1,082 | 25 (5) | 51% |
|  |
| 03/2020 |
| TaniokaS41 | K6-J |  |  | Participants aged 15 to 30 years who took part in a comprehensive prospective research project on sleep behavior, sleep problems, psychological distress, and quality of life in young adults | Japan | 10/2019 | 2,222 | 21 (4) | 76% |
| SF-8 - MCS |  |
|  | 05/2020 |
| VilladsenS42 | K6 |  |  | Participants from the Millennium Cohort Study who were born in 2001 | UK | NR/2018 | 1,615 | Range: 19-20 | NR |
|  |
| 05/2020 |
| Watkins-MartinS43 |  | GAD-7 | CES-D-12 | Participants born in 1997-98 in Quebec, Canada who participated in the Québec Longitudinal Study of Child Development | Canada | NR/2018 | 1,039 | 22 (NR) | 60% |
|  |
| 08/2020 |
| **University Students** | | | | | | | | | |
| ConceiçãoS44 |  | GAD-7 | PHQ-9 | First-year students at the University of Porto | Portugal | 10/2019 | 341 | 20 (2) | 75% |
|  |
| 06/2020 |
| DongS45 | SCL-90-R |  |  | First-year undergraduate students from a single university recruited online | China | 09/2019 | 4,085-4,341 | 19 (1) | 77% |
|  |
| NR/2020 |
| ElmerS46 |  | GAD-7 | CES-D | Undergraduate students in engineering and natural sciences from a single university recruited by email invitation | Switzerland | 09/2019 | 209 | NR | 22% |
|  |
| 04/2020 |
| EvansS47 | WEMWBS | HADS-A | HADS-D | First or second year undergraduate psychology students | UK | 10/2019 | 254 | 20 (1) | 86% |
|  |
| 05/2020 |
| Fuller-RowellS48 |  |  | BDI-II | Undergraduate students at a four-year university in the southeastern United States | USA | 09/2018-04/2019 | 263 | 19 (1) | 53% |
|  |
| 04-06/2020 |
| GelezelyteS49 |  | DASS-21 Anxiety | DASS-21 Depression | First-year university students | Lithuania | 10-12/2019 | 474 | 19 (1) | 76% |
|  |
| 10-12/2020 |
| GopalanS50 |  | CCAPS-62 - Anxiety | CES-D-10 | Undergraduate students from a large, multicampus public university | USA | 11/2019 | 1,004 | 19 (1) | 62% |
|  |
| 05/2020 |
| HamzaS51 |  | GAD-7 | CES-D-R | Undergraduate students from single university recruited by email invitation | Canada | 05/2019 | 733 | 19 (1) | 74% |
|  |
| 05/2020 |
| HeS52 |  | STAI-Trait |  | Individuals who took part in the Behavioral Brain Research Project of Chinese Personality | China | 09-12/2019 | 589 | 19 (1) | 71% |
|  |
| 02/2020 |
| KoelenS53 |  | GAD-7 | CES-D | Students at the University of Amsterdam | The Netherlands | 01/2019-01/2020h | 671-683 | 23 (6) | 70% |
|  |
| 04-05/2020 |
| Li, HS54 | PHQ-4 |  |  | Undergraduate students from a single university enrolled in an ongoing longitudinal study | China | 12/2019 | 555 | 20 (3) | 77% |
| PANAS-PA |  |
| PANAS-NA | 02/2020 |
| Li, RS55 | SCL-90-R |  |  | Undergraduate students from multiple universities in Szechuan province recruited online | China | 09/2019 | 2,603 | NR | 53% |
|  |
| 04/2020 |
| Li, Wendy WenS56 |  | DASS-21 Anxiety | DASS-21 Depression | Undergraduate students from single university recruited by email invitation | China | 11/2019 | 173 | 20 (1) | 78% |
|  |
| 03/2020 |
| LiuS57 |  |  | PHQ-9 | First-year students of two medical universities located in three cities (Jining, Weifang, Rizhao) | China | 04-10/2018-04-10/2019 | 5,373-8,079 | 18 (1) | 60% |
| CIDI 3.0 |  |
|  | 09-10/2020 |
| LuS58 |  | GAD-7 | PHQ-9 | Students from Chinese Undergraduate Cohort study | China | 09-10/2019 | 5,181 | 14-17: 0.5%; 18-24: 99.5% | 62% |
|  |
| 04/2020 |
| MauerS59 |  | DASS-21 |  | Undergraduate students from 11 American universities | USA | 09-12/2019 | 1,434 | 20 (1) | 76% |
|  |
| 03-06/2020 |
| MehusS60 |  | GAD-7 | PHQ-9 | First year college students aged 18 to 23 years | USA | 08,12/2019 | 727 | 18 (94%)  19 (6%) | 64% |
|  |
| 04/2020 |
| RatnerS61 |  |  | BDI-II | Fourth-year university students from Cornell University | USA | 09/2019 | 152 | 21 (1) | 72% |
|  |
| 04/2020 |
| SaraswathiS62 |  | DASS-21 Anxiety | DASS-21 Depression | Convenience sample of undergraduate university medical students | India | 12/2019 | 217 | 20 (2) | 64% |
|  |
| 06/2020 |
| Savage, 2020S63,i | WEMWBS |  |  | Undergraduate students from single university recruited by email invitation and enrolled in an ongoing longitudinal study | UK | 10/2019 | 214 | 18-21 (64) | 72% |
|  | 22-25 (22) |
| 04/2020 | 26-35 (8) |
|  | 35+ (6) |
| Savage, 2021S64,i | WEMWBS |  |  | Undergraduate students from single university recruited by email invitation and enrolled in an ongoing longitudinal study | UK | 10/2019 | 255 | 18 (0)  19 (16)  20 (28)  21 (26)  22-25 (20)  26-35 (8)  35+ (2) | 76% |
|  |
| 10/2020 |
| ShiratoriS65 |  |  | PHQ-9 | Students enrolled at the University of Tsukuba | Japan | NR/2019 | 6,847 | 23 (6) | 41% |
|  |
| 06/2020 |
| Truskauskaite-KunevicieneS66 | PMH | DASS-21 - Anxiety | DASS-21 - Depression | Emerging adults studying at a large university in the Ruhr region (Germany) or Vilnius (Lithuania) | Lithuania Germany | 10-12/2019 | Lithuania: 450; Germany: 325 | Lithuania: 19 (1);  Germany: 23 (3) | Lithuania: 79; Germany: 78 |
|  |
| 03-04/2020 |
| VoltmerS67 |  | BSI-18 Anxiety | BSI-18 Depression | Students attending the University of Lübeck | Germany | NR/2019 | 890 | 24 (3) | 79% |
|  |
| 06/2020 |
| Wang, YitaoS68 | SCL-90-R | SCL-90-R Anxiety | SCL-90-R Depression | First-year students at a medical university | China | 11/2019 | 2,559 | NR | NR |
|  |
| 06/2020 |
| Yang, XS69 |  |  | CES-D | First-year students at Wenzhou Medical University in Zhejiang province | China | 12/2018 | 195 | NR | 59% |
|  |
| 06/2020 |
| Yang, ZiyanS70 |  | DASS-21 Anxiety | DASS-21 Depression | College students from Zhejiang Ocean University | China | 10/2019 | 2,364 | 20 (1) | 54% |
|  |
| 05/2020 |
| ZimmermanS71 |  | GAD-7 | PHQ-9 | Undergraduate students at a single university enrolled in a mental health prevention program study | USA | 08/2019 | 205 | 18 (1) | 76% |
|  |
| 04/2020 |
| **Children and Adolescents** | | | | | | | | | |
| AchterbergS72 | SDQ-Internalizing Behaviors |  |  | Children aged 10 to 13 years who enrolled in a longitudinal twin study in 2015-2016 | The Netherlands | 01-11/2019 | 151 | 12 (1) | 47% |
| SDQ-Externalizing Behaviors |  |
|  | 04-05/2020 |
| AdachiS73 |  |  | PHQ-A | Fourth to seventh graders from the Assessment of Preschool to Adolescence—Longitudinal Epidemiological study | Japan | 09/2019 | 4,118-4,126 | Range: 9-12 | 50% |
|  |
| 07/2020 |
| BadoS74 | SDQ - Total score |  |  | Primarily adolescents from the Brazilian High-Risk Cohort for Mental Conditions | Brazil | NR/2018-2019 | 672 | Mean: 19  Range: 16-24 | 53% |
| SDQ - Emotion subscale |  |
|  | 04/2020-04/2021 |
| BernascoS75 | RCADS - Parent  RCADS - Adolescents |  |  | Urban young adolescents in their final year of primary school | The Netherlands | 09-12/2019 | 245 | 12 (1) | 50% |
|  |
| 04-07/2020 |
| BoschS76 | SDQ - Emotion Symptoms SDQ - Total |  |  | Students in secondary education from INSchool study | Spain | NR/2019 | 552 | 15 (1) | 61% |
|  |
| 05-06/2020 |
| CharmaramanS77 |  |  | CES-D-R-10 | Students in grades 6 to 9 in two school districts in northeastern United States | USA | NR/2019 | 586 | 14 (1) | 53% |
|  |
| 10-12/2020 |
| Chen, I-HS78 | DASS-21 |  |  | Primary school students | China | 10-11/2019 | 535 | 10 (1) | 50% |
|  |
| 03/2020 |
| Chen, C-YS79 | DASS-21 | DASS-21 - Anxiety | DASS-21 - Depression | Schoolchildren in grades 3 to 6 enrolled in 3 primary schools in Sichuan province | China | 10-11/2019 | 575 | 11 (1) | NR |
|  |
| 01/2020 |
| DaniunaiteS80 | SDQ - Emotional Symptoms |  |  | Adolescents aged 12 to 16 years from the Stress and Resilience in Adolescence study | Lithuania | 03-05/2019 | 331 | 14 (2) | 57% |
|  |
| 09-10/2020 |
| EzpeletaS81 | SDQ-total Parent Version |  |  | Families of children who were enrolled in a longitudinal cohort at age 3 (parents responded to measure of child mental health) | Spain | NR/2019 | 197 | 14 (0) | 52% |
|  |
| 06/2020 |
| FujiharaS82 | K6 |  |  | Japanese junior high school students | Japan | 12/2019 | 1,854 | NR | 51% |
|  |
| 02/2020 |
| HuS83 | SDQ - Emotion Problems |  |  | Adolescents aged 10 to 16 years who took part in the Understanding Society survey | UK | NR | 886 | 13 (1) | 52% |
|  |
| 07/2020 |
| KnowlesS84 | SDQ score | GAD-7 | SMFQ | Adolescents recruited from twelve local secondary schools. Participants were part of the Resilience, Ethnicity, and AdolesCent Mental Health cohort study | UK | NR/2018-2019 | 1,047 | Range: 12-18 | 55% |
|  |
| 05-08/2020 |
| Li, YS85 |  | ZSAS | BDI-II | Students aged 14 to 19 years from three public commuter secondary vocational schools in Southern China province | China | 12/2019 | 831 | 16 (1) | 61% |
|  |
| 03/2020 |
| LiaoS86 |  |  | CES-DC | Students from 3 junior high schools in Sichuan province | China | 12/2019 | 2,496 | 13 (1) | 50% |
|  |
| 07/2020 |
| MagsonS87 |  | SCAS | SMFQ | Adolescents aged 13 to 16 years who were enrolled in a longitudinal cohort 4 years prior | Australia | NR/2019 | 248 | 14 (1) | 51% |
|  |
| 05/2020 |
| MastorciS88 | KIDSCREEN-52 (psychological wellbeing) |  |  | Students aged 10 to 14 years | Italy | 09-10/2019 | 1,019 | 13 (1) | 52% |
|  |  |
| KIDSCREEN-52 (mood/emotion) | 04/2020 |
| MeirelesS89 | KIDSCREEN-10 |  |  | Adolescents aged 12 to 16 years who attended schools in the north of Portugal | Portugal | 04-07/2019 | 1,099 | 13 (1) | 53% |
|  |
| 05-06/2020 |
| NaumannS90 |  |  | STDS | Adolescents and young adults from the German Family Panel Pairfam study | Germany | 11/2018-07/2019 | 854 | Range: 16-19 | 58% |
|  |
| 05-07/2020 |
| PaizanS91 | SWLS |  |  | 6th to 10th graders in schools with a high proportion of ethnic minorities | Germany | 06-10/2019 | 226 | 14 (1) | 56% |
|  |
| 05-07/2020 |
| PolackS92 |  |  | CDI-S | Individuals aged 9 to 15 years | USA | 01-09/2019 | 112 | 13 (2) | 55% |
|  |
| 03-06/2020 |
| RauS93 | KIDSCREEN-10 | RCADS - Anxiety | RCADS - Depression | 5th to 11th graders from 3 German schools | Germany | 10-11/2019 | 777 | 13 (2) | 53% |
|  |
| 06-07/2020 |
| ShoshaniS94 | PANAS-C - PE | BSI-18 - Anxiety | BSI-18 - Depression | 5th to 11th graders from 38 schools in three representative geographical areas in Israel | Israel | 09/2019 | 1,537 | 14 (2) | 52% |
| PANAS-C - NE |  |
| GSI-18 - BSI | 05/2020 |
| TengS95 |  | STAI-Trait | CES-D | Primary and middle school students | China | 10-11/2019 | 1,778 | NR | 49% |
|  |
| 04-05/2020 |
| ViraS96 | SDQ-emotional problems |  |  | Middle school students from the Peer Relations In School from an Ecological perspective project | Sweden | 10/2019-01/2020h | 849 | 10 (0) | 52% |
|  |
| 11/2020-02/2021 |
| Wang, WanxinS97 |  | GAD-7 | CES-D | 7th and 10th graders from six middle schools and four high schools in Guangzhou | China | 10-12/2019 | 1,790-1,831 | 14 (1) | 50% |
|  |
| 10-12/2020 |
| WidnallS98 |  | HADS-A |  | Secondary students aged 13 to 15 years in South West England | UK | 10/2019 | 603 | Range: 13-15 | NR |
|  |
| 05/2020 |
| Wong, RS99 |  | DASS-21 - Anxiety | DASS-21 - Depression | Young adolescents from the Healthy Kids cohort | China | 04-08/2019 | 233 | 12 (0) | 61% |
|  |
| 02/2020 |
| Yang, ZhengqianS100 |  |  | CES-D | Adolescents from three public junior high schools in Heilongjiang, who were part of the Life History Strategies and Adolescents' Adaptation Project | China | 11/2019 | 1,125 | 14 (1) | 51% |
|  |
| 08/2020 |
| ZhangS101 |  | HBQ | MFQ | Students in grades 4 through 8 enrolled in an ongoing longitudinal cohort | China | 11/2019 | 1,241 | 13 (1) | 59% |
|  |
| 05/2020 |
| **Parents** | | | | | | | | | |
| AchterbergS72 | BSI |  |  | Parents of children aged 10 to 13 years who enrolled in a longitudinal twin study in 2015-2016 | The Netherlands | 01-11/2019 | 106 | 45 (5) | 93% |
|  |
| 04-05/2020 |
| AdesoganS102 |  |  | CES-D | Black men and women in the rural South who took part in the Protecting Strong African American Families project. | USA | NR/2018-03/2020h | 329 | 43 (8) | 58% |
|  |
| 06-09/2020 |
| BoschS76 | SDQ - Emotion Symptoms SDQ - Total |  |  | Parents with children aged 6 to 17 from the INSchool study | Spain | NR/2019 | 669 | 13 (3) | 48% |
|  |
| 05-06/2020 |
| FrankS103 |  |  | PHQ-9 | Physician parents enrolled in the Intern Health Study | USA | 08/2018 | 180 | 40 (4) | 53% |
|  |
| 08/2020 |
| GagnéS104 | K10 |  |  | Parents with at least one child aged 5 to 17 years previously enrolled in a parenting support program | Canada | 03-05/2019 | 127 | NR | 80% |
|  |
| 05-07/2020 |
| Loret de MolaS105 |  | GAD-7 | EPDS | Mothers from the Rio Grande birth cohort | Brazil | 01-12/2019 | 1,136 | 28 (7) | 100% |
|  |
| 05-07/2020 |
| PitchikS106 |  |  | CES-D | Primary caregivers of children 6 to 24 months with no physical or cognitive disabilities | Bangladesh | 05-06/2019 | 517 | NR (NR) | 100% |
|  |
| 07-09/2020 |
| RiveraS107 |  |  | EDS | Women enrolled in the Programming Research in Obesity, Growth, Environment and Social Stressors study | Mexico | NR/2018-2019 | 466 | 39 (6) | 100% |
|  |
| 05-11/2020 |
| ThompsonS108 |  | GAD-7 | CES-D | First-time mothers of young toddlers living in low-income contexts | USA | NR/2018-2019 | 147 | 27 (6) | 100% |
|  |
| 04/2020 |
| **People with Pre-existing Medical Conditions** | | | | | | | | | |
| BeckerS109 | SF-36 (role emotional) |  | CESD-10 | Individuals with multiple sclerosis | USA | 03/2019 | 119-121 | 69 (8) | 86% |
|  |
| 03/2020 |
| BonenkampS110 | SF-12 Mental Component Summary |  |  | Dialysis patients from the ongoing Dutch nOcturnal and hoMe dialysis Study To Improve Clinical Outcomes | The Netherlands | 08/2019 | 177 | 65 (12) | 37% |
|  |
| 07/2020 |
| ChaoS111 |  |  | PHQ-8 | Older adults with Type 2 diabetes who were enrolled in Look AHEAD. | USA | 02/2018-02/2020h | 2,679-2,829 | 76 (6) | 63% |
|  |
| 07-12/2020 |
| ChiuS112 |  | HADS-A | HADS-D | Individuals with Multiple Sclerosis | USA | 10/2018 | 133 | 49 (12) | 86% |
| SPANE-P |  |
| SPANE-N | 09/2020 |
| DerksenS113 | EORTC QLQ-C30-Global quality of life | HADS-A | HADS-D | Patients included in the nationwide Prospective Dutch Colorectal Cancer cohort | The Netherlands | 01/2019-01/2020h | 2,176 | 67 (10) | 37% |
|  |  |
| EORTC QLQ-C30-Emotional functioning | 04-06/2020 |
| Dunlop-ThomasS114 | PROMIS - Global mental health |  | PROMIS - Depression | Patients with systemic lupus erythematosus who were part of the Georgians Organized Against Lupus (GOAL) cohort | USA | NR/2017-2019g | 852 | 48 (NR) | 94% |
|  |
| NR/2020-2021 |
| FujiwaraS115 | EQ-5D-5L | HADS-A | HADS-D | Outpatients with chronic pain undergoing treatment | Japan | 07-09/2019 | 245 | 73 (12) | 55% |
|  |
| 07-09/2020 |
| García-RudolphS116 | WHOQOL-BREF | HADS-A | HADS-D | Adult community residents with diagnosed spinal cord injury | Spain | NR | 175 | 55 (14) | 30% |
|  |
| 11/2020 |
| GulS117 |  |  | BDI | Patients with epilepsy . | Turkey | 10-11/2019 | 116 | Median: 33 Range: 18-65 | 56% |
|  |
| 06-07/2020 |
| HenryS118 |  | PROMIS Anxiety | PHQ-8 | People with systemic sclerosis enrolled in an ongoing longitudinal cohort | Canada, France, UK, USA | 07-12/2019 | 435 | 57 (13) | 89% |
|  |
| 04/2020j |
| 12/2020j |
| 03/2021j |
| JohnstoneS119 | QOLS | HADS-A | HADS-D | Individuals with rheumatoid arthritis or ankylosing spondylitis from the Patient Opinion Real-Time Anonymous Liaison study | New Zealand | NR/2018 | 104 | 57 (12) | 74% |
|  |
| 07-09/2020 |
| Katz, PS120 |  | GAD-2 | PHQ-2 | People with rheumatic diseases enrolled in a longitudinal registry (National Databank for Rheumatic Diseases) | USA | NR/2019  03-06/2020 | 1,504 | 66 (11) | 86% |
| LiangS121 |  | ZSAS | ZSDS | Patients with maintenance hemodialysis under medical quarantine in a single hospital | China | 12/2019 | 114 | 59 (16) | 32% |
|  |
| 02-03/2020 |
| LimS122 | PROMIS Mental Health | PROMIS Anxiety | PROMIS Depression | People with systemic lupus erythematosus | USA | NR/2018 | 316 | 47 (13) | 93% |
|  |
| 04/2020 |
| MöllerS123 | DASS-21 |  |  | Adults with coeliac disease | Australia, New Zealand | 08-10/2019 | 674 | 57 (14) | 83% |
|  |  |
| EUROHIS-QOL | 05-07/2020 |
| ParkS124 | EQ-5D-3L | HADS-A | HADS-D | Adults with pulmonary arterial hypertension who were part of the PEPPAH-study | Germany | 09/2019–02/2020h | 152 | Median: 58 IQR: 49-67 | 73% |
|  |
| 05-08/2020 |
| RentscherS29 |  | STAI-State | CES-D | Women aged 60 years and older who were nonmetastatic breast cancer survivors | USA | 02-06/2019 | 262 | 68 (5) | 100% |
|  |
| 05-09/2020 |
| SacreS125 | PAID | GAD-7 | PHQ-8 | Adults with type 2 diabetes from the PREDICT cohort study | Australia | NR/2018-2019 | 450 | 66 (9) | 31% |
|  |
| 05-06/2020 |
| SbragiaS126 | HADS | HADS-A | HADS-D | Patients with multiple sclerosis | Italy | 01/2019 | 106 | 43 (11) | 70% |
|  |
| 05/2020 |
| UbaraS127 |  |  | PHQ-9 | Patients from a sleep outpatient clinic from a single hospital | Japan | 04-07/2019 | 164 | 64 (14) | 13% |
|  |
| 05/2020 |
| UchidaS128 |  |  | CES-D-SF | Hemodialysis patients | Japan | 04/2019-03/2020h | 142 | 66 (11) | 42% |
|  |
| 07/2020-03/2021 |
| Wong, SS35 |  | GAD-7 | PHQ-9 | Adults aged ≥ 60 years with ≥ 2 chronic medical conditions recruited from 4 primary care clinics | Hong Kong, China | 04/2018-03/2019 | 583 | 71 (6) | 73% |
|  |
| 03-04/2020 |
|  |
| 03-06/2020 |
| **People with Pre-existing Mental Health Conditions** | | | | | | | | | |
| GentileS129 |  | HAM-A | HAM-D | Psychiatric outpatients based in a large area of central-southern Italy and Department of Psychiatry of University of Asuncion, Paraguay. | Italy, Paraguay | 10-12/2019 | 110k | 39(14) | 55% |
|  |
| 03-04/2020 |
| HuongS130 | BSRS-5 |  |  | Patients with treatment-refractory depression referred by two psychiatrists in the study hospitals | Taiwan | 01-12/2018 | 114 | 57 (14) | 71% |
|  |
| 01-05/2020 |
| SwerdlowS131 |  | MASQ-30 - Anxiety | MASQ-30 - Depression | A community sample of adults with pre-existing mental health concerns | USA | NR/2018-04/2020h | 144 | 29 (NR) | 74% |
|  |
| 04-06/2020 |
| YoungS132 |  | GAD-7 | PHQ-9 | UK residents aged ≥ 16 years with current or history of depressive or anxiety disorder diagnosis from the Genetic Links to Anxiety and Depression study | UK | 09/2018-02/2020h | 12,653 | Range (%): 16-18 (3); 19-25 (12); 26-35 (23); 36-45 (19); 46-55 (22); 56-65 (15); 66-70 (3); 71-75 (2); 76+ (1) | 80% |
|  |
| 04-09/2020 |
| **Medical Staff** | | | | | | | | | |
| FrankS103 |  |  | PHQ-9 | Physician parents enrolled in the Intern Health Study | USA | 08/2018 | 180 | 40 (4) | 53% |
|  |
| 08/2020 |
| Li, WeidongS133 |  | GAD-7 | PHQ-9 | Training physicians from 12 Shanghai hospitals | China | 10-11/2019 | 385 | Median: 25 IQR: 23-28 | 64% |
|  |
| 01-02/2020 |
| **Sexual or Gender Minority Individuals** | | | | | | | | | |
| BavintonS134 |  | GAD-7 | PHQ-9 | Gay and bisexual men enrolled in a longitudinal cohort | Australia | NR/2019 | 681 | NR | 0% |
|  |
| 04/2020 |
| FlentjeS135 |  | GAD-7 | PHQ-9 | Convenience sample of sexual and gender minority adults enrolled in a longitudinal cohort | USA | 06/2019 | 2,288 | 37 (15) | 63%l |
|  |
| 03-04/2020 |
| GhabrialS136 |  | OASIS | CES-D | Trans and non-binary individuals who were part of the Trans PULSE Canada (TPC) study | Canada | NR/2019 | 780 | 33 (12) | 25% |
|  |
| 09-10/2020 |
| **Immigrants** | | | | | | | | | |
| GosselinS137 |  |  | PHQ-9 | Immigrants from sub-Saharan Africa | France | 04/2018-NR/2019 | 100 | Range (%): 19-29 (34); 30-39 (39); 40+ (27) | 21% |
|  |
| 06/2020 |

BDI-II = Beck Depression Inventory (second edition); BJSQ = Brief Job Stress Questionnaire; BSI = Brief Symptom Inventory; BSRS = Brief-Symptom Rating Scale; CCAPS-62 = Counseling Center Assessment of Psychological Symptoms; CDI-S = Children’s Depression Inventory-Short; CES-DC = Center for Epidemiologic Studies Depression Scale Children; CES-D(-R/10) = Center for Epidemiologic Studies Depression (– Revised/10); CIDI = The Composite International Diagnostic Interview; DASS-21 = Depression, Anxiety, and Stress Scale; DToS = Distress Tolerance Scale; EDS = Edinburgh Depression Scale; EORTC QLQ-C30 = European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire; EPDS = Edinburgh Postnatal Depression Scale; EQ-5D-5L = The 5-level European Quality of Life 5-dimensions version; GAD-7 = Generalized Anxiety Disorder; GAI-SF = Geriatric Anxiety Inventory - Short Form; GDS = Geriatric Depression Scale; GHQ = General Health Questionnaire; GSI = Global Severity Index; HADS-A/D = Hospital Anxiety and Depression Scale-Anxiety/Depression; HAI = Health Anxiety Inventory; HAM-A/D = Hamilton Anxiety/Depression Rating Scale; HBQ = MacArthur Health and Behavior Questionnaire; K6/10 = Kessler Psychological Distress Scale-6/10; MASQ = Mood and Anxiety Symptom Questionnaire; MDI = Major Depression Inventory; (S)MFQ = (Short) Mood and Feelings Questionnaire; MHI-5 = Mental Health Index-5; OASIS = Overall Anxiety Severity and Impairment Scale; PAID = Problem Areas in Diabetes scale; PANAS-PA/NA = Positive and Negative Affect Schedule – Positive Affect/Negative Affect; PERMA – PA/NA = Positive emotion, Engagement, Relationships, Meaning, and Accomplishment Profiler – Positive/Negative Affect; PHQ-2/4/8/9/A = Patient Health Questionnaire 2/4/8/9/Adolescents; PMH = Positive Mental Health Scale; PROMIS = Patient-Reported Outcomes Measurement Information System; PWBS = Psychological Well-being scale; QOLS = Quality of Life Scale; RCADS = Revised Children's Anxiety and Depression Scale; RPOMIS = Patient-Reported Outcomes Measurement Information System; RRQ = Reflection and Rumination Scale; SCAS = Spence Children’s Anxiety Scale; SCL-90-R = Symptom Check List-90-Revised; SDQ = Strengths and Difficulties Questionnaire; SF-8/12/36(-MCS) = Short-Form-8/12/36 Health Survey (Mental Component Summary); SMGAD = Severity Measure for Generalized Anxiety Disorder; SPANE-P/N = Scale of Positive and Negative Experience-Positive/Negative; STAI = State-Trait Anxiety Inventory; STDS = State-Trait Depression Scale; SWLS = Satisfaction with Life Scale; UK = United Kingdom; USA = United States of America; (S)WEMWBS = (Short) Warwick Edinburgh Mental Wellbeing Scale; WHO-5-J = World Health Organization (Five) Wellbeing Index; WHOQOL-BREF/AGE = World Health Organization Quality of Life Questionnaire for Older adults; ZSAS = Zung Self-rating Anxiety Scale; ZSDS = Zung Self-rating Depression Scale.

aStudies with data on females or women and males or men are not listed separately because they represent subgroup data from other studies in the table. bBased on 671 participants with data during COVID-19. cAnalyses compared COVID-19 symptom levels to preceding trends across multiple assessments. dNumber included in fixed effects regression analysis from where the majority of data were extracted. eAge groups reported for DalyS12; for Pierce,S11 16-24 = 9%, 25-34 = 11%, 35-44 = 16%, 45-54 = 20%, 55-69 = 29%, 70+ = 15%. fBased on van der Velden.S17  gIncluded because estimated that over 80% of pre-COVID-19 data would have been collected after January 01, 2018. hIncluded because estimated that over 80% of pre-COVID-19 data would have been collected by December 31, 2019. iRecruited participants from the same longitudinal cohort. Of cohort participants who completed pre-COVID-19 assessments, 946 agreed to be contacted again. 214S63 and 255S64 completed assessments during early 2020 and later 2020, but the authors did not report how many participants overlapped between COVID-19 assessments in 2020. jMental health assessments conducted at 15 time points during COVID-19. We have reported first (April 2020), last in 2020 (December 2020) and last in 2021 (March 2021). kN = 60 from Italy and 50 from Paraguay (results not reported by country).  lBased on female sex assigned at birth; 12 gender categories listed in study.

**Supplementary Table 2. Risk of Bias and Adequacy of Methods and Reporting**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author** | **Appropriate sample frame** | **Appropriate participant recruitment** | **Adequate sample size** | **Participants and setting adequately described** | **Adequate response rate and data analysis with sufficient coverage** | **Valid methods for identification of outcome variable** | **Standard, reliable outcome measurement** | **Appropriate statistical analysis** | **Adequate follow-up response rate/ appropriate management of low response rate** |
| **General Population** | | | | | | | | | |
| BulbuliaS1 | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | No |
| CastelliniS2 | Unclear | No | Unclear | Yes | Unclear | Yes | Yes | Yes | Yes |
| ChanS3 | No | No | Yes | No | Unclear | Yes | Yes | Yes | Unclear |
| FinucaneS4 | No | Yes | Yes | Yes | Unclear | Yes | Unclear | Yes | No |
| GeS5 | No | No | Yes | No | Unclear | Yes | Yes | Yes | Unclear |
| HaliwaS6 | No | No | Unclear | Yes | Unclear | Yes | Yes | Yes | No |
| KanburS7 | No | Unclear | Yes | No | Unclear | Yes | Unclear | No | Unclear |
| Katz, BS8 | No | No | Yes | Yes | Unclear | Yes | Yes | Yes | Unclear |
| LatikkaS9 | Unclear | Unclear | Yes | Yes | No | Yes | Yes | Yes | Yes |
| Megias-RoblesS10 | Unclear | No | Unclear | No | Unclear | Yes | Yes | Yes | No |
| PierceS11 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | Unclear |
| DalyS12 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | No |
| ShimuraS13 | No | Unclear | Yes | No | Unclear | Yes | Yes | Yes | Yes |
| SoltanzadehS14 | No | Yes | Yes | Yes | Yes | Yes | Unclear | Yes | Yes |
| ThygesenS15 | Yes | Unclear | Yes | Yes | No | Yes | Unclear | Yes | Unclear |
| van der Velden, 2020S16 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| van der Velden, 2021S17 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| WanbergS18 | Yes | Yes | Yes | Yes | Unclear | Yes | Unclear | Yes | No |
| **Older Adults** | | | | | | | | | |
| BartlettS19 | Yes | No | Yes | Yes | Unclear | Yes | Yes | Yes | No |
| BriggsS20 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | No |
| CreeseS21 | Yes | No | Yes | Yes | No | Yes | Yes | Yes | Yes |
| EliasenS22 | No | Yes | Yes | Yes | No | Yes | Yes | Yes | No |
| HerreraS23 | Yes | Yes | Yes | Yes | Unclear | Yes | No | No | No |
| KeraS24 | No | Unclear | Yes | No | Unclear | Yes | Yes | Yes | No |
| KiviS25 | Yes | Unclear | Yes | Yes | No | Yes | Yes | Yes | No |
| LeeS26 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | No | Unclear |
| MartínezS27 | No | Unclear | Unclear | Yes | Unclear | Yes | Yes | Yes | Unclear |
| OkelyS28 | No | No | Unclear | Yes | No | Yes | Yes | Yes | No |
| RentscherS29 | Yes | Unclear | Yes | Yes | Unclear | Yes | No | Yes | Yes |
| SardellaS30 | No | No | Unclear | Yes | Unclear | Yes | Yes | Yes | No |
| SiewS31 | Yes | No | Yes | Yes | Unclear | Yes | No | Yes | No |
| van den BesselaarS32 | Unclear | No | Yes | Yes | Unclear | Yes | No | Yes | Unclear |
| van TilburgS33 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Wang, YiS34 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | Yes |
| Wong, SS35 | No | Unclear | Yes | Yes | Unclear | Yes | Yes | Yes | Yes |
| YuS36 | Yes | No | Yes | Yes | Unclear | Yes | Yes | Yes | No |
| **Young Adults** | | | | | | | | | |
| IslamS37 | No | Yes | Yes | Yes | No | Yes | Yes | Yes | No |
| MarmetS38 | Yes | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | No |
| RimfeldS39 | Yes | Unclear | Yes | Yes | Unclear | Yes | Yes | Yes | Unclear |
| RommS40 | No | No | Yes | Yes | Unclear | Yes | Yes | Yes | Unclear |
| TaniokaS41 | No | Unclear | Yes | Yes | Unclear | Yes | Yes | Yes | No |
| VilladsenS42 | Unclear | Unclear | Yes | Yes | Unclear | Yes | Yes | Yes | No |
| Watkins-MartinS43 | Yes | Unclear | Yes | Yes | Unclear | Yes | Yes | Yes | No |
| **University Students** | | | | | | | | | |
| ConceiçãoS44 | No | Yes | Yes | Yes | Unclear | Yes | Unclear | Yes | No |
| DongS45 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| ElmerS46 | No | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | Unclear |
| EvansS47 | No | Unclear | Yes | Yes | Unclear | Yes | No | Yes | Yes |
| Fuller-RowellS48 | No | Unclear | Yes | Yes | Unclear | Yes | Unclear | Yes | Yes |
| GelezelyteS49 | No | Unclear | Yes | Yes | No | Yes | Yes | Yes | No |
| GopalanS50 | No | Unclear | Yes | Yes | Unclear | Yes | Yes | Yes | No |
| HamzaS51 | No | Unclear | Yes | Yes | Unclear | Yes | Yes | Yes | Yes |
| HeS52 | Unclear | Unclear | Yes | Yes | Unclear | Yes | Unclear | Yes | Yes |
| KoelenS53 | No | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | No |
| Li, HS54 | No | Unclear | Yes | Yes | Unclear | Yes | Yes | Yes | Yes |
| Li, RS55 | No | Yes | Yes | No | Unclear | Yes | Yes | Yes | Yes |
| Li, Wendy WenS56 | No | No | Unclear | Yes | No | Yes | Yes | Yes | Yes |
| LiuS57 | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| LuS58 | Unclear | Yes | Yes | Yes | Unclear | Yes | Unclear | Yes | Unclear |
| MauerS59 | Yes | No | Yes | Yes | Unclear | Yes | Yes | Yes | No |
| MehusS60 | No | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | Unclear |
| RatnerS61 | No | Unclear | Unclear | Yes | Unclear | Yes | Yes | Yes | No |
| SaraswathiS62 | No | Yes | Unclear | Yes | Yes | Yes | Yes | Yes | Yes |
| Savage, 2020S63 | No | Yes | Yes | Yes | No | Yes | Yes | Yes | No |
| Savage, 2021S64 | Unclear | Unclear | Yes | Yes | No | Yes | Yes | No | No |
| ShiratoriS65 | No | Unclear | Yes | Yes | Unclear | Yes | Yes | Yes | No |
| Truskauskaite-KunevicieneS66 | No | Unclear | Yes | Yes | Unclear | Yes | Yes | Yes | No |
| VoltmerS67 | No | No | Yes | Yes | No | Yes | Yes | Yes | Unclear |
| Wang, YitaoS68 | No | Yes | Yes | No | Unclear | Yes | Yes | Yes | Yes |
| Yang, XS69 | No | Unclear | Unclear | No | Unclear | Yes | Yes | Yes | Unclear |
| Yang, ZiyanS70 | No | Unclear | Yes | Yes | Unclear | Yes | Unclear | Yes | Unclear |
| ZimmermanS71 | No | No | Yes | Yes | Unclear | Yes | Yes | Yes | No |
| **Children and Adolescents** | | | | | | | | | |
| AchterbergS72,a | No | No | Unclear | Yes | Unclear | Yes | No | Yes | No |
| AdachiS73 | No | Unclear | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| BadoS74 | No | No | Yes | Yes | Unclear | Yes | Unclear | Yes | Unclear |
| BernascoS75 | No | Unclear | Yes | Yes | Unclear | Yes | Yes | Yes | Unclear |
| BoschS76 | Yes | Unclear | Yes | Yes | No | Yes | Yes | Yes | No |
| CharmaramanS77 | No | Unclear | Yes | Yes | Unclear | Yes | Unclear | Yes | No |
| Chen, I-HS78 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Chen, C-YS79 | No | Unclear | Yes | No | Yes | Yes | Yes | Yes | No |
| DaniunaiteS80 | No | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | Yes |
| EzpeletaS81 | No | No | Unclear | Yes | No | Yes | No | Yes | Unclear |
| FujiharaS82 | No | Unclear | Yes | No | No | Yes | Yes | Yes | Unclear |
| HuS83 | Unclear | Unclear | Yes | Yes | Unclear | Yes | Yes | Yes | Unclear |
| KnowlesS84 | Unclear | Unclear | Yes | Yes | No | Yes | Yes | Yes | Unclear |
| Li, YS85 | No | Unclear | Yes | Yes | Unclear | Yes | Yes | Yes | Yes |
| LiaoS86 | No | Yes | Yes | Yes | Unclear | Yes | Unclear | Yes | Yes |
| MagsonS87 | No | Unclear | Yes | Yes | Unclear | Yes | Yes | Yes | No |
| MastorciS88 | No | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | No |
| MeirelesS89 | No | Unclear | Yes | Yes | Unclear | Yes | Yes | Yes | Unclear |
| NaumannS90 | Yes | Unclear | Yes | Yes | Unclear | Yes | Yes | Yes | No |
| PaizanS91 | No | No | Yes | Yes | Unclear | Yes | Yes | Yes | Unclear |
| PolackS92 | No | No | Unclear | No | Unclear | Yes | Yes | Yes | Yes |
| RauS93 | No | Unclear | Yes | Yes | No | Yes | Yes | Yes | No |
| ShoshaniS94 | No | Unclear | Yes | Yes | Unclear | Yes | Yes | Yes | Yes |
| TengS95 | No | Yes | Yes | Yes | Unclear | Yes | Yes | Yes | Yes |
| ViraS96 | Unclear | Unclear | Yes | Yes | Unclear | Yes | No | Yes | Unclear |
| Wang, WanxinS97 | No | Yes | Yes | Yes | Yes | Yes | Unclear | Yes | Yes |
| WidnallS98 | No | Unclear | Yes | No | Unclear | Yes | Unclear | Yes | Unclear |
| Wong, RS99 | Unclear | Unclear | Yes | Yes | Unclear | Yes | Yes | Yes | Unclear |
| Yang, ZhengqianS100 | No | Unclear | Yes | Yes | Unclear | Yes | Yes | Yes | Unclear |
| ZhangS101 | No | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| **Parents** | | | | | | | | | |
| AchterbergS72,a | No | No | Unclear | Yes | Unclear | Yes | Yes | Yes | No |
| AdesoganS102 | No | No | Yes | Yes | Unclear | Yes | No | Yes | Yes |
| BoschS76 | Yes | Unclear | Yes | Yes | No | Yes | Yes | Yes | No |
| FrankS103 | No | Unclear | Unclear | Yes | Unclear | Yes | Yes | Yes | Unclear |
| GagnéS104 | Unclear | Unclear | Unclear | No | Unclear | Yes | Yes | Yes | Yes |
| Loret de MolaS105 | No | No | Yes | Yes | Unclear | Yes | Yes | Yes | No |
| PitchikS106 | No | Yes | Yes | No | Unclear | Yes | Yes | Yes | No |
| RiveraS107 | No | Unclear | Yes | Yes | Unclear | Yes | Unclear | Yes | Unclear |
| ThompsonS108 | Yes | Unclear | Unclear | Yes | Unclear | Yes | Yes | Yes | Yes |
| **People with Pre-existing Medical Conditions** | | | | | | | | | |
| BeckerS109 | Yes | No | Yes | Yes | No | Yes | Yes | Yes | Unclear |
| BonenkampS110 | Yes | Unclear | Yes | Yes | Unclear | Yes | Unclear | Yes | Unclear |
| ChaoS111 | No | Unclear | Yes | Yes | Unclear | Yes | Yes | Yes | Unclear |
| ChiuS112 | No | No | Unclear | Yes | Unclear | Yes | Yes | Yes | No |
| DerksenS113 | Yes | Unclear | Yes | Yes | Unclear | Yes | Unclear | Yes | No |
| Dunlop-ThomasS114 | Yes | Unclear | Yes | Yes | Unclear | Yes | Yes | Yes | Unclear |
| FujiwaraS115 | No | Unclear | Yes | No | Unclear | Yes | Unclear | Yes | Unclear |
| García-RudolphS116 | No | No | Unclear | Yes | Unclear | Yes | Unclear | Yes | Yes |
| GulS117 | No | Unclear | Unclear | Yes | Unclear | Yes | Unclear | Yes | Unclear |
| HenryS118 | Yes | No | Yes | Yes | Unclear | Yes | Yes | Yes | No |
| JohnstoneS119 | No | No | Unclear | No | Unclear | Yes | Yes | Yes | Yes |
| Katz, PS120 | Unclear | Unclear | Yes | Yes | Unclear | Yes | Yes | Yes | No |
| LiangS121 | No | No | Unclear | Yes | Yes | Yes | Yes | Yes | Yes |
| LimS122 | Yes | Unclear | Yes | Yes | Unclear | Yes | Unclear | Yes | Unclear |
| MöllerS123 | Yes | No | Yes | Yes | No | Yes | Yes | Yes | Yes |
| ParkS124 | No | No | Unclear | No | Unclear | Yes | Yes | Yes | Yes |
| RentscherS29 | Yes | Unclear | Yes | Yes | Unclear | Yes | No | Yes | Yes |
| SacreS125 | No | No | Yes | Yes | Unclear | Yes | No | Yes | Yes |
| SbragiaS126 | No | No | Unclear | Yes | Unclear | Yes | Unclear | Yes | No |
| UbaraS127 | No | Unclear | Unclear | No | Unclear | Yes | Yes | Yes | Unclear |
| UchidaS128 | No | Unclear | Unclear | Yes | Unclear | Yes | Unclear | Yes | Unclear |
| Wong, SS35 | No | Unclear | Yes | Yes | Unclear | Yes | Yes | Yes | Yes |
| **People with Pre-existing Mental Health Conditions** | | | | | | | | | |
| GentileS129 | Yes | Unclear | Unclear | Yes | Unclear | Yes | No | Yes | Unclear |
| HuongS130 | No | Unclear | Unclear | Yes | Unclear | Yes | Yes | Yes | Yes |
| SwerdlowS131 | Yes | No | Unclear | Yes | Unclear | Yes | No | Yes | Yes |
| YoungS132 | Yes | No | Yes | Yes | Unclear | Yes | Yes | Yes | No |
| **Medical Staff** | | | | | | | | | |
| FrankS103 | No | Unclear | Unclear | Yes | Unclear | Yes | Yes | Yes | Unclear |
| Li, WeidongS133 | No | Unclear | Yes | Yes | No | Yes | Yes | Yes | No |
| **Sexual or Gender Minority Individuals** | | | | | | | | | |
| BavintonS134 | Yes | Unclear | Yes | No | Unclear | Yes | Yes | Yes | Unclear |
| FlentjeS135 | Yes | No | Yes | Yes | Unclear | Yes | Yes | Yes | Unclear |
| GhabrialS136 | Unclear | Unclear | Yes | Yes | Unclear | Yes | No | Yes | Unclear |
| **Immigrants** | | | | | | | | | |
| GosselinS137 | No | No | Unclear | Yes | No | Yes | Yes | Yes | Unclear |

aAchterberg et al. has two samples, parents, and their children, with independent risk of bias coding.

**Supplementary Table 3. Individual Study Results for General Mental Health**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **First Author**  **Study Country** | **Pre- and Post-COVID-19 Data Collection** | **N** | **Continuous**  **Outcome Measure** | **Pre-**  **COVID-19 Mean (SD)** | **Post-**  **COVID-19 Mean (SD)** | **Mean (SD) Change**a | **Hedges’ g Standardized Mean Difference (95% CI)** | **Dichotomous Outcome Measure** | **% pre-COVID-19 (95% CI)** | **% post-COVID-19 (95% CI)** | **% Change with 95% CI**a |
| **General Population** | | | | | | | | | | | |
| BulbuliaS1  New Zealand | NR/2018 | 940 | K6 | 5.42 (4.05) | 5.65 (3.78) | 0.23 (NR) | 0.06 (-0.03, 0.15) | ---------- | ---------- | ---------- | ---------- |
|  |
| 03-04/2020 |
| CastelliniS2  Italy | 12/2019 | 130 | BSI-GSI | 0.51 (0.39) | 0.46 (0.46) | -0.05 (NR) | -0.12 (-0.36, 0.13) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04-05/2020 |
| FinucaneS4  USA | 05/11-2018 | 416 | K6 | 4.00 (4.40) | 4.70 (4.60) | 0.70 (NR) | 0.16 (0.02, 0.29) | K6 ≥ 13 | 6.0 (4.1, 8.7) | 6.5 (4.5, 9.2) | 0.5 (-2.0, 3.0) |
|  |
| 06-09/2020 |
| KanburS7  Turkey | NR/2019 | 400 | SCL-90-R | 0.36 (NR) | 0.78 (NR) | 0.42 (NR) | NR (NR) | ---------- | ---------- | ---------- | ---------- |
|  |
| NR/2020 |
| Katz, BS8  Canada, Ireland, UK, USA | 04/2019 | 218 | RRQ | 42.46 (11.74) | 41.66 (12.15) | -0.80 (7.43) | -0.07 (-0.25, 0.12) | ---------- | ---------- | ---------- | ---------- |
|  |  |  |  |  |  |  |  |  |  |
| 04/2020 | DToS | 41.95 (9.95) | 41.03 (10.08) | -0.92 (7.63) | -0.09 (-0.28, 0.10) | ---------- | ---------- | ---------- | ---------- |
| LatikkaS9  Finland | 09/2019-10/2019 | 840 | GHQ-12 | 12.20 (5.67) | 12.41 (5.45) | 0.21 (NR) | 0.04 (-0.06, 0.13) | ---------- | ---------- | ---------- | ---------- |
|  |
| 03/2020-04/2020 |
| Megias-RoblesS10  Spain | 11/2019 | 102 | PANAS-NA | 1.92 (0.65) | 2.22 (0.75) | 0.31 (0.80) | 0.44 (0.16, 0.71) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04/2020 |
| PierceS11  UK | Pre-COVID-19 waves | 15,37630,b 10,91834 | GHQ-12 |  |  |  |  | GHQ-12 ≥ 4 |  |  |  |
| DalyS12  UK |  |  |  |  |  |  |  |  |
|  | 04/2020 | 11.50 (5.50) | 12.60 (6.60) | 1.10 (NR)c | 0.18 (0.16, 0.21) | 20.8 (19.4, 22.2)e | 29.5 (28.0, 31.0)e | 8.7 (6.9, 10.4)e |
|  |  |  |  | 0.48 (NR)d | 0.08 (0.05, 0.10) |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  | 09/2020 | ---------- | ---------- | ---------- | ---------- | 20.8 (19.4, 22.2)e | 20.8 (19.5, 22.1)e | 0.0 (-2.0, 1.9)e |
| ShimuraS13  Japan | NR/2019 | 3,123 | BJSQ (Psychological and Physical) | NR (NR) | NR (NR) | -0.31 (11.02) | -0.05 (-0.10, 0.00) | ---------- | ---------- | ---------- | ---------- |
|  |
| NR/2020 |
| SoltanzadehS14  Iran | 11/2019 | 823 | GHQ-28 | 45.13 (11.65) | 51.41 (12.89) | 6.28 (NR) | 0.51 (0.41, 0.61) | ---------- | ---------- | ---------- | ---------- |
|  |
| 07/2020 |
| ThygesenS15  Denmark | 09-12/2019 | 4,234 | SWEMWBS | 25.50 (4.98) | 24.60 (4.98) | -0.90 (NR) | 0.18 (0.14, 0.22) | ---------- | ---------- | ---------- | ---------- |
|  |
| 09-11/2020 |
| van der Velden, 2020S16  Netherlands | 03/2019 | 3,983 | MHI-5f |  |  |  |  | MHI-5 ≤ 59 |  |  |  |
| van der Velden, 2021S17  Netherlands | 11-12/2019 | 4,064 |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
|  | 03/2020 |  | 74.20 (16.70) | 74.10 (16.40) | -0.10 (NR) | 0.01 (-0.04, 0.05) | ---------- | ---------- | ---------- |
|  |  |  |  |  |  |  |  |  |  |
|  | 11-12/2020 |  | ---------- | ---------- | ---------- | ---------- | 16.9 (15.8, 18.1) | 16.9 (15.8, 18.1) | 0.0 (-1.2, 1.3) |
| **Older Adults** | | | | | | | | | | | |
| EliasenS22  Denmark | 12/2017-01/2019 | 225 | WHOQOL-BREF | 74.33 (14.96) | 71.88 (15.21) | -2.45 (NR) | 0.16 (-0.02, 0.35) | ---------- | ---------- | ---------- | ---------- |
|  | WHOQOL-BREF (psychological health) | 77.07 (11.52) | 80.53 (10.89) | 3.46 (NR) | -0.31 (-0.49, -0.12) |
| 06/2020-07/2020 |  |  |  |  |  |
| KeraS24  Japan | 10/2019 | 533 | WHO-5-J | 16.70 (4.79) | 15.10 (4.79) | -1.60 (NR) | 0.33 (0.21, 0.45) | ---------- | ---------- | ---------- | ---------- |
|  |
| 06-07/2020 |
| KiviS25  Sweden | NR/2019 | 1,071 | SWLSf | 5.12 (1.30) | 5.16 (1.26) | 0.04 (NR) | -0.03 (-0.12, 0.05) | ---------- | ---------- | ---------- | ---------- |
|  |
| 03-04/2020 |
|  |
| MartínezS27  Spain | 10/2019 | 141 | PWBS | 97.85 (21.30) | 99.50 (19.30) | 1.65 (11.53) | -0.08 (-0.32, 0.15) | ---------- | ---------- | ---------- | ---------- |
|  | PERMA - PA | 7.27 (1.38) | 7.20 (1.40) | -0.07 (1.14) | 0.05 (-0.18, 0.28) |
| 04/2020 | PERMA - NA | 4.12 (1.50) | 3.90 (1.60) | -0.22 (1.22) | -0.14 (-0.38, 0.09) |
| OkelyS28  Scotland (UK) | NR/2017-NR/2019 | 137 | WEMWBSf | 37.45 (8.37) | 36.45 (8.23) | -1.00 (NR) | 0.12 (-0.12, 0.36) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05-06/2020 |
| PierceS11  UK | Pre-COVID-19 waves | 2,491 (≥70 years)30,b 3,447 (≥65 years)34 | GHQ-12 |  |  |  |  | GHQ-12 ≥ 4 |  |  |  |
| DalyS12  UK |  |  |  |  |  |  |  |  |
|  | 04/2020 | 10.10 (4.57) | 10.90 (5.35) | 0.80 (NR)c | 0.16 (0.11, 0.21) | 12.7 (10.3, 15.1)e | 19.4 (17.1, 21.8)e | 6.8 (3.7, 9.8)e |
|  |  |  |  | 0.05 (NR)d | 0.01 (-0.04, 0.06) |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  | 09/2020 | ---------- | ---------- | ---------- | ---------- | 12.7 (10.3, 15.1)e | 14.9 (12.9, 16.9)e | 2.2 (-0.8, 5.2)e |
| SardellaS30  Italy | 10/2018-10/2019 | 104 | SF-12 Mental Component Summary | 49.99 (9.99) | 46.35 (10.06) | -3.64 (NR) | -0.36 (-0.64, -0.09) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04/2020 |
| SiewS31  Singapore | 02/2018-01/2020 | 411 | WHOQOL-AGE | 50.36 (5.71) | 52.19 (6.42) | 1.83 (NR) | -0.30 (-0.44, -0.16) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05-06/2020 |
| ThygesenS15  Denmark | 09-12/2019 | 423 | SWEMWBS | 25.70 (6.82) | 25.00 (5.77) | -0.70 (NR) | 0.11 (-0.02, 0.25) | ---------- | ---------- | ---------- | ---------- |
|  |
| 09-11/2020 |
| van der Velden, 2020S16  Netherlands | 03/2019 | 949-1,038 |  |  |  |  |  |  |  |  |  |
| van der Velden, 2021S17  Netherlands | 11-12/2019 | 968-1,052 |  |  |  |  |  |  |  |  |  |
| van TilburgS33  Netherlands |  | 1,679 |  |  |  |  |  |  |  |  |  |
|  | 03/202036 |  |  |  |  |  |  | MHI-5 ≤ 59 | 10.9 (9.0, 13.0) | 10.6 (8.9, 12.6) | -0.2 (-2.3, 1.9) |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  | 05/202041 |  |  | 4.93 (0.75) | 5.02 (0.73) | 0.09 (0.58) | -0.12 (-0.19, -0.05) | ---------- | ---------- | ---------- | ---------- |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  | 11-12/202037 |  |  |  |  |  |  | MHI-5 ≤ 59 | 12.1 (10.2, 14.3)g | 10.5 (8.8, 12.5)g | -1.7 (-3.7, 0.4) |
| Wang, YiS34  China | 05-06/2019 | 2,745 | K10 | 16.64 (7.44) | 18.23 (8.06) | 1.35 (6.15) | 0.17 (0.12, 0.23) | ---------- | ---------- | ---------- | ---------- |
|  |
| 08-09/2020 |
| **Young Adults** | | | | | | | | | | | |
| IslamS37  Australia | NR/2018 | 1,110 | K10 | ---------- | ---------- | ---------- | ---------- | K10 ≥ 25 | 41.3 (38.4, 44.2) | 41.3 (38.4, 44.2) | 0.0 (-3.8, 3.8) |
|  |
| 10-12/2020 |
| PierceS11  UK | Pre-COVID-19 waves | 1,999 (25-34 years)30,b 1,260 (18-34 years)34 | GHQ-12 |  |  |  |  | GHQ-12 ≥ 4 |  |  |  |
| DalyS12  UK |  |  |  |  |  |  |  |  |
|  | 04/2020 | 12.10 (5.46) | 14.20 (6.32) | 2.10 (NR)c | 0.36 (0.29, 0.42) | 25.4 (21.6, 29.2)e | 39.9 (35.5, 44.4)e | 14.5 (9.6,19.4)e |
|  |  |  |  | 1.61 (NR)d | 0.27 (0.21, 0.34) |  |  |  |
|  |  | ---------- | ---------- |  |  |  |  |  |
|  | 09/2020 |  |  | ---------- | ---------- | 25.4 (21.6, 29.2)e | 23.7 (19.8, 27.6)e | -1.7 (-5.9, 2.5)e |
| TaniokaS41  Japan | 10/2019 | 2,222 | K6-J | 6.10 (5.70) | 6.10 (5.80) | 0.00 (NR) | 0.00 (-0.06, 0.06) | ---------- | ---------- | ---------- | ---------- |
|  | SF-8 - MCS | 46.60 (7.90) | 47.20 (7.80) | 0.60 (NR) | 0.08 (0.02, 0.14) |
| 05/2020 |  |  |  |  |  |
| van der Velden, 2020S16  Netherlands | 03/2019 | 993-1,062 | ---------- | ---------- | ---------- | ---------- | ---------- | MHI-5 ≤ 59 |  |  |  |
| van der Velden, 2021S17  Netherlands | 11-12/2019 | 1,018-1,083 |  |  |  |
|  |  |  |  |  |  |
|  | 03/2020 |  | 23.1 (20.6, 25.7) | 19.7 (17.4, 22.3) | -3.3 (-6.1, -0.6) |
|  |  |  |  |  |  |
|  | 11-12/2020 |  | 20.7 (18.4, 23.2)g | 22.5 (20.0, 25.2)g | 1.8 (-1.1, 4.7) |
| VilladsenS42  UK | NR/2018 | 1,615 | K6 | ---------- | ---------- | ---------- | ---------- | K6 ≥ 13 | 18.0 (15.2, 21.2) | 18.7 (15.7, 22.1) | 0.7 (-1.4, 2.8) |
|  |
| 05/2020 |
| **University Students** | | | | | | | | | | | |
| DongS45  China | 09/2019 | 4,085-4,341 | ---------- | ---------- | ---------- | ---------- | ---------- | SCL-90-R ≥ 160 | 18.4 (17.3, 19.6) | 26.4 (25.1, 27.8) | 8.0 (6.4, 9.5) |
|  |
| NR/2020 |
| EvansS47  UK | 10/2019 | 251 | WEMWBSf | 23.04 (4.96) | 21.12 (4.87) | -1.92 (NR) | 0.39 (0.21, 0.57) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05/2020 |
| Li, HS54  China | 12/2019 | 555 | PHQ-4 | 0.95 (0.65) | 0.76 (0.61) | -0.19 (0.66) | -0.30 (-0.42, -0.18) | ---------- | ---------- | ---------- | ---------- |
| 02/2020 | PANAS- PAf | 3.21 (0.79) | 3.26 (0.79) | 0.06 (0.78) | -0.08 (-0.19, 0.04) |
|  | PANAS- NA | 2.38 (0.79) | 2.24 (0.80) | -0.15 (0.78) | -0.19 (-0.31, -0.07) |
| Li, RS55  China | 09/2019 | 2,603 | SCL-90-R | 1.60 (0.40) | 1.52 (0.41) | -0.08 (0.66) | -0.20 (-0.25, -0.14) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04/2020 |
| Savage, 2020S63  UK | 10/2019 | 214 | WEMWBSf | 44.12 (9.16) | 41.12 (10.14) | -3.00 (NR) | 0.31 (0.12, 0.50) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04/2020 |
| Savage, 2021S64  UK | 10/2019 | 255 | WEMWBSf | 45.2 (9.39) | 42.3 (9.98) | -2.90 (NR) | 0.30 (0.12, 0.47) | ---------- | ---------- | ---------- | ---------- |
|  |
| 10/2020 |
| Truskauskaite-KunevicieneS66  Lithuania Germany | 10-12/2019 | Lithuania: 450; Germany: 325 | PMH | Lithuania: 15.66 (5.57); Germany: 18.45 (5.68) | Lithuania: 16.44 (5.46); Germany: 18.64 (5.76) | Lithuania: 0.78 (NR); Germany: 0.19 (NR) | Lithuania: -0.14 (-0.27, -0.01); Germany: -0.03 (-0.19, 0.12) | ---------- | ---------- | ---------- | ---------- |
|  |
| 03-04/2020 |
| Wang, YitaoS68  China | 11/2019 | 2,559 | SCL-90-R | 139.64 (38.46) | 134.57 (40.44) | -5.07 (NR) | -0.13 (-0.18, -0.07) | ---------- | ---------- | ---------- | ---------- |
|  |
| 06/2020 |
| **Children and Adolescents** | | | | | | | | | | | |
| AchterbergS72  Netherlands | 01-11/2019 | 151 | SDQ-Internalizing Behaviors | 0.28 (0.35) | 0.29 (0.35) | 0.01 (NR) | 0.03 (-0.16, 0.22) | ---------- | ---------- | ---------- | ---------- |
|  |  |  |  |  |  |  |  |  |  |
| 04-05/2020 | SDQ-Externalizing Behaviors | 0.42 (0.39) | 0.39 (0.38) | -0.03 (NR) | -0.08 (-0.27, 0.11) | ---------- | ---------- | ---------- | ---------- |
| BadoS74  Brazil | NR/2018-2019 | 672 | SDQ - Total score | 13.93 (6.16) | 13.23 (6.43) | -0.70 (NR) | -0.11 (-0.22, 0.00) | ---------- | ---------- | ---------- | ---------- |
|  | SDQ - Emotion subscale | 4.21 (2.63) | 3.82 (2.74) | -0.39 (NR) | -0.15 (-0.25, -0.04) |
| 04/2020-04/2021 |  |  |  |  |  |
| BernascoS75  Netherlands | NR/2019 | 245 | RCADS - Parents  RCADS - Adolescents | 1.17 (0.17) | 1.18 (0.19) | 0.01 (NR) | 0.06 (-0.12, 0.23) | ---------- | ---------- | ---------- | ---------- |
|  | 1.47 (0.31) | 1.43 (0.33) | -0.04 (NR) | -0.12 (-0.30, 0.05) |
| 04-07/2020 |  |  |  |  |
| BoschS76  Spain | NR/2019 | 552 | SDQ - Emotion Symptoms | 2.42 (2.14) | 3.29 (2.29) | 0.87 (NR) | 0.39 (0.27, 0.51) | ---------- | ---------- | ---------- | ---------- |
|  | SDQ - Total | 8.62 (5.59) | 11.20 (5.62) | 2.58 (NR) | 0.46 (0.34, 0.58) |
| 05/2020-06/2020 |  |  |  |  |  |
| Chen, I-HS78  China | 10-11/2019 | 535 | DASS-21 | 0.46 (0.49) | 1.22 (0.30) | 0.76 (NR) | 1.87 (1.72, 2.01) | ---------- | ---------- | ---------- | ---------- |
|  |
| 03/2020 |
| Chen, C-YS79  China | 10-11/2019 | 575 | DASS-21 | 21.85 (22.94) | 19.15 (22.13) | -2.70 (NR) | -0.12 (-0.24, 0.00) | ---------- | ---------- | ---------- | ---------- |
|  |
| 01/2020 |
| DaniunaiteS80  Lithuania | 03-05/2019 | 331 | SDQ - Emotional Symptoms | 2.86 (2.29) | 3.27 (2.47) | 0.41 (NR) | 0.17 (0.02, 0.32) | ---------- | ---------- | ---------- | ---------- |
|  |
| 09-10/2020 |
| EzpeletaS81  Spain | NR/2019 | 197 | SDQ-total Parent Version | 5.45 (4.65) | 6.20 (4.44) | 0.75 (3.75) | 0.16 (-0.03, 0.36) | ---------- | ---------- | ---------- | ---------- |
|  |
| 06/2020 |
| FujiharaS82  Japan | 12/2019 | 1,854 | K6 | 5.04 (5.07) | 5.73 (5.14) | 0.69 (NR) | 0.14 (0.07, 0.20) | ---------- | ---------- | ---------- | ---------- |
|  |
| 02/2020 |
| HuS83  UK | NR | 886 | SDQ - Emotion Problems | 3.22 (2.44) | 3.45 (2.44) | 0.23 (NR) | 0.09 (0.00, 0.19) | ---------- | ---------- | ---------- | ---------- |
|  |
| 07/2020 |
| KnowlesS84  UK | NR/2018-2019 | 958-1,055 | SDQ score | ---------- | ---------- | ---------- | ---------- | SDQ score ≥ 18 | 18.3 (13.9, 23.8) | 15.9 (13.0, 19.4) | -2.4 (-4.9, 0.1) |
|  |
| 05-08/2020 |
| MastorciS88  Italy | 09-10/2019 | 1,019 | KIDSCREEN-52 (psychological wellbeing) | 50.23 (9.37) | 48.87 (9.83) | -1.36 (NR) | 0.14 (0.05, 0.23) | ---------- | ---------- | ---------- | ---------- |
|  | KIDSCREEN-52 (mood/emotion) | 48.62 (9.90) | 48.03 (9.82) | -0.59 (NR) | 0.06 (0.03, 0.15) |
| 04/2020 |
| MeirelesS89  Portugal | 04-07/2019 | 1,099 | KIDSCREEN-10 | 3.72 (0.61) | 3.80 (0.56) | 0.08 (NR) | -0.14 (-0.22, -0.05) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05-06/2020 |
| PaizanS91  Germany | 06-10/2019 | 226 | SWLS | 5.37 (1.19) | 5.11 (1.27) | -0.26 (NR) | 0.21 (0.03, 0.40) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05-07/2020 |
| RauS93  Germany | 10-11/2019 | 777 | KIDSCREEN-10 | 51.40 (13.10) | 52.30 (13.90) | 0.90 (NR) | -0.07 (-0.17, 0.03) | ---------- | ---------- | ---------- | ---------- |
|  |
| 06-07/2020 |
| ShoshaniS94  Israel | 09/2019 | 1,537 | PANAS-C - PE | 18.15 (3.74) | 16.20 (3.88) | -1.95 (NR) | 0.51 (0.44, 0.58) | ---------- | ---------- | ---------- | ---------- |
|  | PANAS-C - NE | 9.58 (3.27) | 9.54 (3.29) | -0.04 (NR) | -0.01 (-0.08, 0.06) |
| 05/2020 | GSI-18 - BSI | 16.47 (11.26) | 19.18 (12.03) | 2.71 (NR) | 0.23 (0.16, 0.30) |
| ViraS96  Sweden | 10/2019-01/2020 | 849 | SDQ-emotional problems | 1.50 (0.45) | 1.53 (0.46) | 0.03 (NR) | 0.07 (-0.03, 0.16) | ---------- | ---------- | ---------- | ---------- |
|  |
| 11/2020-02/2021 |
| **Parents** | | | | | | | | | | | |
| AchterbergS72  Netherlands | 01-11/2019 | 106 | BSI | 0.19 (0.22) | 0.34 (0.32) | 0.15 (NR) | 0.54 (0.27, 0.82) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04-05/2020 |
| BoschS76  Spain | NR/2019 | 699 | SDQ - Emotion Symptoms | 1.63 (1.85) | 2.16 (2.03) | 0.53 (NR) | 0.27 (0.17, 0.38) | ---------- | ---------- | ---------- | ---------- |
|  | SDQ - Total | 7.02 (5.57) | 9.40 (5.61) | 2.38 (NR) | 0.43 (0.32, 0.53) |
| 05/2020-06/2020 |  |  |  |  |  |
| GagnéS104  Canada | 03-05/2019 | 127 | K10 | 1.75 (0.52) | 1.85 (0.61) | 0.10 (NR) | 0.18 (-0.07, 0.42) | K10 ≥ 9 | 41.7 (33.5, 50.4) | 40.2 (32.0, 48.9) | -1.6 (-12.3, 9.2) |
|  |
| 05-07/2020 |
| **People with Pre-existing Medical Conditions** | | | | | | | | | | | |
| BeckerS109  USA | 03/2019 | 119 | SF-36 (role emotional) | 77.30 (26.30) | 73.70 (27.60) | -3.60 (NR) | -0.13 (-0.39, 0.12) | ---------- | ---------- | ---------- | ---------- |
|  |
| 03/2020 |
| BonenkampS110  Netherlands | 08/2019 | 177 | SF-12 Mental Component Summary | 48.08 (10.15) | 49.00 (10.04) | 0.91 (10.18) | 0.09 (-0.12, 0.30) | ---------- | ---------- | ---------- | ---------- |
|  |
| 07/2020 |
| ChiuS112  USA | 10/2018 | 133 |  |  |  |  |  | ---------- | ---------- | ---------- | ---------- |
|  | SPANE-P | 22.78 (3.88) | 21.11 (4.18) | -1.67 (5.31) | 0.41 (0.17, 0.66) |
| 09/2020 | SPANE-N | 14.50 (4.35) | 16.11 (4.51) | 1.61 (5.95) | 0.36 (0.12, 0.60) |
| DerksenS113  Netherlands | 01/2019-01/2020 | 2176 | EORTC QLQ-C30-Global quality of life | 79.83 (16.38) | 79.41 (16.18) | -0.42 (10.23) | 0.03 (-0.03, 0.09) | ---------- | ---------- | ---------- | ---------- |
|  |  |  |  |  |  |
| 04-06/2020 | EORTC QLQ-C30-Emotional functioning | 86.93 (17.37) | 87.92 (15.79) | 0.99 (14.95) | -0.06 (-0.12, -0.00) |
| Dunlop-ThomasS114  USA | NR/2017-2019 | 852 | PROMIS - Global mental health | 43.57 (9.34) | 43.75 (9.08) | 0.18 (NR) | 0.02 (-0.08, 0.11) | ---------- | ---------- | ---------- | ---------- |
|  |
| NR/2020-2021 |
| FujiwaraS115  Japan | 07-09/2019 | 245 | EQ-5D-5L | Median (IQR): 0.69 (0.27) | Median (IQR): 0.69 (0.30) | NR (NR) | NR (NR) | ---------- | ---------- | ---------- | ---------- |
|  |
| 07-09/2020 |
| García-RudolphS116  Spain | NR | 175 | WHOQOL-BREF | 61.71 (19.75) | 57.95 (21.96) | -3.76 (NR) | 0.18 (-0.03, 0.39) | ---------- | ---------- | ---------- | ---------- |
|  |
| 11/2020 |
| JohnstoneS119  New Zealand | NR/2018 | 104 | QOLS | 78.74 (14.18) | 73.17 (17.66) | -5.57 (NR) | 0.35 (0.07, 0.62) | ---------- | ---------- | ---------- | ---------- |
|  |
| 07-09/2020 |
| LimS122  USA | NR/2018 | 316 | PROMIS Mental Health | 44.30 (9.30) | 44.50 (8.90) | 0.20 (7.40) | 0.02 (-0.13, 0.18) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04/2020 |
| MöllerS123  Australia, New Zealand | 08-10/2019 | 674 | DASS-21 | 18.95 (18.35) | 18.07 (17.53) | -0.88 (NR) | -0.05 (-0.16, 0.06) | ---------- | ---------- | ---------- | ---------- |
|  |  |  |  |  |  |
| 05-07/2020 | EUROHIS-QOL | 32.35 (5.34) | 32.70 (5.06) | 0.35 (NR) | -0.07 (-0.17, 0.04) |
| ParkS124  Germany | 09/2019–02/2020 | 152 | EQ-5D-3L | Median (IQR): 8.00 (7.00, 9.00) | Median (IQR): 8.00 (6.00, 9.00) | NR (NR) | NR (NR) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05-09/2020 |
| SacreS125  Australia | NR/2018-2019 | 450 | PAID | ---------- | ---------- | ---------- | ---------- | PAID ≥ 40 | 14.7 (11.7, 18.2) | 7.8 (5.7, 10.6) | -6.9 (-9.6, 4.5) |
|  |
| 05-06/2020 |
| SbragiaS126  Italy | 01/2019 | 106 | HADS | 12.91 (6.52) | 11.60 (7.17) | -1.31 (NR) | -0.19 (-0.46, 0.08) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05/2020 |
| SoltanzadehS14  Iran | 11/2019 | 136 | GHQ-28 | 47.51 (11.37) | 54.61 (13.23) | 7.10 (NR) | 0.56 (0.09, 1.04) | ---------- | ---------- | ---------- | ---------- |
|  |
| 07/2020 |
| ThygesenS15  Denmark | 09-12/2019 | 1,543 | SWEMWBS | 24.20 (3.01) | 23.60 (2.00) | -0.60 (NR) | 0.23 (0.16, 0.31) | ---------- | ---------- | ---------- | ---------- |
|  |
| 09-11/2020 |
| **People with Pre-existing Mental Health Conditions** | | | | | | | | | | | |
| HuongS130  Taiwan | 01-12/2018 | 114 | BSRS-5 | 12.04 (6.19) | 10.58 (7.00) | -1.46 (NR) | -0.22 (-0.48, 0.04) | BSRS-5 ≥ 10 | 67.5 (58.5, 75.4) | 57.9 (48.7, 66.6) | -9.6 (-23.0, 4.1) |
|  |
| 01-05/2020 |
| ThygesenS15  Denmark | 09-12/2019 | 343 | SWEMWBS | 24.20 (3.01) | 23.60 (2.00) | -0.60 (NR) | -0.22 (-0.37, -0.07) | ---------- | ---------- | ---------- | ---------- |
|  |
| 09-11/2020 |
| **Women or Females** | | | | | | | | | | | |
| DongS45  China | 09/2019 | 3,162-3,277 | ---------- | ---------- | ---------- | ---------- | ---------- | SCL-90-R ≥ 160 | 19.7 (18.4, 21.1) | 27.9 (26.4, 29.5) | 8.2 (6.3, 10.0) |
|  |
| NR/2020 |
| FujiharaS82  Japan | 12/2019 | 942 | K6 | 5.07 (NR) | 5.85 (NR) | 0.78 (NR) | NR (NR) | ---------- | ---------- | ---------- | ---------- |
|  |
| 02/2020 |
| Megias-RoblesS10  Spain | 11/2019 | 67 | PANAS-NA | 1.93 (0.65) | 2.28 (0.79) | 0.34 (0.86) | 0.48 (0.13, 0.82) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04/2020 |
| MeirelesS89  Portugal | 04-07/2019 | 582 | KIDSCREEN-10 | 3.75 (0.61) | 3.73 (0.55) | -0.02 (NR) | 0.03 (-0.08, 0.15) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05-06/2020 |
| PierceS11  UK | Pre-COVID-19 waves | 7,18130,b 6,38034 | GHQ-12 |  |  |  |  | GHQ-12 ≥ 4 |  |  |  |
| DalyS12  UK |  |  |  |  |  |  |  |  |
|  | 04/2020 | 12.00 (5.91) | 13.60 (7.14) | 1.60 (NR)c | 0.24 (0.21, 0.28) | 24.5 (22.5, 26.4)e | 36.8 (34.8, 38.9)e | 12.4 (9.9, 14.9)e |
|  |  |  |  | 0.88 (NR)d | 0.13 (0.10, 0.17) |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  | 09/2020 | ---------- | ---------- | ---------- | ---------- | 24.5 (22.5, 26.4)e | 25.0 (23.3, 26.8)e | 0.5 (-1.8, 2.9)e |
| Savage, 2020S63  UK | 10/2019 | 154 | WEMWBSf | 43.00 (9.00) | 40.00 (10.00) | -3.00 (NR) | 0.31 (0.09, 0.54) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04/2020 |
| SoltanzadehS14  Iran | 11/2019 | 161 | GHQ-28 | 45.11 (12.07) | 50.91 (12.69) | 5.80 (NR) | 0.47 (0.24, 0.69) | ---------- | ---------- | ---------- | ---------- |
|  |
| 07/2020 |
| ThygesenS15  Denmark | 09-12/2019 | 2,184 | SWEMWBS | 25.10 (9.54) | 24.10 (4.77) | -1.00 (NR) | 0.13 (0.07, 0.19) | ---------- | ---------- | ---------- | ---------- |
|  |
| 09-11/2020 |
| van der Velden, 2020S16  Netherlands | 03/2019 | 2,020 | MHI-5f | ---------- | ---------- | ---------- | ---------- | MHI-5 ≤ 59 |  |  |  |
| van der Velden, 2021S17  Netherlands | 11-12/2019 | 2,062 |  |  |  |
|  |  |  |  |  |  |
|  | 03/2020 |  | 18.9 (17.3, 20.7) | 18.3 (16.7, 20.1) | -0.6 (-2.5, 1.3) |
|  |  |  |  |  |  |
|  | 11-12/2020 |  | 19.1 (17.4, 20.8) | 17.8 (16.2, 19.5) | -1.3 (-3.1, 0.6) |
| **Men or Males** | | | | | | | | | | | |
| DongS45  China | 09/2019 | 923-1,064 | ---------- | ---------- | ---------- | ---------- | ---------- | SCL-90-R ≥ 160 | 14.3 (12.3, 16.5) | 21.2 (18.7, 24.0) | 6.9 (4.0, 9.9) |
|  |
| NR/2020 |
| FujiharaS82  Japan | 12/2019 | 912 | K6 | 5.01 (NR) | 5.61 (NR) | 0.60 (NR) | NR (NR) | ---------- | ---------- | ---------- | ---------- |
|  |
| 02/2020 |
| Megias-RoblesS10  Spain | 11/2019 | 35 | PANAS-NA | 1.88 (0.67) | 2.11 (0.66) | 0.23 (0.66) | 0.34 (-0.14, 0.82) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04/2020 |
| MeirelesS89  Portugal | 04-07/2019 | 517 | KIDSCREEN-10 | 3.69 (0.61) | 3.88 (0.56) | 0.19 (NR) | -0.32 (-0.45, -0.20) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05-06/2020 |
| PierceS11  UK | Pre-COVID-19 waves | 8,19530,b 4,53834 | GHQ-12 |  |  |  |  | GHQ-12 ≥ 4 |  |  |  |
| DalyS12  UK |  |  |  |  |  |  |  |  |
|  | 04/2020 | 10.80 (4.99) | 11.50 (5.75) | 0.70 (NR)c | 0.13 (0.10, 0.16) | 16.7 (14.6, 18.7)e | 21.1 (19.0, 23.3)e | 4.5 (2.0, 7.0)e |
|  |  |  |  | 0.03 (NR)d | 0.01 (-0.03, 0.04) |  |  |  |
|  |  |  |  |  |  |  |  |  |
|  | 09/2020 | ---------- | ---------- | ---------- | ---------- | 16.7 (14.6, 18.7)e | 16.0 (14.0, 17.9)e | -0.7 (-2.9, 1.5)e |
| Savage, 2020S63  UK | 10/2019 | 60 | WEMWBSf | 47.00 (9.00) | 44.00 (10.00) | -3.00 (NR) | 0.31 (-0.04, 0.67) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04/2020 |
| SoltanzadehS14  Iran | 11/2019 | 689 | GHQ-28 | 46.12 (11.36) | 51.38 (12.34) | 5.26 (NR) | 0.44 (0.34, 0.55) | ---------- | ---------- | ---------- | ---------- |
|  |
| 07/2020 |
| ThygesenS15  Denmark | 09-12/2019 | 2,050 | SWEMWBS | 25.10 (5.78) | 24.40 (16.17) | -0.70 (NR) | 0.06 (-0.00, 0.12) | ---------- | ---------- | ---------- | ---------- |
|  |
| 09-11/2020 |
| van der Velden, 2020S16  Netherlands | 03/2019 | 1,962-1,963 | MHI-5f | ---------- | ---------- | ---------- | ---------- | MHI-5 ≤ 59 |  |  |  |
| van der Velden, 2021S17  Netherlands | 11-12/2019 | 2,002 |  |  |  |
|  |  |  |  |  |  |
|  | 03/2020 |  | 14.6 (13.1, 16.3) | 15.6 (14.1, 17.3) | 1.0 (-0.8, 2.7) |
|  |  |  |  |  |  |
|  | 11-12/2020 |  | 14.7 (13.2, 16.3) | 15.9 (14.4, 17.6) | 1.2 (-0.5, 3.0) |

BSI = Brief Symptom Inventory; DToS = Distress Tolerance Scale; GHQ-12 = General Health Questionnaire-12; MHI-5 = Mental Health Index-5; PANAS – NA = Positive and Negative Affect Schedule – Negative Affect; PANAS – PA = Positive and Negative Affect Schedule – Positive Affect; PHQ-4 = Patient Health Questionnaire-4; RRQ = Reflection and Rumination Scale; SCL-90-R = Symptom Check List-90-Revised; SDQ – Extern = Strengths and Difficulties Questionnaire – Externalizing Behavior; SDQ – Intern = Strengths and Difficulties Questionnaire – Internalizing Behavior; SDQ – Total = Strengths and Difficulties Questionnaire – Total; SWLS = Satisfaction with Life Scale; WEMWBS = Warwick Edinburgh Mental Wellbeing Scale.

aPositive Hedges’ g effect sizes and increases in proportions above a threshold indicate worse mental health in COVID-19 compared to pre-COVID-19. Effects for measures where high scores = positive outcomes were reversed to reflect this. bNumber included in fixed effects regression analysis from where majority of data were extracted. cBased on difference between 2020 and 2019 outcomes. dBased on estimate from fixed effects regression model that estimates within-person change accounting for pre-COVID-19 trends. eIncluded proportion outcomes from Daly,31 since Daly reported for two time points.  fHigher scale scores reflect better mental health; thus, direction of effect sizes reversed. gProportions in the study were calculated using age categories based on previous year’s age.

**Supplementary Table 4.** **Individual Study Results for Anxiety Symptoms**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **First Author** | **Pre- and Post-COVID-19 Data Collection** | **N** | **Continuous**  **Outcome Measure** | **Pre-**  **COVID-19 Mean (SD)** | **Post-**  **COVID-19 Mean (SD)** | **Mean (SD) Change**a | **Hedges’ g Standardized Mean Difference (95% CI)** | **Dichotomous Outcome Measure** | **% pre-COVID-19 (95% CI)** | **% post-COVID-19 (95% CI)** | **% Change with 95% CI**a |
| **General Population** | | | | | | | | | | | |
| ChanS3  Hong Kong, China | 07/2019 | 279 | HAI | 15.33 (6.31) | 15.52 (6.70) | 0.19 (NR) | 0.03 (-0.14, 0.20) | ---------- | ---------- | ---------- | ---------- |
|  |
| 07/2020 |
| GeS5  China | 01-12/2019 | 1,547-1,978 | GAD-7 | 9.24 (2.33) | 10.02 (2.28) | 0.78 (NR) | 0.1 (0.03, 0.18) | ---------- | ---------- | ---------- | ---------- |
|  |
| 02-03/2020 |
| HaliwaS6  USA | 09-12/2019 | Sample 1: 300; Sample 2: 146; Sample 3: 142 | Sample 1: GAD-7 Sample 2: DASS-21-Anxiety Sample 3: GAD-7 | Sample 1: 5.58 (5.02) Sample 2: 3.53 (4.89) Sample 3: 4.64 (5.35) | Sample 1: 6.55 (5.98) Sample 2: 3.25 (4.51) Sample 3: 4.82 (5.60) | Sample 1: 0.97 (4.93) Sample 2: -0.28 (2.82) Sample 3: 0.18 (4.21) | Sample 1: 0.18 (0.01, 0.34) Sample 2: -0.08 (-0.31, 0.15) Sample 3: 0.03 (-0.20, 0.27) | Sample 1: GAD-7 ≥ 10 Sample 2: DASS-21-Anxiety ≥ 6 Sample 3: GAD-7 ≥ 10 | Sample 1: 19.0 (15.0, 23.8) Sample 2: 21.9 (16.0, 29.3) Sample 3: 20.4 (14.6, 27.8) | Sample 1: 29.7 (24.8, 35.1) Sample 2: 23.3 (17.2, 30.8) Sample 3: 19.7 (14.0, 27.0) | Sample 1: 10.7 (4.6, 16.6) Sample 2: 1.4 (-6.5, 9.2) Sample 3: -0.7 (-8.0, 6.5) |
|  |
| 04-06/2020 |
| KanburS7  Turkey | NR/2019 | 400 | SCL-90-R Anxiety | 0.27 (NR) | 0.51 (NR) | 0.24 (NR) | NR (NR) | ---------- | ---------- | ---------- | ---------- |
|  |
| NR/2020 |
| Katz, BS8  Canada, Ireland, UK, USA | 04/2019 | 218 | DASS-21 Anxiety | 3.25 (3.91) | 2.83 (3.61) | -0.42 (3.13) | -0.11 (-0.30, 0.08) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04/2020 |
| **Older Adults** | | | | | | | | | | | |
| BartlettS19  Australia | 10/2019 | 1,671 | HADS-A | 5.56 (3.55) | 4.88 (3.34) | -0.68 (NR) | -0.20 (-0.27, -0.13) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04-06/2020 |
| CreeseS21  UK | 10/2019 | 3,281 | GAD-7 | 1.55 (2.64) | 1.94 (2.84) | 0.39 (NR) | 0.14 (0.09, 0.19) | GAD-7 ≥ 10 | 2.2 (1.8, 2.8) | 2.7 (2.2, 3.3) | 0.5 (-0.1, 1.1) |
|  |
| 05-06/2020 |
| HerreraS23  Chile | 11/2019 | 721 | GAI-SF | 2.04 (NR) | 2.26 (NR) | 0.22 (NR) | NR (NR) | GAI-SF ≥ 3 | 40.0 (36.5, 43.6) | 42.9 (39.3, 46.5) | 2.9 (-1.9, 7.7) |
|  |
| 09/2020 |
| RentscherS29  USA | 02-06/2019 | 165 | STAI-State | 27.50 (7.10) | 30.60 (9.60) | 3.10 (NR) | 0.37 (0.15, 0.58) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05-09/2020 |
| RentscherS29  USA | 02-06/2019 | 262 | STAI-State | 27.90 (6.50) | 30.10 (9.10) | 2.20 (NR) | 0.28 (0.11, 0.45) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05-09/2020 |
| SiewS31  Singapore | 02/2018-01/2020 | 411 | GAI-SF | 1.12 (2.63) | 1.40 (3.17) | 0.28 (NR) | 0.10 (-0.04, 0.23) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05-06/2020 |
| van den BesselaarS32  Netherlands | NR/2018-2019 | 984 | HADS-A | 2.58 (2.70) | 3.35 (2.99) | 0.77 (NR) | 0.27 (0.18, 0.36) | ---------- | ---------- | ---------- | ---------- |
|  |
| 06-10/2020 |
| Wong, SS35  Hong Kong, China | 04/2018-03/2019 | 583 | GAD-7 | 2.50 (NR) | 3.00 (NR) | 0.48 (NR) | NRb | ---------- | ---------- | ---------- | ---------- |
|  |
| 03-04/2020 |
| YuS36  Singapore | 02/2018-01/2020 | 419 | GAI | 1.12 (2.58) | 1.38 (3.14) | 0.26 (2.31) | 0.09 (-0.05, 0.23) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05-06/2020 |
| **Young Adults** | | | | | | | | | | | |
| RimfeldS39  UK | NR/2018 | 3,563-3,694 | SMGAD | 7.48 (7.35) | 8.69 (7.54) | 1.21 (6.83) | 0.16 (0.12, 0.21) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04-05/2020 |
| Watkins-MartinS43  Canada | NR/2018 | 1,039 | SMGAD | 4.73 (4.61) | 4.45 (4.70) | -0.28 (NR) | -0.06 (-0.15, 0.03) | GAD-7 ≥ 15 | 4.9 (3.8, 6.4) | 4.7 (3.6, 6.2) | -0.2 (-1.5, 1.1) |
|  |
| 08/2020 |
| **University Students** | | | | | | | | | | | |
| ConceiçãoS44  Portugal | 10/2019 | 341 | GAD-7 | 9.89 (6.19) | 12.15 (6.50) | 2.26 (NR) | 0.36 (0.20, 0.51) | GAD-7 ≥ 10 | 46.0 (40.8, 51.4) | 64.5 (59.3, 69.4) | 18.5 (10.1, 26.5) |
|  |
| 06/2020 |
| ElmerS46  Switzerland | 09/2019 | 209 | GAD-7 | NR | NR | 0.60 (3.47) | 0.17 (-0.02, 0.36) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04/2020 |
| EvansS47  UK | 10/2019 | 251 | HADS-A | 9.35 (4.28) | 9.42 (4.47) | 0.07 (NR) | 0.02 (-0.16, 0.19) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05/2020 |
| GelezelyteS49  Lithuania | 10-12/2019 | 474 | DASS-21 Anxiety | 6.99 (4.94) | 5.87 (4.58) | -1.12 (4.32) | -0.23 (-0.36, -0.11) | ---------- | ---------- | ---------- | ---------- |
|  |
| 10-12/2020 |
| GopalanS50  USA | 11/2019 | 1,004 | CCAPS-62 - Anxiety | 1.31 (1.04) | 1.34 (1.07) | 0.03 (NR) | 0.03 (-0.06, 0.12) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05/2020 |
| HamzaS51  Canada | 05/2019 | 733 | GAD-7 | 6.68 (5.53) | 6.39 (5.46) | -0.29 (NR) | -0.05 (-0.16, 0.05) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05/2020 |
| HeS52  China | 09-12/2019 | 589 | STAI-Trait | 43.27 (7.35) | 44.76 (8.78) | 1.49 (NR) | 0.18 (0.07, 0.30) | ---------- | ---------- | ---------- | ---------- |
|  |
| 02/2020 |
| KoelenS53  Netherlands | 01/2019-01/2020 | 683 | GAD-7 | ---------- | ---------- | ---------- | ---------- | GAD-7 ≥ 10 | 33.6 (30.1, 37.2) | 36.5 (32.9, 40.1) | 2.9 (-1.6, 7.4) |
|  |
| 04-05/2020 |
| Li, Wendy WenS56  China | 11/2019 | 173 | DASS-21 Anxiety | 9.23 (6.16) | 5.09 (5.90) | -4.14 (NR) | -0.68 (-0.90, -0.47) | ---------- | ---------- | ---------- | ---------- |
|  |
| 03/2020 |
| LuS58  China | 09/2019-10/2019 | 5,181 | GAD-7 | ---------- | ---------- | ---------- | ---------- | GAD-7 ≥ 10 | 3.5 (3.0, 4.0) | 3.7 (3.2, 4.2) | 0.2 (-0.3, 0.7) |
|  |
| 04/2020 |
| MauerS59  USA | 09-12/2019 | 1,434 | DASS-21 | 5.42 (4.68) | 5.04 (4.30) | -0.38 (NR) | -0.08 (-0.16, -0.01) | DASS-21 ≥ 10 | 16.6 (14.8, 18.6) | 16.0 (14.2, 18.0) | -0.6 (-2.7, 1.4) |
|  |
| 03-06/2020 |
| MehusS60  USA | 08,12/2019 | 727 | GAD-7 | 5.07 (4.68) | 5.67 (5.09) | 0.60 (NR) | 0.12 (0.02, 0.23) | GAD-7 ≥ 8 | 24.3 (21.4, 27.6) | 29.6 (26.3, 33.0) | 5.3 (1.3, 9.1) |
|  |
| 04/2020 |
| SaraswathiS62  India | 12/2019 | 217 | DASS-21 Anxiety | 4.60 (6.19) | 6.11 (7.13) | 1.51 (NR) | 0.23 (0.04, 0.41) | DASS-21 Anxiety > 7 | 21.2 (16.3, 27.1) | 33.2 (27.3, 39.7) | 12.0 (4.4, 19.4) |
|  |
| 06/2020 |
| Truskauskaite-KunevicieneS66  Lithuania Germany | 10-12/2019 | Lithuania: 450; Germany: 325 | DASS-21 - Anxiety | Lithuania: 7.07 (4.92); Germany: 3.66 (3.66) | Lithuania: 4.16 (4.21); Germany: 2.33 (2.82) | Lithuania: -2.91 (NR); Germany: -1.33 (NR) | Lithuania: -0.63 (-0.77, -0.50); Germany: -0.41 (-0.56, -0.25) | ---------- | ---------- | ---------- | ---------- |
|  |
| 03-04/2020 |
| VoltmerS67  Germany | NR/2019 | 587 | BSI-18 Anxiety | 4.50 (4.40) | 4.10 (4.10) | -0.40 (NR) | -0.09 (-0.21, 0.02) | ---------- | ---------- | ---------- | ---------- |
|  |
| 06/2020 |
| Wang, YitaoS68  China | 11/2019 | 2,559 | SCL-90-R Anxiety | 1.55 (0.49) | 1.48 (0.50) | -0.07 (NR) | -0.14 (-0.20, -0.09) | ---------- | ---------- | ---------- | ---------- |
|  |
| 06/2020 |
| Yang, ZiyanS70  China | 10/2019 | 2,364 | DASS-21 Anxiety | 9.64 (2.88) | 8.92 (2.96) | -0.72 (NR) | -0.25 (-0.30, -0.19) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05/2020 |
| ZimmermanS71  USA | 08/2019 | 205 | GAD-7 | 8.29 (6.28) | 9.71 (6.83) | 1.42 (0.41) | 0.22 (0.02, 0.41) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04/2020 |
| **Children and Adolescents** | | | | | | | | | | | |
| Chen, C-YS79  China | 10-11/2019 | 575 | DASS-21 - Anxiety | 7.98 (7.93) | 7.01 (7.43) | -0.97 (NR) | -0.13 (-0.24, -0.01) | ---------- | ---------- | ---------- | ---------- |
|  |
| 01/2020 |
| KnowlesS84  UK | NR/2018-2019 | 958-1,055 | GAD-7 | ---------- | ---------- | ---------- | ---------- | GAD-7 ≥ 10 | 20.5 (17.3, 24.3) | 17.3 (14.0, 21.0) | -3.1 (-5.8, -0.5) |
|  |
| 05-08/2020 |
| Li, YS85  China | 09/2019 | 831 | ZSAS | ---------- | ---------- | ---------- | ---------- | ZSAS > 50 | 27.7 (24.7, 30.8) | 23.0 (20.3, 26.0) | -4.7 (-7.9, -1.4) |
|  |
| 03/2020 |
| MagsonS87  Australia | NR/2019 | 248 | SCAS Generalized Anxiety | 4.60 (3.74) | 5.10 (4.05) | 0.50 (1.50) | 0.13 (-0.05, 0.30) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05/2020 |
| RauS93  Germany | 10-11/2019 | 777 | RCADS - Anxiety | 24.40 (17.70) | 21.10 (17.00) | -3.30 (NR) | -0.19 (-0.29, -0.09) | ---------- | ---------- | ---------- | ---------- |
|  |
| 06-07/2020 |
| ShoshaniS94  Israel | 09/2019 | 1,537 | BSI-18 - Anxiety | 3.93 (2.68) | 5.24 (3.14) | 1.31 (NR) | 0.45 (0.38, 0.52) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05/2020 |
| TengS95  China | 10-11/2019 | 1,778 | STAI-Trait | 1.95 (0.65) | 1.98 (0.66) | 0.03 (NR) | 0.05 (-0.02, 0.11) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04-05/2020 |
| Wang, WanxinS97  China | 10-12/2019 | 1,790 | GAD-7 | 3.60 (4.32) | 3.56 (4.22) | -0.04 (NR) | -0.01 (-0.07,0.06) | GAD-7 ≥ 5 | 31.6 (29.5, 33.8) | 32.9 (30.7, 35.1) | 1.3 (-1.4, 3.9) |
|  |
| 10-12/2020 |
| WidnallS98  UK | 10/2019 | 603 | HADS-A | Median (IQR): 7.00 (4.00-11.00) | Median (IQR): 6.00 (3.00-10.00) | NR (NR) | NR (NR) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05/2020 |
| Wong, RS99  China | 04-08/2019 | 233 | DASS-21 - Anxiety | NR (NR) | NR (NR) | 0.13 (5.42) | NR (NR) | ---------- | ---------- | ---------- | ---------- |
|  |
| 02/2020 |
| ZhangS101  China | 11/2019 | 1,241 | HBQ Anxiety | 3.06 (0.90) | 3.02 (1.05) | -0.05 (0.90) | -0.05 (-0.13, 0.03) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05/2020 |
| **Parents** | | | | | | | | | | | |
| Loret de MolaS105  Brazil | 01-12/2019 | 1,028 | GAD-7 | ---------- | ---------- | ---------- | ---------- | GAD-7 ≥ 10 | 9.7 (8.1, 11.7) | 25.9 (23.3, 28.6) | 16.2 (13.2, 19.1) |
|  |
| 05-07/2020 |
| ThompsonS108  USA | NR/2018-2019 | 147 | GAD-7 | 6.05 (4.70) | 7.42 (5.92) | 1.37 (6.02) | 0.25 (0.02, 0.49) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04/2020 |
| **People with Pre-existing Medical Conditions** | | | | | | | | | | | |
| ChiuS112  USA | 10/2018 | 133 | HADS-A | 6.89 (3.92) | 6.95 (3.85) | 0.06 (3.30) | 0.02 (-0.22, 0.25) | ---------- | ---------- | ---------- | ---------- |
|  |
| 09/2020 |
| DerksenS113  Netherlands | 01/2019-01/2020 | 2176 | HADS-A | 3.24 (3.20) | 3.18 (3.16) | -0.06 (2.34) | -0.02 (-0.08, 0.04) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04-06/2020 |
| FujiwaraS115  Japan | 07-09/2019 | 245 | HADS-A | Median (IQR): 6.00 (5.00) | Median (IQR): 6.00 (6.00) | NR (NR) | NR (NR) | ---------- | ---------- | ---------- | ---------- |
|  |
| 07-09/2020 |
| García-RudolphS116  Spain | NR | 175 | HADS-A | 6.21 (4.28) | 6.52 (4.64) | 0.31 (NR) | 0.07 (-0.14, 0.28) | ---------- | ---------- | ---------- | ---------- |
|  |
| 11/2020 |
| HenryS118  Canada, France, UK, USA | 07-12/2019 | 435 | PROMIS Anxiety |  |  |  |  | ---------- | ---------- | ---------- | ---------- |
|  |  |  |  |  |
| 04/2020 | 52.66 (10.41) | 57.54 (8.79) | 4.88 (NR) | 0.51 (0.37, 0.64) |
|  |  |  |  |  |
| 09-10/2020 | 52.66 (10.41) | 53.75 (9.46) | 1.09 (NR) | 0.11 (-0.02, 0.24) |
|  |  |  |  |  |
| 03/2021 | 52.66 (10.41) | 53.19 (9.70) | 0.53 (NR) | 0.05 (-0.08, 0.18) |
| JohnstoneS119  New Zealand | NR/2018 | 104 | HADS-A | 5.88 (4.12) | 5.55 (4.23) | -0.33 (NR) | -0.08 (-0.35, 0.19) | ---------- | ---------- | ---------- | ---------- |
|  |
| 07-09/2020 |
| Katz, PS120  USA | NR/2019 | 1,504 | GAD-2 | 0.66 (1.18) | 0.99 (1.35) | 0.33 (NR) | 0.26 (0.19, 0.33) | ---------- | ---------- | ---------- | ---------- |
|  |
| 03-06/2020 |
| LiangS121  China | 12/2019 | 114 | ZSAS | 32.80 (7.20) | 32.80 (7.20) | 0.00 (NR) | 0.00 (-0.27, 0.27) | ---------- | ---------- | ---------- | ---------- |
|  |
| 02-03/2020 |
| LimS122  USA | NR/2018 | 316 | PROMIS Anxiety | 50.30 (11.30) | 50.30 (11.10) | 0.00 (10.20) | 0.00 (-0.16, 0.16) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04/2020 |
| ParkS124  Germany | 09/2019–02/2020 | 152 | HADS-A | Median (IQR): 6.00 (2.00, 9.00) | Median (IQR): 6.00 (3.00, 8.00) | NR (NR) | NR (NR) | HADS-A ≥ 8 | 17.0 (12.0, 23.9) | 11.0 (6.6, 16.4) | -5.9 (-11.5, -0.6) |
|  |
| 05-09/2020 |
| RentscherS29  USA | 02-06/2019 | 262 | STAI-State | 27.90 (6.50) | 30.10 (9.10) | 2.20 (NR) | 0.28 (0.11, 0.45) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05-09/2020 |
| SacreS125  Australia | NR/2018-2019 | 450 | GAD-7 | 3.30 (4.10) | 3.10 (4.30) | -0.20 (NR) | -0.05 (-0.18, 0.08) | GAD-7 ≥ 10 | 8.4 (6.2, 11.4) | 8.4 (6.2, 11.4) | 0.0 (-2.8, 2.8) |
|  |
| 05-06/2020 |
| SbragiaS126  Italy | 01/2019 | 106 | HADS-A | 7.02 (3.62) | 6.09 (4.05) | -0.93 (NR) | -0.24 (-0.51, 0.03) | HADS-A > 8 | 54.0 (44.3, 63.0) | 46.0 (37.0, 55.7) | -8.0 (-19.9, 5.1) |
|  |
| 05/2020 |
| Wong, SS35  Hong Kong, China | 04/2018-03/2019 | 583 | GAD-7 | 2.50 (NR) | 3.00 (NR) | 0.48 (NR) | NRb | ---------- | ---------- | ---------- | ---------- |
|  |
| 03-04/2020 |
| **People with Pre-existing Mental Health Conditions** | | | | | | | | | | | |
| GentileS129  Italy, Paraguay | 10-12/2019  03-04/2020 | 110 | HAM-A | 16.60 (9.47) | 18.50 (9.68) | 1.90 (NR) | 0.20 (-0.07, 0.46) | ---------- | ---------- | ---------- | ---------- |
| SwerdlowS131  USA | 03/2017-04/2020 | 144 | MASQ-30 - Anxiety | 16.01 (5.29) | 17.89 (6.80) | 1.88 (NR) | 0.31 (0.08, 0.54) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04-06/2020 |
| YoungS132  UK | 09/2018-02/2020  04-09/2020 | 12108 | GAD-7 | 8.78 (5.96) | 8.48 (5.83) | -0.30 (NR) | -0.05 (-0.08, -0.03) | ---------- | ---------- | ---------- | ---------- |
| **Medical Staff** | | | | | | | | | | | |
| Li, WeidongS133  China | 10-11/2019 | 385 | GAD-7 | 4.33 (NR) | 5.43 (NR) | 1.10 (NR) | NRb | ---------- | ---------- | ---------- | ---------- |
|  |
| 01-02/2020 |
| **Sexual or Gender Minority Individuals** | | | | | | | | | | | |
| BavintonS134  Australia | NR/2019 | 681 | GAD-7 | 4.54 (4.95) | 4.96 (5.07) | 0.42 (NR) | 0.08 (-0.02, 0.19) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04/2020 |
| FlentjeS135  USA | 06/2019 | 2,282 | GAD-7 | 5.78 (5.21) | 8.89 (6.22) | 3.11 (5.32) | 0.54 (0.48, 0.60) | ---------- | ---------- | ---------- | ---------- |
|  |
| 03-04/2020 |
| GhabrialS136  Canada | NR/2019 | 780 | OASIS | 10.13 (4.70) | 10.35 (4.42) | 0.22 (NR) | 0.05 (-0.05, 0.15) | ---------- | ---------- | ---------- | ---------- |
|  |
| 09-10/2020 |
| **Women or Females** | | | | | | | | | | | |
| Li, YS85  China | 09/2019 | 328 | ZSAS | EMM (SE): 47.50 (0.50) | EMM (SE): 45.70 (0.52) | NR (NR) | NR (NR) | ---------- | ---------- | ---------- | ---------- |
|  |
| 03/2020 |
| LimS122  USA | NR/2018 | 295 | PROMIS Anxiety | 50.20 (11.50) | 50.40 (11.10) | 0.20 (10.10) | 0.02 (-0.14, 0.18) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04/2020 |
| Loret de MolaS105  Brazil | 01-12/2019 | 1,028 | GAD-7 | ---------- | ---------- | ---------- | ---------- | GAD-7 ≥ 10 | 9.7 (8.1, 11.7) | 25.9 (23.3, 28.6) | 16.2 (13.2, 19.1) |
|  |
| 05-07/2020 |
| MagsonS87  Australia | NR/2019 | 126 | SCAS Generalized Anxiety | 5.55 (4.05) | 6.52 (4.31) | 0.97 (NR) | 0.23 (-0.02, 0.48) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05/2020 |
| RentscherS29  USA | 02-06/2019 | 165 | STAI-State | 27.50 (7.10) | 30.60 (9.60) | 3.10 (NR) | 0.37 (0.15, 0.58) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05-09/2020 |
| RentscherS29  USA | 02-06/2019 | 262 | STAI-State | 27.90 (6.50) | 30.10 (9.10) | 2.20 (NR) | 0.28 (0.11, 0.45) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05-09/2020 |
| RimfeldS39  UK | NR/2018 | 2,513 | SMGAD | 8.15 (7.53) | 9.69 (7.69) | 1.54 (7.61) | 0.20 (0.14, 0.26) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04-05/2020 |
| SaraswathiS62  India | 12/2019 | 139 | DASS-21 | 4.59 (6.29) | 5.94 (6.93) | 1.35 (NR) | 0.20 (-0.03, 0.44) | DASS-21 Anxiety > 7 | 18.7 (13.1, 26.0) | 32.4 (25.2, 40.5) | 13.7 (4.4, 22.7) |
|  | Anxiety |
| 06/2020 |  |
| **Men or Males** | | | | | | | | | | | |
| Li, YS85  China | 09/2019 | 503 | ZSAS | EMM (SE): 44.70 (0.59) | EMM (SE): 44.80 (0.62) | NR (NR) | NR (NR) | ---------- | ---------- | ---------- | ---------- |
|  |
| 03/2020 |
| LimS122  USA | NR/2018 | 21 | PROMIS Anxiety | 50.50 (9.90) | 48.60 (11.00) | -1.90 (12.10) | -0.17 (-0.79, 0.45) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04/2020 |
| MagsonS87  Australia | NR/2019 | 122 | SCAS Generalized Anxiety | 3.63 (3.13) | 3.64 (3.16) | 0.01 (NR) | 0.00 (-0.25, 0.25) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05/2020 |
| RimfeldS39  UK | NR/2018 | 1,050 | SMGAD | 5.88 (6.66) | 6.30 (6.58) | 0.42 (6.62) | 0.06 (-0.02, 0.15) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04-05/2020 |
| SaraswathiS62  India | 12/2019 | 78 | DASS-21 Anxiety | 4.62 (6.04) | 6.41 (7.50) | 1.79 (NR) | 0.26 (-0.05, 0.57) | DASS-21 Anxiety > 7 | 25.6 (17.3, 36.3) | 34.6 (25.0, 45.7) | 9.0 (-4.0, 21.5) |
|  |
| 06/2020 |

BSI-18-Anxiety = Brief Symptom Inventory - Anxiety; DASS-21 Anxiety = Depression, Anxiety, and Stress Scale – Anxiety subscale; GAD-2 = Generalized Anxiety Disorder-2; GAD-7 = Generalized Anxiety Disorder-; HBQ = MacArthur Health and Behavior Questionnaire; SCAS = Spence Children's Anxiety Scale; SMGAD= Severity Measure for Generalized Anxiety Disorder; ZSAS = Zung Self-rating Anxiety Scale.

aPositive Hedges’ g effect sizes and increases in proportions above a threshold indicate worse mental health in COVID-19 compared to pre-COVID-19. Effects for measures where high scores = positive outcomes were reversed to reflect this. bNot enough information reported to calculate. cProvided by authors. dIncluded because it is estimated that over 80% of pre-COVID-19 data would have been collected by December 31, 2019.

**Supplementary Table 5.** **Individual Study Results for Depression Symptoms**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **First Author** | **Pre- and Post-COVID-19 Data Collection** | **N** | **Continuous**  **Outcome Measure** | **Pre-**  **COVID-19 Mean (SD)** | **Post-**  **COVID-19 Mean (SD)** | **Mean (SD) Change**a | **Hedges’ g Standardized Mean Difference (95% CI)** | **Dichotomous Outcome Measure** | **% pre-COVID-19 (95% CI)** | **% post-COVID-19 (95% CI)** | **% Change with 95% CI**a |
| **General Population** | | | | | | | | | | | |
| GeS5  China | 01-12/2019 | 1,547-1,978 | PHQ-9 | 12.93 (2.71) | 13.58 (2.46) | 0.65 (NR) | 0.25 (0.19, 0.31) | ---------- | ---------- | ---------- | ---------- |
|  |
| 02-03/2020 |
| HaliwaS6  USA | 09-12/2019 | Sample 1: 300; Sample 2: 146; Sample 3: 142 | Sample 1:PHQ-8 Sample 2: DASS-21-Depression Sample 3: PHQ-8 | Sample 1: 5.92 (5.26) Sample 2: 4.81 (5.92) Sample 3: 5.15 (5.81) | Sample 1: 5.79 (6.04) Sample 2: 4.79 (5.67) Sample 3: 5.32 (6.08) | Sample 1: -0.13 (4.09) Sample 2: -0.02 (4.83) Sample 3: 0.17 (4.13) | Sample 1: -0.02 (-0.18, 0.14) Sample 2: 0.00 (-0.23, 0.23) Sample 3: 0.03 (-0.20, 0.26) | Sample 1:PHQ-8 ≥ 10 Sample 2: DASS-21-Depression ≥ 7 Sample 3: PHQ-8 ≥ 10 | Sample 1: 21.3 (17.1, 26.3) Sample 2: 30.8 (23.9, 38.7) Sample 3: 24.6 (18.3, 32.3) | Sample 1: 27.0 (22.3, 32.3) Sample 2: 32.9 (25.8, 40.9) Sample 3: 23.9 (17.7, 31.6) | Sample 1: 5.7 (-0.2, 11.5) Sample 2: 2.1 (-7.1, 11.2) Sample 3: -0.7 (-8.6, 7.2) |
|  |
| 04-06/2020 |
| KanburS7  Turkey | NR/2019 | 400 | SCL-90-R Depression | 0.33 (NR) | 0.69 (NR) | 0.36 (NR) | NR (NR) | ---------- | ---------- | ---------- | ---------- |
|  |
| NR/2020 |
| Katz, BS8  Canada, Ireland, UK, USA | 04/2019 | 218 | DASS-21 Depression | 5.85 (5.64) | 6.28 (5.50) | 0.43 (4.38) | 0.08 (-0.11, 0.26) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04/2020 |
| WanbergS18  USA | 04-06/2019 | 1,117 | PHQ-8 | 4.18 (4.60) | 4.77 (4.83) | 0.59 (NR) | 0.13 (0.04, 0.21) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04/2020 |
| **Older Adults** | | | | | | | | | | | |
| BartlettS19  Australia | 10/2019 | 1,671 | HADS-D | 2.07 (2.09) | 2.05 (2.19) | -0.02 (NR) | -0.01 (-0.08, 0.06) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04-06/2020 |
| BriggsS20  Ireland | NR/2018 | 3,490 | CES-D-8 | ---------- | ---------- | ---------- | ---------- | CES-D-8 ≥ 9 | 5.9 (5.1, 6.8) | 19.8 (18.5, 21.2) | 13.9 (12.5, 15.3) |
|  |
| 07-11/2020 |
| CreeseS21  UK | 10/2019 | 3,281 | PHQ-9 | 2.51 (3.29) | 3.07 (3.58) | 0.56 (NR) | 0.16 (0.11, 0.21) | PHQ-9 ≥ 10 | 4.1 (3.5, 5.0) | 5.6 (4.9, 6.4) | 1.5 (0.6, 2.3) |
|  |
| 05-06/2020 |
| HerreraS23  Chile | 11/2019 | 721 | PHQ-9 | 4.25 (NR) | 5.05 (NR) | 0.80 (NR) | NR (NR) | PHQ-9 ≥ 7 | 23.8 (20.8, 27.0) | 30.2 (26.9, 33.6) | 6.4 (2.4, 10.4) |
|  |
| 09/2020 |
| LeeS26  Singapore | 12/2017-11/2019 | 496 | PHQ-9 | 0.95 (2.47) | 0.64 (1.49) | -0.31 (NR) | -0.15 (-0.28, -0.03) | PHQ-9 ≥ 6 | 4.8 (3.3, 7.1) | 2.2 (1.2, 3.9) | -2.6 (-4.4, -1.3) |
|  |
| 05-06/2020 |
| MartínezS27  Spain | 10/2019 | 141 | CES-D | 11.90 (8.90) | 14.20 (9.10) | 2.30 (9.42) | 0.25 (0.02, 0.49) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04/2020 |
| RentscherS29  USA | NR | 262 | CES-D | 6.30 (7.00) | 8.10 (7.60) | 1.80 (NR) | 0.25 (0.07, 0.42) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05-09/2020 |
| RentscherS29  USA | NR | 165 | CES-D | 4.50 (5.40) | 7.60 (8.00) | 3.10 (NR) | 0.45 (0.23, 0.67) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05-09/2020 |
| UchidaS128  Japan | 04/2019-03/2020 | 35 | CES-D-SF | Median (IQR): 8.00 (5.00, 11.00) | Median (IQR): 7.00 (6.00, 9.00) | NR (NR) | NR (NR) | CES-D-SF ≥ 10 | 31.4 (18.6, 48.0) | 22.9 (12.1, 39.0) | -8.6 (-23.0, 6.1) |
|  |
| 07/2020-03/2021 |
| van den BesselaarS32  Netherlands | NR/2018-2019 | 984 | CES-D-10 | 4.49 (4.05) | 5.92 (4.11) | 1.43 (NR) | 0.35 (0.26, 0.44) | ---------- | ---------- | ---------- | ---------- |
|  |
| 06-10/2020 |
| Wong, SS35  Hong Kong, China | 04/2018-03/2019 | 583 | PHQ-9 | 4.40 (NR) | 4.50 (NR) | 0.19 (NR) | NRc | ---------- | ---------- | ---------- | ---------- |
|  |
| 03-04/2020 |
| YuS36  Singapore | 02/2018-01/2020 | 419 | GDS-15 | 1.02 (1.76) | 2.11 (2.30) | 1.09 (2.10) | 0.53 (0.39, 0.67) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05-06/2020 |
| **Young Adults** | | | | | | | | | | | |
| MarmetS38  Switzerland | 04/2019-02/2020f | 2,228 | MDI | 9.07 (7.69) | 7.60 (7.79) | -1.47 (NR) | -0.19 (-0.25, -0.13) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05-06/2020 |
| RimfeldS39  UK | NR/2018 | 3,563-3,694 | SMFQ | 4.36 (4.07) | 4.36 (3.94) | 0.00 (3.82) | 0.00 (-0.05, 0.05) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04-05/2020 |
| RommS40  USA | 09/2019 | 1,082 | PHQ-2 | 1.71 (1.72) | 2.10 (1.74) | 0.38 (1.80) | 0.22 (0.14, 0.30) | ---------- | ---------- | ---------- | ---------- |
|  |
| 03/2020 |
| Watkins-MartinS43  Canada | NR/2018 | 1,039 | CES-D-12 | 9.30 (6.42) | 9.59 (6.79) | 0.29 (NR) | 0.04 (-0.04, 0.13) | CES-D-12 ≥ 21 | 6.2 (4.9, 7.8) | 8.1 (6.2, 9.5) | 1.9 (0.2, 3.7) |
|  |
| 08/2020 |
| **University Students** | | | | | | | | | | | |
| ConceiçãoS44  Portugal | 10/2019 | 341 | PHQ-9 | 9.66 (7.45) | 12.89 (6.99) | 3.23 (NR) | 0.45 (0.29, 0.60) | PHQ-9 ≥ 15 | 22.6 (18.7, 27.6) | 37.0 (32.3, 42.5) | 14.4 (8.1, 20.5) |
|  |  |  |  |  |  |  |  |  |  |  |
| 06/2020 |  |  |  |  |  |  |  |  |  |  |
| ElmerS46  Switzerland | 09/2019 | 209 | CES-D | NR | NR | 4.44 (7.23) | 0.53 (0.33, 0.72) | ---------- | ---------- | ---------- | ---------- |
|  |  |  |  |  |  |  |  |  |  |  |
| 04/2020 |  |  |  |  |  |  |  |  |  |  |
| EvansS47  UK | 10/2019 | 259 | HADS-D | 4.33 (3.26) | 6.31 (3.74) | 1.97 (NR) | 0.56 (0.38, 0.73) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05/2020 |
| Fuller-RowellS48  USA | 09/2018-04/2019 | 263 | BDI-II | 6.50 (7.25) | 10.75 (8.95) | 4.25 (NR) | 0.52 (0.35, 0.69) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04-06/2020 |
| GelezelyteS49  Lithuania | 10-12/2019 | 474 | DASS-21 Depression | 7.88 (5.64) | 7.26 (5.27) | -0.62 (5.25) | -0.11 (-0.24, 0.01) | ---------- | ---------- | ---------- | ---------- |
|  |
| 10-12/2020 |
| GopalanS50  USA | 11/2019 | 1,004 | CES-D-10 | 10.34 (6.21) | 13.12 (6.93) | 2.78 (NR) | 0.42 (0.33, 0.51) | CES-D-10 > 10 | 44.2 (41.2, 47.3) | 60.9 (57.8, 63.8) | 16.6 (11.9 , 21.3) |
|  |
| 05/2020 |
| HamzaS51  Canada | 05/2019 | 733 | CES-D-R | 17.62 (13.46) | 18.44 (13.24) | 0.82 (NR) | 0.06 (-0.04, 0.16) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05/2020 |
| KoelenS53  Netherlands | 01/2019-01/2020 | 671 | CES-D | ---------- | ---------- | ---------- | ---------- | CES-D ≥ 16 | 48.7 (45.0, 52.5) | 55.3 (51.5, 59.0) | 6.6 (0.9, 12.1) |
|  |
| 04-05/2020 |
| Li, Wendy WenS56  China | 11/2019 | 173 | DASS-21 Depression | 6.25 (6.15) | 4.99 (6.15) | -1.26 (NR) | -0.20 (-0.41, 0.01) | ---------- | ---------- | ---------- | ---------- |
|  |
| 03/2020 |
| LiuS57  China | (04-10/2018)-(04-10/2019) | 8079 | PHQ-9 | 4.64 (3.39) | 3.33 (3.90) | -1.31 (NR) | -0.36 (-0.39, -0.33) | PHQ-9 ≥ 10 | 6.6 (6.1, 7.2) | 6.3 (5.7, 7.0) | -0.3 (-0.8, 0.3) |
|  | CIDI 3.0 | 2.7 (2.3, 3.1) | 2.1 (1.7, 2.5) | -0.6 (-0.9, -0.3) |
| 09-10/2020 |  |  |  |  |
| LuS58  China | 09/2019-10/2019 | 5,181 | PHQ-9 | ---------- | ---------- | ---------- | ---------- | PHQ-9 ≥ 10 | 5.8 (5.1, 6.4) | 7.2 (6.6, 8.0) | 1.4 (0.7, 2.1) |
|  |
| 04/2020 |
| MehusS60  USA | 08,12/2019 | 727 | PHQ-9 | 5.70 (5.09) | 6.83 (5.50) | 1.13 (NR) | 0.21 (0.11, 0.32) | PHQ-9 ≥ 10 | 19.3 (16.6, 22.3) | 27.8 (24.7, 31.2) | 8.5 (4.7, 12.3) |
|  |
| 04/2020 |
| RatnerS61  USA | 09/2019 | 152 | BDI-II | 0.38 (0.40) | 0.43 (0.45) | 0.05 (NR) | 0.12 (-0.11, 0.34) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04/2020 |
| SaraswathiS62  India | 12/2019 | 217 | DASS-21 Depression | 7.55 (7.86) | 8.16 (8.9) | 0.61 (NR) | 0.07 (-0.12, 0.26) | DASS-21 Depression > 9 | 33.2 (27.3, 39.7) | 35.5 (29.4, 42.1) | 2.3 (-5.6, 10.2) |
|  |
| 06/2020 |
| ShiratoriS65  Japan | NR/2019 | 6,847 | PHQ-9 | 2.89 (3.44) | 4.05 (4.17) | 1.16 (NR) | 0.30 (0.27, 0.34) | PHQ-9 ≥ 10 | 5.2 (4.7, 5.8) | 9.8 (9.1, 10.5) | 4.6 (3.9, 5.3) |
|  |
| 06/2020 |
| Truskauskaite-KunevicieneS66  Lithuania Germany | 10-12/2019 | Lithuania: 450; Germany: 325 | DASS-21 - Depression | Lithuania: 7.72 (5.66); Germany: 5.09 (4.57) | Lithuania: 6.54 (5.18); Germany: 4.71 (4.36) | Lithuania: -1.18 (NR); Germany: -0.38 (NR) | Lithuania: -0.22 (-0.35, -0.09); Germany: -0.08 (-0.24, 0.07) | ---------- | ---------- | ---------- | ---------- |
|  |
| 03-04/2020 |
| VoltmerS67  Germany | NR/2019 | 588 | BSI-18 Depression | 4.80 (5.00) | 4.50 (4.80) | -0.30 (NR) | -0.06 (-0.18, 0.05) | ---------- | ---------- | ---------- | ---------- |
|  |
| 06/2020 |
| Wang, YitaoS68  China | 11/2019 | 2,559 | SCL-90-R Depression | 1.55 (0.53) | 1.51 (0.54) | -0.04 (NR) | -0.07 (-0.13, -0.02) | ---------- | ---------- | ---------- | ---------- |
|  |
| 06/2020 |
| Yang, XS69  China | 12/2018 | 195 | CES-D | 15.93 (9.97) | 19.08 (6.63) | 3.15 (NR) | 0.37 (0.17, 0.57) | ---------- | ---------- | ---------- | ---------- |
|  |
| 06/2020 |
| Yang, ZiyanS70  China | 10/2019 | 2,364 | DASS-21 Depression | 8.87 (2.62) | 8.67 (2.92) | -0.20 (NR) | -0.07 (-0.13, -0.02) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05/2020 |
| ZimmermanS71  USA | 08/2019 | 205 | PHQ-9 | 8.91 (6.59) | 12.09 (7.73) | 3.19 (0.51) | 0.44 (0.25,0.64) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04/2020 |
| **Children and Adolescents** | | | | | | | | | | | |
| AdachiS73  Japan | 09/2019 | 4,118 | PHQ-A | 4.14 (4.60) | 3.84 (4.24) | -0.30 (NR) | -0.07 (-0.11, -0.02) | PHQ-A ≥ 10 | 12.2 (11.2, 13.2) | 9.9 (9.1, 10.9) | -2.3 (-3.2, -1.3) |
|  |
| 07/2020 |
| CharmaramanS77  USA | NR/2019 | 586 | CESDR-10 | NR (NR) | NR (NR) | Change estimate (B): 2.23 | NR (NR) | ---------- | ---------- | ---------- | ---------- |
|  |
| 10-12/2020 |
| Chen, C-YS79  China | 10-11/2019 | 575 | DASS-21 - Depression | 5.86 (7.89) | 5.08 (7.38) | -0.78 (NR) | -0.10 (-0.22, 0.01) | ---------- | ---------- | ---------- | ---------- |
|  |
| 01/2020 |
| KnowlesS84  UK | NR/2018-2019 | 958-1,055 | SMFQ | ---------- | ---------- | ---------- | ---------- | SMFQ ≥ 12 | 27.8 (22.6, 33.7) | 22.6 (19.3, 26.4) | -5.1 (-8.1, -2.1) |
|  |
| 05-08/2020 |
| Li, YS85  China | 09/2019 | 831 | BDI-II | ---------- | ---------- | ---------- | ---------- | BDI-II > 13 | 35.4 (32.2, 38.7) | 27.8 (24.9, 30.9) | -7.6 (-11.1, -4.0) |
|  |
| 03/2020 |
| LiaoS86  China | 12/2019 | 2,496 | CES-DC | 15.10 (10.50) | 15.90 (11.10) | 0.80 (NR) | 0.07 (0.02, 0.13) | ---------- | ---------- | ---------- | ---------- |
|  |
| 07/2020 |
| MagsonS87  Australia | NR/2019 | 248 | SMFQ | 3.81 (4.31) | 6.12 (6.04) | 2.31 (5.81) | 0.44 (0.26, 0.62) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05/2020 |
| NaumannS90  Germany | 11/2018-07/2019 | 854 | STDS | ---------- | ---------- | ---------- | ---------- | STDS > 25 | 10.4 (8.4, 12.5) | 25.3 (22.4, 28.2) | 14.9 (11.7, 18.1) |
|  |
| 05/2020-07/2020 |
| PolackS92  USA | 01-09/2019 | 112 | CDI-S | 2.85 (3.14) | 3.96 (3.79) | 1.11 (2.77) | 0.32 (0.06, 0.58) | ---------- | ---------- | ---------- | ---------- |
|  |
| 03-06/2020 |
| RauS93  Germany | 10-11/2019 | 777 | RCADS - Depression | 6.27 (5.30) | 5.41 (5.35) | -0.86 (NR) | -0.16 (-0.26, -0.06) | ---------- | ---------- | ---------- | ---------- |
|  |
| 06-07/2020 |
| ShoshaniS94  Israel | 09/2019 | 1,537 | BSI-18 - Depression | 6.14 (4.73) | 7.59 (5.25) | 1.45 (NR) | 0.29 (0.22, 0.36) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05/2020 |
| TengS95  China | 10-11/2019 | 1,778 | CES-D | 0.81 (0.59) | 0.83 (0.60) | 0.02 (NR) | 0.03 (-0.03, 0.10) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04-05/2020 |
| Wang, WanxinS97  China | 10-12/2019 | 1,790 | CES-D | 13.69 (10.53) | 13.44 (10.28) | -0.25 (NR) | -0.02 (-0.09, 0.04) | CES-D ≥ 16 | 30.0 (27.9, 32.2) | 29.2 (27.1, 31.4) | -0.8 (-3.3, 1.7) |
|  |
| 10-12/2020 |
| Wong, RS99  China | 04-08/2019 | 233 | DASS-21 - Depression | NR (NR) | NR (NR) | 0.84 (6.22) | NR (NR) | ---------- | ---------- | ---------- | ---------- |
|  |
| 02/2020 |
| Yang, ZhengqianS100  China | 11/2019 | 1,125 | CES-D | 0.94 (0.63) | 0.75 (0.64) | -0.19 (NR) | -0.30 (-0.38, -0.22) | ---------- | ---------- | ---------- | ---------- |
|  |
| 08/2020 |
| ZhangS101  China | 11/2019 | 1,241 | MFQ | 16.6 (12.20) | 17.7 (14.40) | 1.49 (11.41) | 0.11 (0.03, 0.19) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05/2020 |
| **Parents** | | | | | | | | | | | |
| AdesoganS102  USA | NR/2018-03/2020 | 329 | CES-D | 6.56 (4.22) | 8.22 (5.52) | 1.66 (NR) | 0.34 (0.18, 0.49) | ---------- | ---------- | ---------- | ---------- |
|  |
| 06-09/2020 |
| FrankS103  USA | 08/2018 | 180 | PHQ-9 | 3.65 (5.77) | 4.33 (6.24) | 0.68 (NR) | 0.11 (-0.09, 0.32) | ---------- | ---------- | ---------- | ---------- |
|  |
| 08/2020 |
| Loret de MolaS105  Brazil | 01-12/2019 | 1,042 | EPDS | ---------- | ---------- | ---------- | ---------- | EPDS ≥ 13 | 5.1 (3.8, 6.5) | 29.5 (26.6, 32.1) | 24.4 (21.3, 27.2) |
|  |
| 05-07/2020 |
| PitchikS106  Bangladesh | 05-06/2019 | 517 | CES-D | 13.40 (8.70) | 12.80 (9.20) | -0.60 (NR) | -0.07 (-0.19, 0.05) | ---------- | ---------- | ---------- | ---------- |
|  |
| 07-09/2020 |
| RiveraS107  Mexico | NR/2018-2019 | 466 | EDS | 7.48 (5.80) | 7.34 (5.83) | -0.14 (NR) | -0.02 (-0.15, 0.10) | EDS > 12 | 19.5 (16.4, 23.6) | 19.1 (16.0, 23.1) | -0.4 (-4.4, 3.5) |
|  |
| 05-11/2020 |
| ThompsonS108  USA | NR/2018-2019 | 147 | CES-D | 14.22 (10.13) | 19.28 (11.74) | 5.06 (13.08) | 0.46 (0.23, 0.69) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04/2020 |
| **People with Pre-existing Medical Conditions** | | | | | | | | | | | |
| BeckerS109  USA | 03/2019 | 121 | CESD-10 | 8.40 (5.50) | 9.10 (5.60) | 0.70 (NR) | 0.13 (-0.13, 0.38) | ---------- | ---------- | ---------- | ---------- |
|  |
| 03/2020 |
| ChaoS111  USA | 02/2018-02/2020 | 2,679 | PHQ-8 | 2.50 (3.30) | 3.50 (4.00) | 1.00 (NR) | 0.27 (0.22, 0.33) | PHQ-8 ≥ 10 | 4.6 (3.8, 5.5) | 8.5 (7.4, 9.6) | 3.9 (2.8, 5.0) |
|  |
| 07-12/2020 |
| ChiuS112  USA | 10/2018 | 133 | HADS-D | 4.61 (3.65) | 5.82 (3.85) | 1.21 (3.50) | 0.32 (0.08, 0.56) | ---------- | ---------- | ---------- | ---------- |
|  |
| 09/2020 |
| DerksenS113  Netherlands | 01/2019-01/2020 | 2176 | HADS-D | 2.98 (3.22) | 2.78 (3.10) | -0.20 (3.20) | -0.06 (-0.12, 0.00) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04-06/2020 |
| Dunlop-ThomasS114  USA | NR/2017-2019 | 852 | PROMIS - Depression | 51.40 (10.65) | 49.80 (9.87) | -1.60 (NR) | -0.16 (-0.25, -0.06) | ---------- | ---------- | ---------- | ---------- |
|  |
| NR/2020-2021 |
| FujiwaraS115  Japan | 07-09/2019 | 245 | HADS-D | Median (IQR): 7.00 (6.00) | Median (IQR): 7.00 (6.00) | NR (NR) | NR (NR) | ---------- | ---------- | ---------- | ---------- |
|  |
| 07-09/2020 |
| García-RudolphS116  Spain | NR | 175 | HADS-D | 4.63 (4.25) | 5.73 (4.95) | 1.10 (NR) | 0.24 (0.03, 0.45) | ---------- | ---------- | ---------- | ---------- |
|  |
| 11/2020 |
| GulS117  Turkey | 10-11/2019 | 116 | BDI | 11.53 (9.40) | 12.54 (11.30) | 1.01 (NR) | 0.10 (-0.16, 0.35) | BDI ≥ 19 | 17.2 (11.5, 25.1) | 23.3 (16.5, 31.8) | 6.0 (-2.8, 14.8) |
|  |
| 06-07/2020 |
| HenryS118  Canada, France, UK, USA | 07-12/2019 | 388 | PHQ-8 |  |  |  |  | ---------- | ---------- | ---------- | ---------- |
|  |  |  |  |  |
| 04/2020 | 6.73 (5.73) | 6.44 (5.44) | -0.29 (NR) | -0.05 (-0.19, 0.09) |
|  |  |  |  |  |
| 09-10/2020 | 6.73 (5.73) | 5.59 (5.05) | -1.14 (NR) | -0.21 (-0.35, -0.07) |
|  |  |  |  |  |
| 03/2021 | 6.73 (5.73) | 5.60 (5.28) | -1.13 (NR) | -0.20 (-0.35, -0.06) |  |  |  |  |
| JohnstoneS119  New Zealand | NR/2018 | 104 | HADS-D | 3.82 (3.12) | 3.80 (3.39) | -0.02 (NR) | -0.01 (-0.28, 0.26) | ---------- | ---------- | ---------- | ---------- |
|  |
| 07-09/2020 |
| Katz, PS120  USA | NR/2019 | 1,504 | PHQ-2 | 0.79 (1.25) | 0.84 (1.24) | 0.05 (NR) | 0.04 (-0.03, 0.11) | ---------- | ---------- | ---------- | ---------- |
|  |
| 03-06/2020 |
| LiangS121  China | 12/2019 | 114 | ZSDS | 37.70 (9.10) | 37.40 (9.50) | -0.3 (NR) | -0.03 (-0.31, 0.24) | ---------- | ---------- | ---------- | ---------- |
|  |
| 02-03/2020 |
| LimS122  USA | NR/2018 | 316 | PROMIS Depression | 50.80 (10.50) | 49.30 (9.80) | -1.50 (9.20) | -0.15 (-0.30, 0.01) | ---------- | ---------- | ---------- | ---------- |
|  |
|  |
| 04/2020 |
| ParkS124  Germany | 09/2019–02/2020 | 152 | HADS-D | Median (IQR): 5.00 (2.00, 7.00) | Medina (IQR): 4.00 (2.00, 7.00) | NR (NR) | NR (NR) | HADS-D ≥ 8 | 13.0 (8.7, 19.5) | 8.0 (4.6, 13.3) | -5.3 (-10.3, -0.8) |
|  |
| 05-08/2020 |
| RentscherS29  USA | NR | 262 | CES-D | 6.30 (7.00) | 8.10 (7.60) | 1.80 (NR) | 0.25 (0.07, 0.42) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05-09/2020 |
| SacreS125  Australia | NR/2018-2019 | 450 | PHQ-8 | 4.10 (4.70) | 4.10 (4.70) | 0.00 (NR) | 0.00 (-0.13, 0.13) | PHQ-8 ≥ 10 | 5.3 (3.6, 7.8) | 5.6 (3.8, 8.1) | 0.3 (-2.1, 2.5) |
|  |
| 05-06/2020 |
| SbragiaS126  Italy | 01/2019 | 106 | HADS-D | 5.93 (3.77) | 5.51 (3.93) | -0.42 (NR) | -0.11 (-0.38, 0.16) | HADS-D > 8 | 38.1 (29.1, 47.2) | 34.0 (25.7, 43.4) | -3.8 (-14.6, 7.2) |
|  |
| 05/2020 |
| UbaraS127  Japan | 04-07/2019 | 164 | PHQ-9 | Median (IQR): | Median (IQR): | NRc | NRc | ---------- | ---------- | ---------- | ---------- |
|  | 2.00 (1.00-5.00) | 3.00 (0.25-6.00) |
| 05/2020 |  |  |
| UchidaS128  Japan | 04/2019-03/2020 | 142 | CES-D-SF | Median (IQR): 6.00 (4.80, 10.00) | Median (IQR): 7.00 (5.00, 10.00) | NR (NR) | NR (NR) | CES-D-SF ≥ 10 | 26.1 (19.5, 33.8) | 26.1 (19.5, 33.8) | 0.0 (-8.3, 8.3) |
|  |
| 07/2020-03/2021 |
| Wong, SS35  Hong Kong, China | 04/2018-03/2019 | 583 | PHQ-9 | 4.40 (NR) | 4.50 (NR) | 0.19 (NR) | NRc | ---------- | ---------- | ---------- | ---------- |
|  |
| 03-04/2020 |
| YoungS132  UK | 09/2018-02/2020 | 12,098 | PHQ-9 | 11.18 (6.86) | 10.80 (6.68) | -0.38 (NR) | -0.06 (-0.08, -0.03) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04-09/2020 |
| **People with Pre-existing Mental Health Conditions** | | | | | | | | | | | |
| GentileS129  Italy, Paraguay | 10-12/2019 | 110 | HAM-D | 11.40 (7.26) | 11.90 (7.56) | 0.50 (NR) | 0.07 (-0.20, 0.33) | ---------- | ---------- | ---------- | ---------- |
|  |
| 03-04/2020 |
| SwerdlowS131  USA | NR/2018-04/2020 | 144 | MASQ-30 - Depression | 35.99 (6.83) | 35.74 (7.36) | -0.25 (NR) | -0.04 (-0.26, 0.19) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04-06/2020 |
| YoungS132  UK | 09/2018-02/2020 | 12,098 | PHQ-9 | 11.18 (6.86) | 10.80 (6.68) | -0.38 (NR) | -0.06 (-0.08, -0.03) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04-09/2020 |
| **Medical Staff** | | | | | | | | | | | |
| FrankS103  USA | 08/2018 | 180 | PHQ-9 | 3.65 (5.77) | 4.33 (6.24) | 0.68 (NR) | 0.11 (-0.09, 0.32) | ---------- | ---------- | ---------- | ---------- |
|  |
| 08/2020 |
| Li, WeidongS133  China | 10-11/2019 | 385 | PHQ-9 | 5.17 (NR) | 5.77 (NR) | 0.60 (NR) | NRc | ---------- | ---------- | ---------- | ---------- |
|  |
| 01-02/2020 |
| **Sexual or Gender Minority Individuals** | | | | | | | | | | | |
| BavintonS134  Australia | NR/2019 | 681 | PHQ-9 | 5.98 (5.93) | 6.56 (6.03) | 0.58 (NR) | 0.10 (-0.01, 0.20) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04/2020 |
| FlentjeS135  USA | 06/2019 | 2,280 | PHQ-9 | 7.10 (5.99) | 8.31 (6.43) | 1.21 (5.10) | 0.19 (0.14, 0.25) | ---------- | ---------- | ---------- | ---------- |
|  |
| 03-04/2020 |
| GhabrialS136  Canada | NR/2019 | 780 | CES-D | 14.47 (7.69) | 16.50 (7.34) | 2.03 (NR) | 0.27 (0.17, 0.37) | ---------- | ---------- | ---------- | ---------- |
|  |
| 09-10/2020 |
| **Women or Females** | | | | | | | | | | | |
| AdesoganS102  USA | NR/2018-03/2020 | 191 | CES-D | 6.82 (4.70) | 9.23 (5.77) | 2.41 (NR) | 0.46 (0.25, 0.66) | ---------- | ---------- | ---------- | ---------- |
|  |
| 06-09/2020 |
| FrankS103  USA | 08/2018 | 95 | PHQ-9 | 3.69 (5.26) | 5.05 (6.64) | 1.36 (NR) | 0.23 (-0.06, 0.51) | ---------- | ---------- | ---------- | ---------- |
|  |
| 08/2020 |
| Li, YS85  China | 09/2019 | 328 | BDI-II | EMM (SE): 13.02 (0.54) | EMM (SE): 10.77 (0.55) | NR (NR) | NR (NR) | ---------- | ---------- | ---------- | ---------- |
|  |
| 03/2020 |
| LimS122  USA | NR/2018 | 295 | PROMIS Depression | 50.80 (10.70) | 49.30 (9.80) | -1.50 (9.30) | -0.15 (-0.31, 0.02) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04/2020 |
| Loret de MolaS105  Brazil | 01-12/2019 | 1,042 | EPDS | ---------- | ---------- | ---------- | ---------- | EPDS ≥ 13 | 5.1 (3.8, 6.5) | 29.5 (26.6, 32.1) | 24.4 (21.3, 27.2) |
|  |
| 05-07/2020 |
| MagsonS87  Australia | NR/2019 | 126 | SMFQ | 4.77 (5.00) | 8.16 (6.46) | 3.39 (NR) | 0.58 (0.33, 0.83) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05/2020 |
| RentscherS29  USA | NR | 165 | CES-D | 4.50 (5.40) | 7.60 (8.00) | 3.10 (NR) | 0.45 (0.23, 0.67) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05-09/2020 |
| RentscherS29  USA | NR | 262 | CES-D | 6.30 (7.00) | 8.10 (7.60) | 1.80 (NR) | 0.25 (0.07, 0.42) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05-09/2020 |
| RimfeldS39  UK | NR/2018 | 2,578 | SMFQ | 4.65 (4.20) | 4.81 (4.07) | 0.16 (4.14) | 0.04 (-0.02, 0.09) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04-05/2020 |
| SaraswathiS62  India | 12/2019 | 139 | DASS-21 Depression | 7.71 (7.57) | 7.94 (8.77) | 0.23 (NR) | 0.03 (-0.21, 0.26) | DASS-21 Depression > 9 | 36.7 (29.1, 45.0) | 34.5 (27.1, 42.8) | -2.2 (-11.7, 7.4) |
|  |
| 06/2020 |
| UchidaS128  Japan | 04/2019-03/2020 | 60 | CES-D-SF | Median (IQR): 7.00 (5.00, 9.00) | Median (IQR): 7.00 (5.00, 10.00) | NR (NR) | NR (NR) | CES-D-SF ≥ 10 | 23.3 (14.4, 35.4) | 28.3 (18.5, 40.8) | 5.0 (-8.4, 18.2) |
|  |
| 07/2020-03/2021 |
| **Men or Males** | | | | | | | | | | | |
| AdesoganS102  USA | NR/2018-03/2020 | 138 | CES-D | 6.20 (3.46) | 6.86 (5.17) | 0.66 (NR) | 0.15 (-0.09, 0.38) | ---------- | ---------- | ---------- | ---------- |
|  |
| 06-09/2020 |
| FrankS103  USA | 08/2018 | 85 | PHQ-9 | 3.60 (6.30) | 3.52 (5.75) | -0.08 (NR) | -0.01 (-0.32, 0.29) | ---------- | ---------- | ---------- | ---------- |
|  |
| 08/2020 |
| Li, YS85  China | 09/2019 | 503 | BDI-II | EMM (SE): 9.25 (0.63) | EMM (SE): 7.87 (0.66) | NR (NR) | NR (NR) | ---------- | ---------- | ---------- | ---------- |
|  |
| 03/2020 |
| LimS122  USA | NR/2018 | 21 | PROMIS Depression | 50.70 (8.60) | 49.90 (9.70) | -0.80 (8.20) | -0.08 (-0.70, 0.54) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04/2020 |
| MagsonS87  Australia | NR/2019 | 122 | SMFQ | 2.81 (3.18) | 4.02 (4.76) | 1.21 (NR) | 0.30 (0.05, 0.55) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05/2020 |
| MarmetS38  Switzerland | 04/2019-02/2020 | 2,345 | MDI | 9.07 (7.69) | 7.60 (7.79) | -1.47 (NR) | -0.19 (-0.25, -0.13) | ---------- | ---------- | ---------- | ---------- |
|  |
| 05-06/2020 |
| RimfeldS39  UK | NR/2018 | 1,116 | SMFQ | 3.71 (3.70) | 3.33 (3.40) | -0.38 (3.55) | -0.11 (-0.19, -0.02) | ---------- | ---------- | ---------- | ---------- |
|  |
| 04-05/2020 |
| SaraswathiS62  India | 12/2019 | 78 | DASS-21 Depression | 7.28 (8.40) | 8.54 (9.17) | 1.26 (NR) | 0.14 (-0.17, 0.45) | DASS-21 Depression > 9 | 26.9 (18.3, 37.7) | 37.2 (27.3, 48.3) | 10.3 (-2.9, 22.9) |
|  |
| 06/2020 |
| UchidaS128  Japan | 04/2019-03/2020 | 82 | CES-D-SF | Median (IQR): 6.00 (4.00, 10.00) | Median (IQR): 7.00 (4.80, 9.30) | NR (NR) | NR (NR) | CES-D-SF ≥ 10 | 28.1 (19.5, 38.6) | 24.4 (16.4, 34.7) | -3.7 (-14.0, 6.7) |
|  |
| 07/2020-03/2021 |
| **Immigrants** |  |  |  |  |  |  |  |  |  |  |  |
| GosselinS137  France | 04/2018-NR/2019 | 100 | PHQ-9 | ---------- | ---------- | ---------- | ---------- | PHQ-9 ≥ 10 | 65.0 (55.3, 73.6) | 72.0 (62.5, 79.9) | 7.0 (-9.4, 23.0) |
|  |
| 06/2020 |

BSI-18-Depression = Brief Symptom Inventory - Depression; CES-D= Center for Epidemiologic Studies Depression Scale; DASS-21 Depression = Depression, Anxiety, and Stress Scale – Depression subscale; MDI= Major Depression Inventory; MFQ = Mood and Feelings Questionnaire; PHQ-2 = Patient Health Questionnaire-2; PHQ-8 = Patient Health Questionnaire-8; PHQ-9 = Patient Health Questionnaire-9; SMFQ = Short Mood and Feelings Questionnaire; ZSDS= Zung Self-rating Depression Scale.

aPositive Hedges’ g effect sizes and increases in proportions above a threshold indicate worse mental health in COVID-19 compared to pre-COVID-19. Effects for measures where high scores = positive outcomes were reversed to reflect this. bNot enough information reported to calculate. cProvided by authors. dIncluded because it is estimated that over 80% of pre-COVID-19 data would have been collected by December 31, 2019.

**Supplementary Figure 1**. Sensitivity Analysis of General Mental Health conducted with results from Savage et al. from October 2020 instead of April 2020

Chart, box and whisker chart

Description automatically generated

**Supplementary Figure 2.** Sensitivity Analysis of Anxiety Symptoms conducted with results from Henry et al. from September to October 2020 instead of April 2020

Chart, scatter chart, box and whisker chart

Description automatically generated

**Supplementary Figure 3.** Sensitivity Analysis of Anxiety Symptoms conducted with results from Henry et al. from March 2021 instead of April 2020**Chart, box and whisker chart

Description automatically generated**

**Supplementary Figure 4.** Sensitivity Analysis of Depression Symptoms conducted with results from Henry et al. from September to October 2020 instead of April 2020**Chart, box and whisker chart

Description automatically generated**

**Supplementary Figure 5.** Sensitivity Analysis of Depression Symptoms conducted with results from Henry et al. from March 2021 instead of April 2020**Chart, box and whisker chart

Description automatically generated**

**References for Included Studies**

1. Bulbulia J, Piven S, Greaves L, et al. Longitudinal study of pandemic and natural disaster distress. *PsyArXiv* 20201123 [Preprint]. https://psyarxiv.com/erfhp/.
2. Castellini G, Rossi E, Cassioli E, et al. A longitudinal observation of general psychopathology before the COVID-19 outbreak and during lockdown in Italy. *J Psychosom Res* 2021;141:110328. <https://doi.org/10.1016/j.jpsychores.2020.110328>.
3. Chan F, Tao TJ, Jin J, et al. The impact of interpretation biases on psychological responses to the COVID-19 pandemic: a prospective study. *Int J Behav Med* 2022. https://doi.org/10.1007/s12529-022-10079-5.
4. Finucane ML, Beckman R, Ghosh-Dastidar M, et al. Do social isolation and neighborhood walkability influence relationships between COVID-19 experiences and wellbeing in predominantly Black urban areas? *Landsc Urban Plan* 2022;217:104264. <https://doi.org/10.1016/j.landurbplan.2021.104264>.
5. Ge F, Zheng A, Wan M, et al. Psychological state among the general Chinese population before and during the COVID-19 epidemic: a network analysis. *Front Psychiatry* 2021;12:591656. <https://doi.org/10.3389/fpsyt.2021.591656>.
6. Haliwa I, Wilson J, Lee J, et al. Predictors of change in mental health during the COVID-19 pandemic. *J Affect Disord* 2021;291:331-337. https://doi.org/10.1016/j.jad.2021.05.045.
7. Kanbur S. Investigation of the effect of COVID-19 pandemic on employees’ psychological symptoms and nutritional habits. *Progress in Nutrition* 2021;23:e2021107. doi:10.23751/pn.v23i1.11052.
8. Katz BA, Yovel I. Mood symptoms predict COVID-19 pandemic distress but not vice versa: an 18-month longitudinal study. *PLoS One* 2022;17:e0273945. https://doi.org/10.1371/journal.pone.0273945.
9. Latikka R, Koivula A, Oksa R, et al. Loneliness and psychological distress before and during the COVID-19 pandemic: relationships with social media identity bubbles. *Soc Sci Med* 2022;293:114674. <https://doi.org/10.1016/j.socscimed.2021.114674>.
10. Megias-Robles A, Gutierrez-Cobo MJ, Cabello R, et al. A longitudinal study of the influence of concerns about contagion on negative affect during the COVID-19 lockdown in adults: the moderating effect of gender and resilience. *J Health Psychol* 2021;27:1165-1175. <https://doi.org/10.1177/1359105321990794>.
11. Pierce M, Hope H, Ford T, et al. Mental health before and during the COVID-19 pandemic: a longitudinal probability sample survey of the UK population. *Lancet Psychiatry* 2020;7:883-92. <https://doi.org/10.1016/>S2215-0366(20)30308-4.
12. Daly M, Robinson E. Longitudinal changes in psychological distress in the UK from 2019 to September 2020 during the COVID-19 pandemic: evidence from a large nationally representative study. *Psychiatry Res* 2021;300:113920. <https://doi.org/10.1016/j.psychres.2021.113920>.
13. Shimura A, Yokoi K, Ishibashi Y, et al. Remote work decreases psychological and physical stress responses, but full-remote work increases presenteeism. *Front Psychol* 2021;12:730969. https://doi.org/10.3389/fpsyg.2021.730969.
14. Soltanzadeh A, Ghasemi M, Sadeghi-Yarandi M, et al. Psychological and psychosocial impact and related factors during the COVID-19 pandemic among Iranian oil refineries personnel: a longitudinal study. *Arch Iran Med* 2021;24:811-821. doi:[10.34172/aim.2021.121](https://doi.org/10.34172/aim.2021.121)
15. Thygesen LC, Moller SP, Ersboll AK, et al. Decreasing mental well-being during the COVID-19 pandemic: a longitudinal study among Danes before and during the pandemic. *J Psychiatr Res* 2021;144:151-157. https://doi.org/10.1016/j.jpsychires.2021.09.035.
16. van der Velden PG, Contino C, Das M, et al. Anxiety and depression symptoms, and lack of emotional support among the general population before and during the COVID-19 pandemic. a prospective national study on prevalence and risk factors. *J Affect Disord* 2020;277:540-548. <https://doi.org/10.1016/j.jad.2020.08.026>.
17. van der Velden, van Bakel H, Das M. Mental health problems among Dutch adolescents of the general population before and 9 months after the COVID-19 outbreaks: a longitudinal cohort study*. Psychiatry Res* 2022;311:114528. <https://doi.org/10.1016/j.psychres.2022.114528>.
18. Wanberg CR, Csillag B, Douglass RP, et al. Socioeconomic status and well-being during COVID-19: a resource-based examination. *J Appl Psychol* 2020;105:1382-1396. http://dx.doi.org/10.1037/apl0000831.
19. Bartlett L, Brady J, Farrow M, et al. Change in modifiable dementia risk factors during COVID-19 lockdown: the experience of over 50s in Tasmania, Australia. *Alzheimers Dement* 2021;7:e12169. https://doi.org/10.1002/trc2.12169.
20. Briggs R, McDowell CP, De Looze C, et al. Depressive symptoms among older adults pre– and post–COVID-19 pandemic. *J Am Med Dir Assoc* 2021;22:2251-2257. <https://doi.org/10.1016/j.jamda.2021.09.003>.
21. Creese B, Khan Z, Henley W, et al. Loneliness, physical activity and mental health during Covid-19: a longitudinal analysis of depression and anxiety in adults over the age of 50 between 2015 and 2020. *Int Psychogeriatr* 2021;33:505-514. <https://doi.org/10.1017/S1041610220004135>.
22. Eliasen EH, Weihe P, Petersen MS. The Faroese Septuagenarians cohort: a comparison of well-being before and during the COVID-19 pandemic among older home-dwelling Faroese. *Scand J Public Health* 2021;50:136-143. <https://doi.org/10.1177/14034948211056209>.
23. Herrera MS, Elgueta R, Fernandez MB, et al. A longitudinal study monitoring the quality of life in a national cohort of older adults in Chile before and during the COVID-19 outbreak. *BMC Geriatr* 2021;21:143. https://doi.org/10.1186/s12877-021-02110-3.
24. Kera T, Kawai H, Ejiri M, et al. Change in subjective health status among frail older Japanese people owing to the coronavirus disease pandemic and characteristics of their responses. *Geriatr Gerontol Int* 2021;21:1053-1059. https://doi.org/10.1111/ggi.14276.
25. Kivi M, Hansson I, Bjälkebring P. Up and about: older adults’ well-being during the COVID-19 pandemic in a Swedish longitudinal study. *J Gerontol B Psychol Sci Soc Sci* 2021;76:e4-e9. https://doi.org/10.1093/geronb/gbaa084.
26. Lee E, Man R, Gan T, et al. The longitudinal psychological, physical activity, and financial impact of a COVID-19 lockdown on older adults in Singapore: the PIONEER-COVID population-based study*. Int J Geriatr Psychiatry* 2021;37:1-10. https://doi.org/10.1002/gps.5645.
27. Martinez M, Granados T, Fernandez-Fernandez V. Psychological impact of confinement in a sample of older adults: longitudinal study before and during COVID-19. *Accion Psicologica* 2021;18:151-164. https://doi.org/10.5944/ap.18.1.29176.
28. Okely JA, Corley J, Welstead M, et al. Change in physical activity, sleep quality, and psychosocial variables during COVID-19 lockdown: evidence from the Lothian Birth Cohort 1936. *Int J Environ Res Public Health* 2021;18:210. <https://doi.org/10.3390/ijerph18010210>.
29. Rentscher KE, Zhao X, Small BJ, et al. Loneliness and mental health during the COVID-19 pandemic in older breast cancer survivors and noncancer controls. *Cancer* 2021;127:3671-3679. doi:10.1002/cncr.33687.
30. Sardella A, Lenzo V, Bonanno GA, et al. Expressive flexibility and dispositional optimism contribute to the elderly’s resilience and health-related quality of life during the COVID-19 pandemic. *Int J Environ Res Public Health* 2021;18:1698. https://doi.org/10.3390/ijerph18041698.
31. Siew S, Mahendran R, Yu J. Directional effects of social isolation and quality of life on anxiety levels among community-dwelling older adults during a COVID-19 lockdown. *Am J Geriatr Psychiatry* 2021;29:1274-1279. http://doi.org/10.1016/j.jagp.2021.03.012.
32. van den Besselaar JH, MacNeil Vroomen JL, Buurman BM, et al. Symptoms of depression, anxiety, and perceived mastery in older adults before and during the COVID-19 pandemic: results from the Longitudinal Aging Study Amsterdam. *J Psychosom Res* 2021;151:110656. https://doi.org/10.1016/j.jpsychores.2021.110656.
33. van Tilburg TG, Steinmetz S, Stolte E, et al. Loneliness and mental health during the COVID-19 pandemic: a study among Dutch older adults. *J Gerontol B Psychol Sci Soc Sci* 2021;76:e249-e255. https://doi.org/10.1093/geronb/gbaa111.
34. Wang Y, Fu P, Li J, et al. Changes in psychological distress before and during the COVID-19 pandemic among older adults: the contribution of frailty transitions and multimorbidity. *Age Ageing* 2021;50:1011-1018. https://doi.org/10.1093/ageing/afab061.
35. Wong S, Zhang D, Sit R, et al. Impact of COVID-19 on loneliness, mental health, and health service utilisation: a prospective cohort study of older adults with multimorbidity in primary care. *Br J Gen Pract* 2020;70:e817-e824. https://doi.org/10.3399/bjgp20X713021.
36. Yu X, Tam W, Wong P, et al. The Patient Health Questionnaire-9 for measuring depressive symptoms among the general population in Hong Kong. *Compr Psychiatry* 2012;53:95-102. doi:10.1016/j.comppsych.2010.11.002.
37. Islam MI, Freeman J, Chadwick V, et al. Healthcare avoidance before and during the COVID-19 pandemic among Australian youth: a longitudinal study. *Healthcare* 2022;10:1261. https://doi.org/10.3390/healthcare10071261.
38. Marmet S, Wicki M, Gmel G, et al. The psychological impact of the COVID-19 crisis on young Swiss men participating in a cohort study. *Swiss Med Wkly* 2021;151:w30028. https://doi.org/10.4414/smw.2021.w30028.
39. Rimfeld K, Malancini M, Allegrini A, et al. Genetic correlates of psychological responses to the COVID-19 crisis in young adult twins in Great Britain. *Behav Genet* 2021;51:110-124. https://doi.org/10.1007/s10519-021-10050-2.
40. Romm KF, Patterson B, Wysota CN, et al. Predictors of negative psychosocial and health behavior impact of COVID-19 among young adults. *Health Educ Res* 2022;36:385-397. https://doi.org/10.1093/her/cyab026.
41. Tanioka K, Kayaba M, Tomishima S, et al. Changes in sleep behavior, sleep problems, and psychological distress/health-related quality of life of young Japanese individuals before and during the COVID-19 pandemic. *Chronobiol Int* 2022;39:781-791. https://doi.org/10.1080/07420528.2022.2034839.
42. Villadsen A, Patalay P, Bann D. Mental health in relation to changes in sleep, exercise, alcohol and diet during the COVID-19 pandemic: examination of five UK cohort studies. *Psychol Med* 2021:1-10. https://doi.org/10.1017/S0033291721004657.
43. Watkins-Martin K, Orri M, Pennestri MH, et al. Depression and anxiety symptoms in young adults before and during the Covid-19 pandemic: evidence from a Canadian population-based cohort. *Ann Gen Psychiatry* 2021;20:42. https://doi.org/10.1186/s12991-021-00362-2.
44. da Conceicao V, Rothes I, Gusmao R, et al. Depression and anxiety before and during the COVID-19 lockdown: a longitudinal cohort study with university students. *MedRxiv* 20210224 [Preprint]. https://doi.org/10.1101/2021.02.23.21252284.
45. Dong X. 新型冠状病毒肺炎疫情对师范类大学生心理健康的影响研究 [Influence study of COVID-2019 on mental health of normal college students]. *Psychologies* 2020;15:37-39. https://www.doi.org/10.19738/j.cnki.psy.2020.20.013.
46. Elmer T, Mepham K, Stadtfeld C. Students under lockdown: comparison of students' social networks and mental health before and during the COVID-19 crisis in Switzerland. *PLoS One* 2020;15:e0236337. https://doi.org/10.1371/journal.pone.0236337.
47. Evans S, Alkan E, Bhangoo JK, et al. Effects of the COVID-19 lockdown on mental health, wellbeing, sleep, and alcohol use in a UK student sample. *Psychiatry Res* 2021;298:113819. https://doi.org/10.1016/j.psychres.2021.113819.
48. Fuller-Rowell TE, Nichols OI, Doan SN, et al. Changes in depressive symptoms, physical symptoms, and sleep-wake problems from before to during the COVID-19 pandemic among emerging adults: inequalities by gender, socioeconomic position, and race. *Emerg Adulthood* 2021;9:492-505. https://doi.org/10.1177/21676968211042111.
49. Gelezelyte O, Kazlauskas E, Brailovskaia J, et al. Suicidal ideation in university students in Lithuania amid the COVID-19 pandemic: a prospective study with pre-pandemic measures. *Death Stud* 2022;46:2395-2403. https://doi.org/10.1080/07481187.2021.1947417.
50. Gopalan M, Linden-Carmichael A, Lanza S. College students’ sense of belonging and mental health amidst the COVID-19 pandemic. *J Adolesc Health* 2022;70:228-233. https://doi.org/10.1016/j.jadohealth.2021.10.010.
51. Hamza CA, Ewing L, Heath NL, et al. When social isolation is nothing new: a longitudinal study psychological distress during COVID-19 among university students with and without preexisting mental health concerns. *Can Psychol* 2021;62:20-30. https://doi.org/10.1037/cap0000255.
52. He L, Wei D, Yang F, et al. Functional connectome prediction of anxiety related to the COVID-19 pandemic. *Am J Psychiatry* 2021;178:530-540. doi:10.1176/appi.ajp.2020.20070979.
53. Koelen J, Mansueto A, Finnemann A, et al. COVID-19 and mental health among at-risk university students: a prospective study into risk and protective factors. *Int J Methods Psychiatr Res* 2021;31:e1901. https://doi.org/10.1002/mpr.1901.
54. Li H, Cao H, Leung D, et al. The psychological impacts of a COVID-19 outbreak on college students in China: a longitudinal study. *Int J Environ Res Public Health* 2020;17:3933. doi:10.3390/ijerph17113933.
55. Li R, Dai J, Yuan X, et al. 新冠肺炎疫情期大学生心理健康状况 [Mental health status of college students during the COVID-19 epidemic]. *Journal of Panzhihua University* 2020;37:18-24. doi:10.13773/j.cnki.51-1637/z.2020.06.004.
56. Li WW, Yu H, Miller DJ, et al. Novelty seeking and mental health in Chinese university students before, during, and after the COVID-19 pandemic lockdown: a longitudinal study. *Front Psychol* 2020;11:600739. <https://doi.org/10.3389/fpsyg.2020.600739>
57. Liu D, Li B, Hao F, et al. The prevalence and incidence of major depressive disorder in 8079 Chinese university freshmen before and during COVID-19. *J Affect Disord* 2022;307:62-68. https://doi.org/10.1016/j.jad.2022.03.022.
58. Lu P, Yang L, Wang C, et al. Mental health of new undergraduate students before and after COVID-19 in China. *Sci Rep* 2021;11:18783. https://doi.org/10.1038/s41598-021-98140-3.
59. Mauer VA, Littleton H, Lim S, et al. Fear of COVID-19, anxiety, and social support among college students. *J Am Coll Health* 2022;1-8. https://doi.org/10.1080/07448481.2022.2053689
60. Mehus C, Lyden G, Bonar E, et al. Association between COVID-19-related loneliness or worry and symptoms of anxiety and depression among first-year college students. *J Am Coll Health* 2021:1-6. https://doi.org/10.1080/07448481.2021.1942009.
61. Ratner K, Burrow A, Mendle J, et al. A prospective study of college student depressive symptoms, sense of purpose, and response to a COVID-19 campus shutdown. *Pers Individ Dif* 2022;189:111475. https://doi.org/10.1016/j.paid.2021.111475.
62. Saraswathi I, Saikarthik J, Kumar KS, et al. Impact of COVID-19 outbreak on the mental health status of undergraduate medical students in a COVID-19 treating medical college: a prospective longitudinal study. *PeerJ* 2020;8:e10164. doi:10.7717/peerj.10164
63. Savage MJ, James R, Magistro D, et al. Mental health and movement behaviour during the COVID-19 pandemic in UK university students: prospective cohort study. *Ment Health Phys Act* 2020;19:100357. https://doi.org/10.1016/j.mhpa.2020.100357.
64. Savage MJ, Hennis PJ, Magistro D, et al. Nine months into the COVID-19 pandemic: a longitudinal study showing mental health and movement behaviours are impaired in UK students. *Int J Environ Res Public Health* 2021;18:2930. https://doi.org/10.3390/ijerph18062930.
65. Shiratori Y, Ogawa T, Ota M, et al. A longitudinal comparison of college student mental health under the COVID-19 self-restraint policy in Japan. *J Affect Disord Rep* 2022;8:100314. https://doi.org/10.1016/j.jadr.2022.100314.
66. Truskauskaite-Kuneviciene I, Brailovskaia J, Margraf J, et al. Evidence on resilient initial response to COVID-19 pandemic among youth: findings from the prospective study of mental health in two European countries. *Emerg Adulthood* 2021;9:566-575. https://doi.org/10.1177/21676968211031120.
67. Voltmer E, Koslich-Strumann S, Walther A, et al. The impact of the COVID-19 pandemic on stress, mental health and coping behavior in German university students - a longitudinal study before and after the onset of the pandemic. *BMC Public Health* 2021;21:1385. https://doi.org/10.1186/s12889-021-11295-6.
68. Wang Y, Xie C, Zhang X. 常态化疫情防控期间医学院校学生心理健康状况对比分析. *China Journal of Multimedia & Network Teaching* 2021;4:104-106.
69. Yang X, Hu H, Zhao C, et al. A longitudinal study of changes in smart phone addiction and depressive symptoms and potential risk factors among Chinese college students. *BMC Psychiatry* 2021;21:252. https://doi.org/10.1186/s12888-021-03265-4.
70. Yang Z, Luo Y, Zhou Q, et al. COVID-19-related stressors and depression in Chinese adolescents: the effects of life history strategies and gender. *J Affect Disord* 2022;304:122-127. https://doi.org/10.1016/j.jad.2022.02.060.
71. Zimmermann M, Bledsoe C, Papa A. Initial impact of the COVID-19 pandemic on college student mental health: a longitudinal examination of risk and protective factors. *Psychiatry Res* 2021;305:114254. https://doi.org/10.1016/j.psychres.2021.114254.
72. Achterberg M, Dobbelaar S, Boer OD, et al. Perceived stress as mediator for longitudinal effects of the COVID-19 lockdown on wellbeing of parents and children. *Sci Rep* 2021;11:2971. doi:10.1038/s41598-021-81720-8.
73. Adachi M, Takahashi M, Shinkawa H, et al. Longitudinal association between smartphone ownership and depression among schoolchildren under COVID-19 pandemic. *Soc Psychiatry Psychiatr Epidemiol* 2022;57:239-243. https://doi.org/10.1007/s00127-021-02196-5.
74. Bado P, Hoffmann MS, Pan P, et al. Mental health problems predict inequalities in accessing online classes during COVID-19 pandemic in youth. *PsyArXiv* 20220617 [Preprint]. https://psyarxiv.com/knq49/
75. Bernasco EL, Nelemans SA, van der Graaff J, et al. Friend support and internalizing symptoms in early adolescence during COVID-19. *J Res Adolesc* 2021;31:692-702. https://doi.org/10.1111/jora.12662.
76. Bosch R, Pagerols M, Prat R, et al. Changes in the mental health of children and adolescents during the COVID-19 lockdown: associated factors and life conditions. *Int J Environ Res Public Health* 2022;19:4120. https://doi.org/10.3390/ijerph19074120.
77. Charmaraman L, Lynch AD, Richer AM, et al. Examining early adolescent positive and negative social technology behaviors and well-being during the COVID-19 pandemic. *Technol Mind Behav* 2022;3. https://doi.org/10.1037/tmb0000062.
78. Chen I, Chen C, Pakpour AH, et al. Problematic internet-related behaviors mediate the associations between levels of internet engagement and distress among schoolchildren during COVID-19 lockdown: a longitudinal structural equation modeling study. *J Behav Addict* 2021;10:135-148. https://doi.org/10.1556/2006.2021.00006.
79. Chen C, Chen I, Hou W, et al. The relationship between children’s problematic internet-related behaviors and psychological distress during the onset of the COVID-19 pandemic: a longitudinal Study*. J Addict Med* 2022;16:e73-e80. doi:10.1097/ADM.0000000000000845.
80. Daniunaite I, Truskauskaite-Kuneviciene I, Thoresen S, et al. Adolescents amid the COVID-19 pandemic: a prospective study of psychological functioning. *Child Adolesc Psychiatry Ment Health* 2021;15:45. https://doi.org/10.1186/s13034-021-00397-z.
81. Ezpeleta L, Navarro JB, de la Osa N, et al. Life conditions during COVID-19 lockdown and mental health in Spanish adolescents. *Int J Environ Res Public Health* 2020;17:7327. doi:10.3390/ijerph17197327.
82. Fujihara S, Tabuchi T. The impact of COVID-19 on the psychological distress of youths in Japan: a latent growth curve analysis. *J Affect Disord* 2022;305:19-27. https://doi.org/10.1016/j.jad.2022.02.055.
83. Hu Y, Qian Y. COVID-19 and adolescent mental health in the United Kingdom. *J Adolesc Health* 2021;69:26-32. https://doi.org/10.1016/j.jadohealth.2021.04.005.
84. Knowles G, Gayer-Anderson C, Turner A, et al. Covid-19, social restrictions, and mental distress among young people: a UK longitudinal, population-based study. *J Child Psychol Psychiatry* 2022. https://doi.org/10.1111/jcpp.13586.
85. Li Y, Zhou Y, Ru T, et al. How does the COVID-19 affect mental health and sleep among Chinese adolescents: a longitudinal follow-up study. *Sleep Med* 2021;85:246-258. https://doi.org/10.1016/j.sleep.2021.07.008.
86. Liao S, Luo B, Liu H, et al. Bilateral associations between sleep duration and depressive symptoms among Chinese adolescents before and during the COVID-19 pandemic. *Sleep Med* 2021;84:289-293. https://doi.org/10.1016/j.sleep.2021.06.007.
87. Magson NR, Freeman J, Rapee RM, et al. Risk and protective factors for prospective changes in adolescent mental health during the COVID-19 pandemic. *J Youth Adolesc* 2021;50:44-57. https://doi.org/10.1007/s10964-020-01332-9.
88. Mastorci F, Bastiani L, Trivellini G, et al. Well-being perception during COVID-19 pandemic in healthy adolescents: from the Avatar Study. *Int J Environ Res Public Health* 2021;18:6388. https://doi.org/10.3390/ijerph18126388.
89. Meireles A, Marques S, Peixoto MM, et al. Portuguese adolescents’ cognitive well-being and basic psychological needs during the COVID-19 outbreak: a longitudinal study. *Appl Psychol Health Well Being* 2022;14:881-898. https://doi.org/10.1111/aphw.12356.
90. Naumann E, von den Driesch E, Schumann A, et al. Increase of depressive symptoms among adolescents during the first COVID-19 lockdown in Germany results from the German family panel pairfam. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 2021;64:1533-1540. https://doi.org/10.1007/s00103-021-03451-5.
91. Paizan M, Benbow A, Aumann L, et al. Home-learning during COVID-19: the psychological adjustment of minority and majority adolescents. *Sch Psychol* 2022;37:75-84. https://doi.org/10.1037/spq0000489.
92. Polack RG, Sened H, Aube S. Connections during crisis: adolescents’ social dynamics and mental health during COVID-19. *Dev Psychol* 2021;57:1633-1647. doi:10.1037/dev0001211.
93. Rau LM, Grothus S, Sommer A, et al. Chronic pain in schoolchildren and its association with psychological wellbeing before and during the COVID-19 pandemic. *J Adolesc Health* 2021;69:721-728. https://doi.org/10.1016/j.jadohealth.2021.07.027.
94. Shoshani A, Kor A. The mental health effects of the COVID-19 pandemic on children and adolescents: risk and protective factors. *Psychol Trauma* 2021. https://doi.org/10.1037/tra0001188.
95. Teng Z, Pontes HM, Nie Q, et al. Depression and anxiety symptoms associated with internet gaming disorder before and during the COVID-19 pandemic: a longitudinal study. *J Behav Addict* 2021;10:169-180. https://doi.org/10.1556/2006.2021.00016.
96. Vira E, Skoog T. Swedish middle school students’ psychosocial well-being during the COVID-19 pandemic: a longitudinal study*. SSM Popul Health* 2021;16:100942. https://doi.org/10.1016/j.ssmph.2021.100942.
97. Wang W, Guo Y, Du X, et al. Associations between poor sleep quality, anxiety symptoms, and depressive symptoms among Chinese adolescents before and during COVID-19: a longitudinal study. *Front Psychiatry* 2022;12:786640. https://doi.org/10.3389/fpsyt.2021.786640.
98. Widnall E, Winstone L, Plackett R. Impact of school and peer connectedness on adolescent mental health and well-being outcomes during the COVID-19 pandemic: a longitudinal panel survey. *Int J Environ Res Public Health* 2022;19:6768. https://doi.org/10.3390/ijerph19116768.
99. Wong RS, Tung K, Li X, et al. Examining family pre-pandemic influences on adolescent psychosocial wellbeing during the COVID-19 pandemic. *Curr Psychol* 2022. https://doi.org/10.1007/s12144-022-02736-5.
100. Yang Z, Luo Y, Zhou Q, et al. COVID-19-related stressors and depression in Chinese adolescents: the effects of life history strategies and gender. *J Affect Disord* 2022;304:122-127. https://doi.org/10.1016/j.jad.2022.02.060.
101. Zhang L, Zhang D, Fang J, et al. Assessment of mental health of Chinese primary school students before and after school closing and opening during the COVID-19 pandemic*. JAMA Netw Open* 2020;3:e2021482. doi:10.1001/jamanetworkopen.2020.21482.
102. Adesogan O, Lavner JA, Carter SE, et al. COVID-19 stress and the health of black Americans in the rural south. *Clin Psychol Sci* 2021;1-18. https://doi.org/10.1177/21677026211049379.
103. Frank E, Zhao Z, Fang Y, et al. Experiences of work-family conflict and mental health symptoms by gender among physician parents during the COVID-19 pandemic. *JAMA Netw Open* 2021;4:e2134315. doi:10.1001/jamanetworkopen.2021.34315.
104. Gagne ME, Piche G, Clement ME, et al. Families in confinement: a pre-post COVID-19 study. *Couple Family Psychol* 2021;10:260-270. https://doi.org/10.1037/cfp0000179.
105. Loret de Mola C, Blumenberg C, Martins RC, et al. Increased depression and anxiety during the COVID-19 pandemic in Brazilian mothers: a longitudinal study. *Braz J Psychiatry* 2021;43:337-338. doi:10.1590/1516-4446-2020-1628.
106. Pitchik HO, Tofail F, Akter F, et al. Effects of the COVID-19 pandemic on caregiver mental health and the child caregiving environment in a low-resource, rural context. *Child Dev* 2021;92:e764-e780. https://doi.org/10.1111/cdev.13651.
107. Rivera N, McGuinn L, Osorio-Valencia E, et al. Changes in depressive symptoms, stress and social support in Mexican women during the COVID-19 pandemic. *Int J Environ Res Public Health* 2021;18:8775. https://doi.org/10.3390/ijerph18168775.
108. Thompson SF, Shimomaeda L, Calhoun R, et al. Maternal mental health and child adjustment problems in response to the COVID-19 pandemic in families experiencing economic disadvantage. *Res Child Adolesc Psychopathol* 2022;50:695-708. https://doi.org/10.1007/s10802-021-00888-9.
109. Becker H, Stuifbergen AK, Lim S, et al. Health promotion, functional abilities, and quality of life before and during COVID-19 in people with multiple sclerosis. *Nurs Res* 2022;71:84-89. doi:10.1097/NNR.0000000000000573.
110. Bonenkamp AA, Druiventak TA, van der Sluijs A, et al. The impact of COVID-19 on the mental health of dialysis patients. *J Nephrol* 2021;34:337-344. https://doi.org/10.1007/s40620-021-01005-1.
111. Chao AM, Wadden TA, Clark JM, et al. Changes in the prevalence of symptoms of depression, loneliness, and insomnia in U.S. older adults with Type 2 Diabetes during the COVID-19 pandemic: the Look AHEAD Study. *Diabetes Care* 2022;45:74-82. doi:10.2337/dc21-1179.
112. Chiu CY, Wilcher K, Jones A. Perceived COVID-19 impacts on stress, resilience, and mental health among people with multiple sclerosis: a longitudinal prospective study. *J Rehabil* 2021;87:80-87.
113. Derksen J, May AM, van de Poll-Franse L, et al. Colorectal cancer care and patients’ perceptions before and during COVID-19: implications for subsequent SARS-CoV-2 infection waves. *JNCI Cancer Spectr* 2021;5:pkab047. https://doi.org/10.1093/jncics/pkab047.
114. Dunlop-Thomas C, Bao G, Lim SS, et al. Psychosocial and health measures in systemic lupus erythematosus: before and during the COVID-19 pandemic in the Georgian’s organized against lupus cohort. *Arthritis Rheumatol* 2021;73:542-545.
115. Fujiwara A, Watanabe K, Ida M, et al. The short-term effect of COVID-19 pandemic on disability, pain intensity, psychological status, and exercise habits in patients with chronic pain. *J Anesth* 2021;35:862-869. https://doi.org/10.1007/s00540-021-02992-y.
116. Garcia-Rudolph A, Sauri J, Carballo JL, et al. The impact of COVID-19 on community integration, quality of life, depression and anxiety in people with chronic spinal cord injury. *J Spinal Cord Med* 2021;45:681-690. https://doi.org/10.1080/10790268.2021.1922230.
117. Gul ZB. Depression and sexual functions in epilepsy patients: comparison before and during the COVID-19 pandemic. *Ann Med Psychol* 2022;180:127-132. https://doi.org/10.1016/j.amp.2021.02.006.
118. Henry RS, Kwakkenbos L, Carrier ME, et al. Mental health before and during the pandemic in people with systemic sclerosis. *Lancet Rheumatol* 2022;4(2):e82-e85. https://doi.org/10.1016/S2665-9913(21)00363-5.
119. Johnstone G, Treharne GJ, Fletcher BD, et al. Mental health and quality of life for people with rheumatoid arthritis or ankylosing spondylitis in Aotearoa New Zealand following the COVID-19 national lockdown. *Rheumatol Int* 2021;41:1763-1772. https://doi.org/10.1007/s00296-021-04952-x.
120. Katz P, Pedro S, Wipfler K, et al. Changes in mental health during the COVID-19 pandemic among individuals with rheumatic disease [abstract]. *Arthritis Rheumatol* 2020;72(Suppl 10).
121. Liang J, Li X, Zhang W, et al. 新冠肺炎流行期住院集中医学观察期间血液透析患者的焦虑抑郁状况 [Anxiety and depression in patients with maintenance hemodialysis under concentrated medical observation in hospital during the COVID-19 epidemic]. *Chinese Mental Health Journal* 2020;12:1050-1055. doi:10.3969/j.issn.1000-6729.2020.12.014.
122. Lim SS, Theis K, Dunlop-Thomas C, et al. Unexpected changes in physical and psychological measures among Georgia lupus patients during the early weeks of the COVID-19 pandemic in the United States, March 30-April 21, 2020 [abstract]. *Arthritis Rheumatol* 2020;72(Suppl 10).
123. Moller SP, Apputhurai P, Tye-Din JA, et al. Longitudinal assessment of the common sense model before and during the COVID-19 pandemic: a large coeliac disease cohort study. *J Psychosom Res* 2022;153:110711. https://doi.org/10.1017/j.jpsychores.2021.110711.
124. Park DH, Fuge J, Meltendorf T, et al. Impact of Sars-CoV-2-Pandemic on mental disorders and quality of life in patients with pulmonary arteriaI hypertension. *Eur Respir J* 2021;58:PA3588. doi:10.1183/13993003.congress-2021.PA3588.
125. Sacre JW, Holmes-Truscott E, Salim A, et al. Impact of the COVID-19 pandemic and lockdown restrictions on psychosocial and behavioural outcomes among Australian adults with type 2 diabetes: findings from the PREDICT cohort study. *Diabet Med* 2021;38:e14611. https://doi.org/10.1111/dme.14611.
126. Sbragia E, Colombo E, Pollio C, et al. Embracing resilience in multiple sclerosis: a new perspective from COVID-19 pandemic. *Psychol Health Med* 2022;27:352-360. https://doi.org/10.1080/13548506.2021.1916964.
127. Ubara A, Sumi Y, Ito K, et al. Self-isolation due to COVID-19 is linked to small one-year changes in depression, sleepiness, and insomnia: results from a clinic for sleep disorders in Shiga Prefecture, Japan. *Int J Environ Res Public Health* 2020;17:8971. https://doi.org/10.3390/ijerph17238971.
128. Uchida J, Yoshikoshi S, Nakajima T, et al. Impact of the COVID-19 pandemic on depressive symptoms in Japanese patients undergoing hemodialysis. *J Nephrol* 2022;35:371-373. https://doi.org/10.1007/s40620-021-01218-4.
129. Gentile A, Torales J, O’Higgins M, et al. Phone-based outpatients’ follow-up in mental health centers during the COVID-19 quarantine. *Int J Soc Psychiatry* 2022;68:129-133. https://doi.org/10.1177/0020764020979732.
130. Huong P, Wu CY, Lee MB, et al. The influence of research follow-up during COVID-19 pandemic on mental distress and resilience: a multicenter cohort study of treatment-resistant depression. *Int J Environ Res Public Health* 2022;19:3738. https://doi.org/10.3390/ijerph19063738.
131. Swerdlow BA, Johnson SL, Timpano KR, et al. Longitudinal associations between internalizing symptoms, social behavior, and social perceptions in the initial months of the COVID-19 pandemic: findings from a transdiagnostic community sample. *J Affect Disord* 2021;294:805-812. https://doi.org/10.1016/j.jad.2021.07.093.
132. Young KS, Purves KL, Hubel C, et al. Depression, anxiety and PTSD symptoms before and during the COVID-19 pandemic in the UK. *Psychol Med* 2022:1-14. <https://doi.org/10.1017/S0033291722002501>.
133. Li W, Frank E, Zhao Z, et al. Mental health of young physicians in China during the Novel Coronavirus Disease 2019 outbreak. *JAMA Netw Open* 2020;3:e2010705. doi:10.1001/jamanetworkopen.2020.10705.
134. Bavinton BR, Chan C, Hammoud MA, et al. Increase in depression and anxiety among Australia gay and bisexual men during COVID-19 restrictions: findings from a prospective online cohort study. *Arch Sex Behav* 2022;51:355-364. doi:10.1007/s10508-021-02276-2.
135. Flentje A, Obedin-Maliver J, Lubensky ME, et al. Depression and anxiety changes among sexual and gender minority people coinciding with onset of COVID-19 pandemic. *J Gen Intern Med* 2020;35:2788-2790. https://doi.org/10.1007/s11606-020-05970-4.
136. Ghabrial MA, Scheim AI, Chih C, et al. Change in finances, peer access, and mental health among trans and non-binary people in Canada during COVID-19. *MedRxiv* 20211214 [Preprint]. https://doi.org/10.1101/2021.12.13.21267077.
137. Gosselin A, Melchior M, Carillon S, et al. Deterioration of mental health and insufficient Covid-19 information among disadvantaged immigrants in the greater Paris area. *J Psychosom Res* 2021;146:110504. https://doi.org/10.1016/j.jpsychores.2021.110504.